[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fgoBffSfXsVBSOteSsWXFhr8YBYh3OEvIEeCtA7VRDqY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":87,"rows":94},"Roswell Park Cancer Institute",[4],410,false,83,6,27132,79,113,[14,17,19,22,25,28,31,34],{"name":15,"count":16},"Leukemia",22,{"name":18,"count":16},"Unspecified Adult Solid Tumor, Protocol Specific",{"name":20,"count":21},"Lung Cancer",20,{"name":23,"count":24},"Lymphoma",18,{"name":26,"count":27},"Prostate Cancer",17,{"name":29,"count":30},"Colorectal Cancer",14,{"name":32,"count":33},"Malignant Solid Neoplasm",11,{"name":35,"count":36},"Esophageal Cancer",10,[38,43,48,53,58,63,67,72,77,82],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT02455557","SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma","2019-10-23","Montanide ISA 51 VG",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT03017131","Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","2020-03-23","Aldesleukin",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT01959698","Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma","2020-06-01","Carboplatin",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT02650986","Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1","2021-03-04","Cyclophosphamide",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT02334865","SVN53-67\u002FM57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy","2022-09-16","Incomplete Freund's Adjuvant",{"nctId":64,"briefTitle":65,"date":66,"intervention":57},"NCT03192397","Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","2023-08-21",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT04032418","Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer","2025-03-14","Pembrolizumab",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04269213","CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old","2025-04-10","Liposome-encapsulated Daunorubicin-Cytarabine",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT02955290","CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer","2025-05-23","Nivolumab",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT06011772","EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","2026-02-05","Recombinant Human EGF-rP64K\u002FMontanide ISA 51 Vaccine",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,126,432,589,1028,1169,1270,1319,1378,1437,1530,1643,1733,1780,1806,1832,1854,1876,1993,2126,2177,2235,2273,2347,2429,2467,2514,2612,2638,2660,2678,2696,2714,2732,2756,2774,2792,2810,2828,2846,2873,2898,2916,2938,2956,2974,2992,3010,3028,3046,3064,3082,3105,3266,3431,3469,3508,3534,3593,3643,3690,3716,3745,3767,3785,3809,3827,3845,3869,3887,3905,3923,3941,3966,3984,4008,4026,4056,4086,4104,4134,4152,4170,4188,4206,4270,4316,4338,4365,4387,4515,4589,4627,4662,4701,4741,4771,4809,4846,4914,4951,4980,5012,5038,5072,5112,5138,5164,5199,5235,5262,5288,5315,5342,5364,5386,5416,5443,5465,5487,5517,5556,5578,5596,5614,5647,5665,5683,5706,5732,5750,5775,5793,5811,5835,5853,5882,5900,5918,5945,5963,5981,5999,6017,6039,6057,6075,6097,6120,6138,6156,6182,6207,6240,6258,6280,6308,6326,6351,6369,6387,6405,6423,6441,6459,6477,6495,6513,6531,6549,6575,6593,6611,6629,6651,6673,6691,6709,6727,6757,6775,6802,6834,6856,6887,6911,6929,6947,6970,6991,7014,7032,7055,7077,7095,7113,7131,7149,7171,7189,7207,7225,7248,7266,7284,7306,7324,7342,7360,7378,7396,7425,7443,7461,7484,7502,7520,7544,7562,7580,7606,7624,7642,7660,7691,7709,7732,7750,7768,7789,7807,7825,7851,7869,7895,7926,7953,7971,8045,8107,8161,8238,8284,8326,8356,8388,8420,8467,8507,8533,8559,8590,8624,8646,8682,8704,8726,8760,8782,8823,8851,8873,8906,8927,8949,8973,8991,9009,9033,9056,9074,9098,9116,9139,9157,9179,9200,9223,9247,9265,9283],{"intervention":96,"totalTrials":97,"cells":98},"Therapeutic Testosterone",1,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":124},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[],{"trials":109,"activeCount":97,"soonestReadout":115},[110],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":123},"NCT06733350","Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance","RECRUITING",[92],"2029-01-15","2025-01-15",600,[119,120,121,122],"Localized Prostate Carcinoma","Stage I Prostate Cancer AJCC v8","Stage II Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8",[96],{"trials":125,"activeCount":101},[],{"intervention":71,"totalTrials":24,"cells":127},{"EARLY_PHASE1":128,"PHASE1":149,"PHASE2":151,"PHASE3":426,"PHASE4":428,"NA":430},{"trials":129,"activeCount":101},[130],{"nctId":131,"briefTitle":132,"status":133,"phases":134,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":145},"NCT03599453","Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer","COMPLETED",[88],"2020-09-02","2023-03-21","2019-01-09",8,[140,141,142,143,144],"Triple -Negative Breast Cancer","Estrogen Receptor Negative","HER2\u002FNeu Negative","Anatomic Stage IV Breast Cancer AJCC","Progesterone Receptor Negative",[146,147,148,71],"Celecoxib","Recombinant Interferon Alfa-2b","Rintatolimod",{"trials":150,"activeCount":101},[],{"trials":152,"activeCount":138,"soonestReadout":70},[153,177,192,206,232,244,258,282,300,313,320,331,344,362,374,393,414],{"nctId":154,"briefTitle":155,"status":113,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":172},"NCT05651594","Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma",[90],"2029-03-30","2023-03-07",40,[161,162,163,164,165,166,167,168,169,170,171],"Clinical Stage II Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Esophageal Adenocarcinoma AJCC v8","Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IV Esophageal Adenocarcinoma AJCC v8","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Locally Advanced Esophageal Adenocarcinoma","Locally Advanced Gastroesophageal Junction Adenocarcinoma","Metastatic Esophageal Adenocarcinoma","Metastatic Gastroesophageal Junction Adenocarcinoma","Unresectable Esophageal Adenocarcinoma","Unresectable Gastroesophageal Junction Adenocarcinoma",[173,174,175,71,176],"Fluorouracil","Leucovorin","Oxaliplatin","Propranolol Hydrochloride",{"nctId":178,"briefTitle":179,"status":113,"phases":180,"primaryCompletion":181,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":190},"NCT04348747","Dendritic Cell Vaccines Against Her2\u002FHer3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer",[90],"2027-06-15","2027-12-15","2022-12-19",23,[186,187,188,189],"Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Malignant Neoplasm in the Brain","Metastatic Triple-Negative Breast Carcinoma","Prognostic Stage IV Breast Cancer AJCC v8",[191,71],"Anti-HER2\u002FHER3 Dendritic Cell Vaccine",{"nctId":193,"briefTitle":194,"status":113,"phases":195,"primaryCompletion":196,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":204},"NCT06863402","Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype",[90],"2029-06-01","2030-06-01","2026-06-15",32,[201,202,203],"Richter Syndrome","Diffuse Large B-Cell Lymphoma","Chronic Lymphocytic Leukemia",[205,71],"Nemtabrutinib",{"nctId":207,"briefTitle":208,"status":113,"phases":209,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":213,"interventions":229},"NCT04919629","APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion",[90],"2028-04-30","2023-04-27",60,[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228],"Fallopian Tube Carcinosarcoma","Fallopian Tube Clear Cell Adenocarcinoma","Fallopian Tube Endometrioid Adenocarcinoma","Fallopian Tube Serous Adenocarcinoma","Ovarian Carcinosarcoma","Ovarian Clear Cell Adenocarcinoma","Ovarian Endometrioid Adenocarcinoma","Ovarian Serous Adenocarcinoma","Primary Peritoneal Carcinosarcoma","Primary Peritoneal Clear Cell Adenocarcinoma","Primary Peritoneal Endometrioid Adenocarcinoma","Primary Peritoneal Serous Adenocarcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma",[230,231,71],"Bevacizumab","Pegcetacoplan",{"nctId":233,"briefTitle":234,"status":235,"phases":236,"primaryCompletion":237,"completion":237,"start":238,"enrollment":101,"conditions":239,"interventions":242},"NCT05539365","Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer","WITHDRAWN",[90],"2027-02-01","2025-02-01",[240,186,188,241],"Anatomic Stage III Breast Cancer AJCC v8","Unresectable Triple-Negative Breast Carcinoma",[243,71],"Alpha-type-1 Polarized Dendritic Cells",{"nctId":245,"briefTitle":246,"status":235,"phases":247,"primaryCompletion":248,"completion":248,"start":249,"enrollment":101,"conditions":250,"interventions":256},"NCT05518032","Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)",[90],"2026-10-01","2024-10-01",[251,252,253,254,255],"Metastatic Microsatellite Stable Colorectal Carcinoma","Recurrent Colorectal Carcinoma","Stage III Colorectal Cancer AJCC v8","Stage IV Colorectal Cancer AJCC v8","Unresectable Colorectal Carcinoma",[71,257],"Therapeutic Autologous Dendritic Cells",{"nctId":78,"briefTitle":79,"status":259,"phases":260,"primaryCompletion":80,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":281},"ACTIVE_NOT_RECRUITING",[89,90],"2027-12-09","2016-12-22",51,[265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280],"Advanced Head and Neck Squamous Cell Carcinoma","Lung Non-Small Cell Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","PD-L1 Positive","Recurrent Head and Neck Squamous Cell Carcinoma","Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","Stage III Lung Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8","Unresectable Lung Non-Small Cell Carcinoma","Advanced Squamous Non-Small Cell Lung Carcinoma",[81,71,86],{"nctId":283,"briefTitle":284,"status":235,"phases":285,"primaryCompletion":286,"completion":287,"start":288,"enrollment":101,"conditions":289,"interventions":296},"NCT03935347","Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy",[90],"2022-05-01","2023-05-01","2019-06-20",[290,291,292,293,294,295],"Metastatic Bladder Urothelial Carcinoma","Metastatic Renal Pelvis Urothelial Carcinoma","Metastatic Ureter Urothelial Carcinoma","Metastatic Urethral Urothelial Carcinoma","Unresectable Renal Pelvis Urothelial Carcinoma","Unresectable Ureter Urothelial Carcinoma",[57,297,298,71,299,47],"Fludarabine","Fludarabine Phosphate","Autologous Tumor Infiltrating Lymphocytes LN-145",{"nctId":301,"briefTitle":302,"status":133,"phases":303,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":311},"NCT02713373","Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery",[89,90],"2020-07-28","2021-07-20","2016-08-05",45,[252,309,310],"Stage IVA Colorectal Cancer","Stage IVB Colorectal Cancer",[312,71],"Cetuximab",{"nctId":68,"briefTitle":69,"status":259,"phases":314,"primaryCompletion":70,"completion":315,"start":316,"enrollment":317,"conditions":318,"interventions":319},[90],"2026-06-14","2020-08-13",9,[266],[71],{"nctId":321,"briefTitle":322,"status":113,"phases":323,"primaryCompletion":324,"completion":324,"start":325,"enrollment":326,"conditions":327,"interventions":329},"NCT07017829","GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer",[90],"2028-12-01","2026-04-01",28,[328,267,271,276],"Advanced Lung Non-Small Cell Carcinoma",[330,71],"Anti-CFH Monoclonal Antibody GT103",{"nctId":332,"briefTitle":333,"status":133,"phases":334,"primaryCompletion":335,"completion":336,"start":337,"enrollment":159,"conditions":338,"interventions":343},"NCT02853318","Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[90],"2019-06-27","2021-06-30","2016-09-01",[215,216,339,217,219,220,340,221,225,226,227,228,341,342],"Fallopian Tube Mucinous Adenocarcinoma","Ovarian Mucinous Adenocarcinoma","Undifferentiated Fallopian Tube Carcinoma","Undifferentiated Ovarian Carcinoma",[230,57,71],{"nctId":345,"briefTitle":346,"status":235,"phases":347,"primaryCompletion":348,"completion":348,"start":349,"enrollment":101,"conditions":350,"interventions":361},"NCT04119830","Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer",[90],"2024-02-01","2022-02-01",[351,352,353,354,253,355,356,357,254,358,359,360,255],"Metastatic Colorectal Adenocarcinoma","Microsatellite Stable","Mismatch Repair Proficient","Refractory Colorectal Adenocarcinoma","Stage IIIA Colorectal Cancer AJCC v8","Stage IIIB Colorectal Cancer AJCC v8","Stage IIIC Colorectal Cancer AJCC v8","Stage IVA Colorectal Cancer AJCC v8","Stage IVB Colorectal Cancer AJCC v8","Stage IVC Colorectal Cancer AJCC v8",[71,148],{"nctId":363,"briefTitle":364,"status":365,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":372},"NCT05756166","Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer","TERMINATED",[89,90],"2025-04-08","2025-06-19","2024-02-16",5,[186,188,241],[146,373,71,148],"Interferon Alpha-2",{"nctId":375,"briefTitle":376,"status":133,"phases":377,"primaryCompletion":158,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":391},"NCT03211416","Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer",[89,90],"2025-08-15","2017-12-07",37,[382,383,384,385,386,387,388,389,390],"Advanced Adult Hepatocellular Carcinoma","Child-Pugh Class A","Stage III Hepatocellular Carcinoma","Stage IIIA Hepatocellular Carcinoma","Stage IIIB Hepatocellular Carcinoma","Stage IIIC Hepatocellular Carcinoma","Stage IV Hepatocellular Carcinoma","Stage IVA Hepatocellular Carcinoma","Stage IVB Hepatocellular Carcinoma",[71,392],"Sorafenib Tosylate",{"nctId":394,"briefTitle":395,"status":113,"phases":396,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":400,"interventions":412},"NCT05231122","Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer",[90],"2027-03-15","2024-03-12",80,[219,401,402,226,403,404,227,405,406,407,408,228,409,410,411],"Platinum-Sensitive Ovarian Carcinoma","Recurrent Endometrial Serous Adenocarcinoma","Recurrent Fallopian Tube Endometrioid Adenocarcinoma","Recurrent Fallopian Tube Serous Adenocarcinoma","Recurrent Ovarian Clear Cell Adenocarcinoma","Recurrent Ovarian Endometrioid Adenocarcinoma","Recurrent Ovarian Serous Adenocarcinoma","Recurrent Platinum-Resistant Ovarian Carcinoma","Recurrent Primary Peritoneal Clear Cell Adenocarcinoma","Recurrent Primary Peritoneal Endometrioid Adenocarcinoma","Recurrent Primary Peritoneal Serous Adenocarcinoma",[413,230,71],"Anti-CD40 Agonist Monoclonal Antibody CDX-1140",{"nctId":415,"briefTitle":416,"status":417,"phases":418,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":425},"NCT03384836","Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery","SUSPENDED",[89,90],"2027-05-31","2018-01-31",47,[423,424],"Stage IIIC Cutaneous Melanoma AJCC v7","Stage IV Cutaneous Melanoma AJCC v6 and v7",[71,176],{"trials":427,"activeCount":101},[],{"trials":429,"activeCount":101},[],{"trials":431,"activeCount":101},[],{"intervention":173,"totalTrials":33,"cells":433},{"EARLY_PHASE1":434,"PHASE1":446,"PHASE2":482,"PHASE3":583,"PHASE4":585,"NA":587},{"trials":435,"activeCount":97,"soonestReadout":85},[436],{"nctId":83,"briefTitle":84,"status":259,"phases":437,"primaryCompletion":85,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":443},[88],"2026-12-04","2023-12-18",2,[442],"Colo-rectal Cancer",[86,174,175,173,230,444,312,445],"Irinotecan","Panitumumbab",{"trials":447,"activeCount":101},[448,463,472],{"nctId":449,"briefTitle":450,"status":133,"phases":451,"primaryCompletion":452,"completion":453,"start":454,"enrollment":184,"conditions":455,"interventions":458},"NCT00537121","Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer",[89],"2012-10","2013-06","2006-11",[35,456,457],"Gastric Cancer","Liver Cancer",[459,460,461,462],"fluorouracil","irinotecan hydrochloride","leucovorin calcium","vorinostat",{"nctId":464,"briefTitle":465,"status":133,"phases":466,"primaryCompletion":467,"completion":468,"start":469,"conditions":470,"interventions":471},"NCT00024141","Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors",[89],"2002-09","2003-01","2001-05",[18],[459,460],{"nctId":473,"briefTitle":474,"status":365,"phases":475,"primaryCompletion":476,"completion":477,"start":478,"enrollment":184,"conditions":479,"interventions":480},"NCT00524186","Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer",[89],"2013-08","2016-04","2007-05",[35,456],[459,460,461,481],"sunitinib malate",{"trials":483,"activeCount":582,"soonestReadout":505},[484,488,501,512,530,542,568],{"nctId":154,"briefTitle":155,"status":113,"phases":485,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":486,"interventions":487},[90],[161,162,163,164,165,166,167,168,169,170,171],[173,174,175,71,176],{"nctId":489,"briefTitle":490,"status":365,"phases":491,"primaryCompletion":492,"completion":493,"start":494,"enrollment":36,"conditions":495,"interventions":498},"NCT01198548","High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer",[90],"2012-04","2012-06","2010-08",[496,497],"Stage IV Colon Cancer","Stage IV Rectal Cancer",[461,499,459,500],"bevacizumab","oxaliplatin",{"nctId":502,"briefTitle":503,"status":113,"phases":504,"primaryCompletion":505,"completion":505,"start":506,"enrollment":21,"conditions":507,"interventions":509},"NCT06821997","NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial",[90],"2027-03-01","2026-03-02",[508],"Borderline Resectable Pancreatic Ductal Adenocarcinoma",[173,510,511,175],"Irinotecan Sucrosofate","Leucovorin Calcium",{"nctId":513,"briefTitle":514,"status":365,"phases":515,"primaryCompletion":516,"completion":517,"start":518,"enrollment":33,"conditions":519,"interventions":528},"NCT03736720","Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin",[90],"2022-10-18","2024-08-26","2019-06-17",[520,521,522,523,524,525,526,527],"Locally Advanced Digestive System Neuroendocrine Carcinoma","Locally Advanced Pancreatic Neuroendocrine Carcinoma","Metastatic Digestive System Neuroendocrine Carcinoma","Metastatic Pancreatic Neuroendocrine Carcinoma","Refractory Digestive System Neuroendocrine Carcinoma","Refractory Pancreatic Neuroendocrine Carcinoma","Unresectable Digestive System Neuroendocrine Carcinoma","Unresectable Pancreatic Neuroendocrine Carcinoma",[173,174,529],"Liposomal Irinotecan",{"nctId":531,"briefTitle":532,"status":113,"phases":533,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":538,"interventions":541},"NCT07214298","Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma",[89,90],"2028-02-16","2028-10-01","2026-02-16",35,[539,540],"Metastatic Pancreatic Ductal Adenocarcinoma","Stage IV Pancreatic Cancer AJCC v8",[173,444,511,175,231],{"nctId":543,"briefTitle":544,"status":235,"phases":545,"primaryCompletion":546,"enrollment":101,"conditions":547,"interventions":565},"NCT02575508","Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer",[89,90],"2020-05",[548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564],"Colon Adenocarcinoma","Metastatic Pancreatic Adenocarcinoma","Pancreatic Adenocarcinoma","Pancreatic Ductal Adenocarcinoma","Rectal Adenocarcinoma","Stage III Pancreatic Cancer","Stage IIIA Colon Cancer","Stage IIIA Rectal Cancer","Stage IIIB Colon Cancer","Stage IIIB Rectal Cancer","Stage IIIC Colon Cancer","Stage IIIC Rectal Cancer","Stage IV Pancreatic Cancer","Stage IVA Colon Cancer","Stage IVA Rectal Cancer","Stage IVB Colon Cancer","Stage IVB Rectal Cancer",[173,566,175,567],"Irinotecan Hydrochloride","pan FGFR Kinase Inhibitor BGJ398",{"nctId":569,"briefTitle":570,"status":133,"phases":571,"primaryCompletion":572,"completion":573,"start":574,"enrollment":575,"conditions":576,"interventions":581},"NCT00942266","Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment",[90],"2011-05","2011-12","2009-07",58,[577,578,579,580,496,497],"Adenocarcinoma of the Colon","Adenocarcinoma of the Rectum","Recurrent Colon Cancer","Recurrent Rectal Cancer",[459,461,462],3,{"trials":584,"activeCount":101},[],{"trials":586,"activeCount":101},[],{"trials":588,"activeCount":101},[],{"intervention":57,"totalTrials":16,"cells":590},{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":697,"PHASE3":926,"PHASE4":960,"NA":962},{"trials":592,"activeCount":101},[],{"trials":594,"activeCount":440,"soonestReadout":46},[595,618,626,640,668,680],{"nctId":596,"briefTitle":597,"status":365,"phases":598,"primaryCompletion":599,"completion":599,"start":600,"enrollment":97,"conditions":601,"interventions":616},"NCT06343376","Genetically Engineered Cells (EGFRt\u002F19-28z\u002FIL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies",[89],"2025-01-03","2024-11-26",[602,603,604,605,606,607,608,609,610,611,612,613,614,615],"Recurrent Chronic Lymphocytic Leukemia","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Follicular Lymphoma","Recurrent High Grade B-Cell Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Transformed Chronic Lymphocytic Leukemia","Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Refractory Chronic Lymphocytic Leukemia","Refractory Diffuse Large B-Cell Lymphoma","Refractory Follicular Lymphoma","Refractory High Grade B-Cell Lymphoma","Refractory Mantle Cell Lymphoma","Refractory Transformed Chronic Lymphocytic Leukemia","Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",[57,617,298],"EGFRt\u002F19-28z\u002FIL-12 CAR T-lymphocytes",{"nctId":44,"briefTitle":45,"status":259,"phases":619,"primaryCompletion":46,"completion":620,"start":621,"enrollment":317,"conditions":622,"interventions":623},[89],"2032-03-23","2017-12-08",[226,227,228],[47,57,624,625],"Decitabine","Genetically Engineered NY-ESO-1-specific T Lymphocytes",{"nctId":627,"briefTitle":628,"status":133,"phases":629,"primaryCompletion":630,"completion":631,"start":632,"enrollment":21,"conditions":633,"interventions":635},"NCT00003974","Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma",[89],"1998-06","2000-11","1997-08",[20,634],"Malignant Mesothelioma",[636,637,638,639],"lung tumor associated antigen","DetoxPC","chemotherapy","cyclophosphamide",{"nctId":641,"briefTitle":642,"status":133,"phases":643,"primaryCompletion":644,"completion":645,"start":646,"enrollment":317,"conditions":647,"interventions":664},"NCT04081389","Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer",[89],"2022-05-24","2023-02-27","2019-12-06",[648,649,650,651,652,653,654,655,141,142,144,656,657,658,659,660,661,662,663],"Anatomic Stage 0 Breast Cancer AJCC v8","Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage IA Breast Cancer AJCC v8","Anatomic Stage IB Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Early-Stage Breast Carcinoma","Prognostic Stage 0 Breast Cancer AJCC v8","Prognostic Stage I Breast Cancer AJCC v8","Prognostic Stage IA Breast Cancer AJCC v8","Prognostic Stage IB Breast Cancer AJCC v8","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Triple-Negative Breast Carcinoma",[146,57,665,666,667,147,148],"Doxorubicin","Doxorubicin Hydrochloride","Paclitaxel",{"nctId":669,"briefTitle":670,"status":113,"phases":671,"primaryCompletion":672,"completion":672,"start":506,"enrollment":673,"conditions":674,"interventions":677},"NCT06871410","Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",[89],"2028-04-01",26,[675,676],"Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia",[678,57,298,679],"Autologous Anti-CD83 CAR T-cells","Hydroxyurea",{"nctId":681,"briefTitle":682,"status":417,"phases":683,"primaryCompletion":684,"completion":685,"start":686,"enrollment":687,"conditions":688,"interventions":695},"NCT06968195","Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma",[89],"2028-05-30","2029-05-30","2026-05-01",24,[689,690,691,692,693,694],"Advanced Hepatocellular Carcinoma","Metastatic Hepatocellular Carcinoma","Recurrent Hepatocellular Carcinoma","Refractory Hepatocellular Carcinoma","Stage III Hepatocellular Carcinoma AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8",[696,57,297],"Anti-GPC3-CAR Autologous T Lymphocytes",{"trials":698,"activeCount":440,"soonestReadout":56},[699,715,759,763,779,797,811,815,834,845,859,917],{"nctId":700,"briefTitle":701,"status":133,"phases":702,"primaryCompletion":703,"completion":703,"start":704,"enrollment":21,"conditions":705,"interventions":709},"NCT00003270","Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer",[90],"2017-10-16","1997-09-04",[706,15,23,707,708],"Graft Versus Host Disease","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes",[710,711,712,639,713,714],"anti-thymocyte globulin","filgrastim","busulfan","cyclosporine","methylprednisolone",{"nctId":716,"briefTitle":717,"status":365,"phases":718,"primaryCompletion":719,"completion":719,"start":379,"enrollment":720,"conditions":721,"interventions":758},"NCT03333486","Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer",[90],"2023-08-28",31,[722,723,724,725,726,727,728,729,730,731,732,203,733,734,735,736,737,738,739,740,741,742,743,744,745,746,747,748,749,750,751,752,753,754,755,756,757],"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Acute Leukemia in Remission","Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Acute Myeloid Leukemia With FLT3\u002FITD Mutation","Acute Myeloid Leukemia With Gene Mutations","Aplastic Anemia","B-Cell Non-Hodgkin Lymphoma","CD40 Ligand Deficiency","Chronic Granulomatous Disease","Chronic Leukemia in Remission","Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Chronic Myelomonocytic Leukemia","Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Congenital Amegakaryocytic Thrombocytopenia","Congenital Neutropenia","Congenital Pure Red Cell Aplasia","Glanzmann Thrombasthenia","Immunodeficiency Syndrome","Myelodysplastic Syndrome","Myelofibrosis","Myeloproliferative Neoplasm","Paroxysmal Nocturnal Hemoglobinuria","Plasma Cell Myeloma","Polycythemia Vera","Recurrent Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","Secondary Acute Myeloid Leukemia","Secondary Myelodysplastic Syndrome","Severe Aplastic Anemia","Shwachman-Diamond Syndrome","Sickle Cell Disease","T-Cell Non-Hodgkin Lymphoma","Thalassemia","Waldenstrom Macroglobulinemia","Wiskott-Aldrich Syndrome",[57,298],{"nctId":283,"briefTitle":284,"status":235,"phases":760,"primaryCompletion":286,"completion":287,"start":288,"enrollment":101,"conditions":761,"interventions":762},[90],[290,291,292,293,294,295],[57,297,298,71,299,47],{"nctId":64,"briefTitle":65,"status":259,"phases":764,"primaryCompletion":66,"completion":765,"start":766,"enrollment":537,"conditions":767,"interventions":775},[89,90],"2027-05-21","2017-08-09",[768,769,770,771,706,772,773,741,743,774,745,751,756],"Acute Myeloid Leukemia in Remission","Adult Acute Lymphoblastic Leukemia in Complete Remission","Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission","Chronic Myelomonocytic Leukemia in Remission","Hodgkin Lymphoma","Minimal Residual Disease","Non-Hodgkin Lymphoma",[57,298,776,777,778],"Melphalan Hydrochloride","Mycophenolate Mofetil","Sirolimus",{"nctId":780,"briefTitle":781,"status":133,"phases":782,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":786,"interventions":790},"NCT00053989","NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer\u002FDisorders",[90],"2018-07-19","2002-01-29",41,[787,15,23,707,708,788,789,728],"Chronic Myeloproliferative Disorders","Myelodysplastic\u002FMyeloproliferative Diseases","Fanconi Anemia",[710,791,792,793,639,794,714,795,796],"graft-versus-tumor induction therapy","sargramostim","therapeutic allogeneic lymphocytes","fludarabine phosphate","mycophenolate mofetil","tacrolimus",{"nctId":798,"briefTitle":799,"status":133,"phases":800,"primaryCompletion":801,"completion":802,"start":803,"enrollment":804,"conditions":805,"interventions":807},"NCT00003877","Peripheral Stem Cell Transplantation With or Without Stromagen Following Chemotherapy in Treating Women With Metastatic Breast Cancer",[89,90],"2000-02","2000-12","1998-09",30,[806],"Breast Cancer",[711,808,639,809,810],"carboplatin","paclitaxel","thiotepa",{"nctId":332,"briefTitle":333,"status":133,"phases":812,"primaryCompletion":335,"completion":336,"start":337,"enrollment":159,"conditions":813,"interventions":814},[90],[215,216,339,217,219,220,340,221,225,226,227,228,341,342],[230,57,71],{"nctId":816,"briefTitle":817,"status":133,"phases":818,"primaryCompletion":819,"completion":820,"start":821,"enrollment":380,"conditions":822,"interventions":828},"NCT01527149","Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma",[90],"2018-04-26","2024-01-11","2011-12-06",[823,824,825,826,827],"Stage I Mantle Cell Lymphoma","Stage II Contiguous Mantle Cell Lymphoma","Stage II Non-Contiguous Mantle Cell Lymphoma","Stage III Mantle Cell Lymphoma","Stage IV Mantle Cell Lymphoma",[57,829,830,666,831,832,833],"Cytarabine","Dexamethasone","Methotrexate","Ofatumumab","Vincristine Sulfate",{"nctId":835,"briefTitle":836,"status":133,"phases":837,"primaryCompletion":838,"completion":838,"start":839,"enrollment":840,"conditions":841,"interventions":843},"NCT00003662","Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases",[90],"2001-01","1998-08",90,[706,15,708,842],"Thymic Carcinoma",[710,712,639,713,844,714],"melphalan",{"nctId":846,"briefTitle":847,"status":133,"phases":848,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":853,"interventions":856},"NCT00060255","High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors",[90],"2006-08","2013-02","1991-12",451,[806,15,23,707,854,18,855],"Testicular Germ Cell Tumor","Unspecified Childhood Solid Tumor, Protocol Specific",[712,808,857,639,858,844,810],"carmustine","etoposide",{"nctId":54,"briefTitle":55,"status":259,"phases":860,"primaryCompletion":56,"completion":861,"start":862,"enrollment":863,"conditions":864,"interventions":915},[89,90],"2032-07-14","2017-07-14",15,[865,866,867,868,869,870,871,872,873,874,875,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,891,892,893,894,895,896,897,898,899,900,901,902,903,904,905,906,907,908,909,910,911,912,913,914],"Advanced Fallopian Tube Carcinoma","Advanced Malignant Solid Neoplasm","Advanced Melanoma","Advanced Ovarian Carcinoma","Advanced Primary Peritoneal Carcinoma","Advanced Synovial Sarcoma","Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Metastatic Fallopian Tube Carcinoma","Metastatic Melanoma","Metastatic Ovarian Carcinoma","Metastatic Primary Peritoneal Carcinoma","Metastatic Synovial Sarcoma","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Platinum-Resistant Fallopian Tube Carcinoma","Platinum-Resistant Ovarian Carcinoma","Platinum-Resistant Primary Peritoneal Carcinoma","Stage III Fallopian Tube Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Primary Peritoneal Cancer AJCC v8","Stage IIIA Fallopian Tube Cancer AJCC v8","Stage IIIA Ovarian Cancer AJCC v8","Stage IIIA Primary Peritoneal Cancer AJCC v8","Stage IIIA1 Fallopian Tube Cancer AJCC v8","Stage IIIA1 Ovarian Cancer AJCC v8","Stage IIIA2 Fallopian Tube Cancer AJCC v8","Stage IIIA2 Ovarian Cancer AJCC v8","Stage IIIB Fallopian Tube Cancer AJCC v8","Stage IIIB Ovarian Cancer AJCC v8","Stage IIIB Primary Peritoneal Cancer AJCC v8","Stage IIIC Fallopian Tube Cancer AJCC v8","Stage IIIC Ovarian Cancer AJCC v8","Stage IIIC Primary Peritoneal Cancer AJCC v8","Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Primary Peritoneal Cancer AJCC v8","Stage IVA Fallopian Tube Cancer AJCC v8","Stage IVA Ovarian Cancer AJCC v8","Stage IVA Primary Peritoneal Cancer AJCC v8","Stage IVB Fallopian Tube Cancer AJCC v8","Stage IVB Ovarian Cancer AJCC v8","Stage IVB Primary Peritoneal Cancer AJCC v8","Unresectable Melanoma","Unresectable Ovarian Carcinoma","Unresectable Synovial Sarcoma",[57,624,916],"TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes",{"nctId":918,"briefTitle":919,"status":133,"phases":920,"primaryCompletion":921,"completion":922,"start":468,"conditions":923,"interventions":925},"NCT00055653","Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders",[90],"2003-09","2005-09",[15,23,708,924],"Myelodysplastic-Myeloproliferative Diseases",[710,711,712,639,713,794,844,714],{"trials":927,"activeCount":101},[928,938,951],{"nctId":929,"briefTitle":930,"status":133,"phases":931,"primaryCompletion":932,"completion":932,"start":933,"enrollment":934,"conditions":935,"interventions":937},"NCT00003816","Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer",[90,91],"2019-07-12","1998-10-19",361,[787,15,23,708,788,936,18,855],"Nonmalignant Neoplasm",[710,712,808,639,858,794,844,810],{"nctId":939,"briefTitle":940,"status":133,"phases":941,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":946,"interventions":947},"NCT00002945","High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia",[91],"2001-08","2011-08","1996-12",61,[15],[948,711,639,949,858,950,844],"aldesleukin","cytarabine","idarubicin",{"nctId":952,"briefTitle":953,"status":133,"phases":954,"primaryCompletion":955,"completion":955,"start":803,"enrollment":956,"conditions":957,"interventions":958},"NCT00004474","Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia",[91],"2007-08",224,[728],[959,57],"Anti-thymocyte globulin",{"trials":961,"activeCount":101},[],{"trials":963,"activeCount":101},[964],{"nctId":965,"briefTitle":966,"status":133,"phases":967,"primaryCompletion":968,"completion":968,"start":969,"enrollment":970,"conditions":971,"interventions":1027},"NCT00536601","High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors",[93],"2018-07-09","2006-06-29",174,[972,973,974,975,976,977,978,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998,999,1000,1001,1002,1003,1004,1005,1006,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,606,1018,1019,1020,1021,609,1022,1023,1024,1025,18,855,1026],"Adult Acute Lymphoblastic Leukemia in Remission","Adult Acute Myeloid Leukemia in Remission","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Adult Nasal Type Extranodal NK\u002FT-cell Lymphoma","Childhood Acute Lymphoblastic Leukemia in Remission","Childhood Acute Myeloid Leukemia in Remission","Childhood Burkitt Lymphoma","Childhood Diffuse Large Cell Lymphoma","Childhood Immunoblastic Large Cell Lymphoma","Childhood Nasal Type Extranodal NK\u002FT-cell Lymphoma","Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor (PNET)","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Hepatosplenic T-cell Lymphoma","Intraocular Lymphoma","Nodal Marginal Zone B-cell Lymphoma","Peripheral T-cell Lymphoma","Plasma Cell Neoplasm","Primary Systemic Amyloidosis","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Adult Acute Myeloid Leukemia","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Hodgkin Lymphoma","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood Acute Myeloid Leukemia","Recurrent Childhood Anaplastic Large Cell Lymphoma","Recurrent Childhood Grade III Lymphomatoid Granulomatosis","Recurrent Childhood Large Cell Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent Childhood Small Noncleaved Cell Lymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Ewing Sarcoma\u002FPeripheral Primitive Neuroectodermal Tumor","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Malignant Testicular Germ Cell Tumor","Recurrent Marginal Zone Lymphoma","Recurrent Neuroblastoma","Recurrent Small Lymphocytic Lymphoma","Recurrent\u002FRefractory Childhood Hodgkin Lymphoma","Refractory Multiple Myeloma","Regional Neuroblastoma","Splenic Marginal Zone Lymphoma","Testicular Lymphoma","Waldenström Macroglobulinemia",[858,639,857,844,712,808,810],{"intervention":175,"totalTrials":30,"cells":1029},{"EARLY_PHASE1":1030,"PHASE1":1036,"PHASE2":1038,"PHASE3":1154,"PHASE4":1156,"NA":1158},{"trials":1031,"activeCount":97,"soonestReadout":85},[1032],{"nctId":83,"briefTitle":84,"status":259,"phases":1033,"primaryCompletion":85,"completion":438,"start":439,"enrollment":440,"conditions":1034,"interventions":1035},[88],[442],[86,174,175,173,230,444,312,445],{"trials":1037,"activeCount":101},[],{"trials":1039,"activeCount":582,"soonestReadout":505},[1040,1044,1054,1058,1082,1091,1095,1099,1108,1115,1119,1127],{"nctId":154,"briefTitle":155,"status":113,"phases":1041,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":1042,"interventions":1043},[90],[161,162,163,164,165,166,167,168,169,170,171],[173,174,175,71,176],{"nctId":1045,"briefTitle":1046,"status":365,"phases":1047,"primaryCompletion":1048,"start":1049,"enrollment":36,"conditions":1050,"interventions":1051},"NCT00087334","Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer",[89,90],"2005-11","2004-01",[29],[1052,1053,500],"capecitabine","gefitinib",{"nctId":489,"briefTitle":490,"status":365,"phases":1055,"primaryCompletion":492,"completion":493,"start":494,"enrollment":36,"conditions":1056,"interventions":1057},[90],[496,497],[461,499,459,500],{"nctId":1059,"briefTitle":1060,"status":133,"phases":1061,"primaryCompletion":1062,"completion":1063,"start":1064,"enrollment":16,"conditions":1065,"interventions":1080},"NCT04097028","Use of Trifluridine\u002FTipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma",[90],"2022-12-16","2025-02-05","2019-12-20",[1066,1067,162,163,1068,1069,1070,1071,1072,1073,1074,1075,1076,1077,1078,1079],"Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8","Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage III Esophageal Adenocarcinoma AJCC v8","Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8","Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",[1081,175],"Trifluridine and Tipiracil Hydrochloride",{"nctId":1083,"briefTitle":1084,"status":133,"phases":1085,"primaryCompletion":452,"start":454,"enrollment":785,"conditions":1086,"interventions":1087},"NCT00470184","Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer",[90],[35],[1052,500,1088,1089,1090],"gene expression analysis","microarray analysis","reverse transcriptase-polymerase chain reaction",{"nctId":502,"briefTitle":503,"status":113,"phases":1092,"primaryCompletion":505,"completion":505,"start":506,"enrollment":21,"conditions":1093,"interventions":1094},[90],[508],[173,510,511,175],{"nctId":531,"briefTitle":532,"status":113,"phases":1096,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":1097,"interventions":1098},[89,90],[539,540],[173,444,511,175,231],{"nctId":1100,"briefTitle":1101,"status":365,"phases":1102,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":370,"conditions":1106,"interventions":1107},"NCT00625183","Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma",[90],"2009-10","2009-12","2008-03",[29],[1052,500],{"nctId":1109,"briefTitle":1110,"status":133,"phases":1111,"primaryCompletion":478,"completion":1112,"start":921,"enrollment":380,"conditions":1113,"interventions":1114},"NCT00086931","Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum",[89,90],"2010-05",[29],[1052,500],{"nctId":543,"briefTitle":544,"status":235,"phases":1116,"primaryCompletion":546,"enrollment":101,"conditions":1117,"interventions":1118},[89,90],[548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564],[173,566,175,567],{"nctId":1120,"briefTitle":1121,"status":365,"phases":1122,"primaryCompletion":1123,"start":1124,"conditions":1125,"interventions":1126},"NCT00093652","Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer",[89,90],"2006-05","2003-05",[35],[1053,500],{"nctId":1128,"briefTitle":1129,"status":133,"phases":1130,"primaryCompletion":1131,"completion":1132,"start":1133,"enrollment":537,"conditions":1134,"interventions":1152},"NCT01178944","Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer",[90],"2015-01","2015-11","2010-09",[1135,1136,1137,1138,1139,1140,1141,1142,1143,1144,1145,1146,1147,1148,1149,1150,1151],"Adenocarcinoma of the Gastroesophageal Junction","Esophageal Undifferentiated Carcinoma","Gastric Adenocarcinoma","Gastric Squamous Cell Carcinoma","Recurrent Esophageal Adenocarcinoma","Recurrent Esophageal Squamous Cell Carcinoma","Recurrent Gastric Carcinoma","Stage IIIB Esophageal Adenocarcinoma","Stage IIIB Esophageal Squamous Cell Carcinoma","Stage IIIB Gastric Cancer","Stage IIIC Esophageal Adenocarcinoma","Stage IIIC Esophageal Squamous Cell Carcinoma","Stage IIIC Gastric Cancer","Stage IV Esophageal Adenocarcinoma","Stage IV Esophageal Squamous Cell Carcinoma","Stage IV Gastric Cancer","Undifferentiated Gastric Carcinoma",[175,1153],"Pralatrexate",{"trials":1155,"activeCount":101},[],{"trials":1157,"activeCount":101},[],{"trials":1159,"activeCount":101},[1160],{"nctId":1161,"briefTitle":1162,"status":133,"phases":1163,"primaryCompletion":1164,"completion":1165,"start":1166,"conditions":1167,"interventions":1168},"NCT00040820","Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer",[93],"2003-08","2004-03","2002-01",[29],[500],{"intervention":230,"totalTrials":36,"cells":1170},{"EARLY_PHASE1":1171,"PHASE1":1177,"PHASE2":1179,"PHASE3":1256,"PHASE4":1258,"NA":1260},{"trials":1172,"activeCount":97,"soonestReadout":85},[1173],{"nctId":83,"briefTitle":84,"status":259,"phases":1174,"primaryCompletion":85,"completion":438,"start":439,"enrollment":440,"conditions":1175,"interventions":1176},[88],[442],[86,174,175,173,230,444,312,445],{"trials":1178,"activeCount":101},[],{"trials":1180,"activeCount":582,"soonestReadout":1245},[1181,1209,1213,1222,1226,1237,1241,1252],{"nctId":1182,"briefTitle":1183,"status":133,"phases":1184,"primaryCompletion":1185,"completion":1185,"start":1186,"enrollment":1187,"conditions":1188,"interventions":1208},"NCT04109924","TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study",[90],"2024-09-05","2019-12-27",42,[1189,1190,1191,1192,1193,1194,1195,253,1196,1197,355,356,1198,1199,357,1200,358,1201,1202,359,1203,1204,360,1205,1206,255,1207],"Advanced Colorectal Carcinoma","Metastatic Colon Adenocarcinoma","Metastatic Rectal Adenocarcinoma","Recurrent Colon Adenocarcinoma","Recurrent Colorectal Adenocarcinoma","Recurrent Rectal Adenocarcinoma","Stage III Colon Cancer AJCC v8","Stage III Rectal Cancer AJCC v8","Stage IIIA Colon Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Colon Cancer AJCC v8","Stage IV Colon Cancer AJCC v8","Stage IVA Rectal Cancer AJCC v8","Stage IVB Colon Cancer AJCC v8","Stage IVB Rectal Cancer AJCC v8","Stage IVC Colon Cancer AJCC v8","Stage IVC Rectal Cancer AJCC v8","Unresectable Colon Adenocarcinoma","Unresectable Rectal Adenocarcinoma",[444,230,1081],{"nctId":207,"briefTitle":208,"status":113,"phases":1210,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":1211,"interventions":1212},[90],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228],[230,231,71],{"nctId":1214,"briefTitle":1215,"status":365,"phases":1216,"primaryCompletion":1217,"start":1218,"enrollment":1219,"conditions":1220,"interventions":1221},"NCT00107315","Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer",[90],"2008-06","2004-07",16,[29],[499,1052],{"nctId":489,"briefTitle":490,"status":365,"phases":1223,"primaryCompletion":492,"completion":493,"start":494,"enrollment":36,"conditions":1224,"interventions":1225},[90],[496,497],[461,499,459,500],{"nctId":1227,"briefTitle":1228,"status":133,"phases":1229,"primaryCompletion":1230,"start":1231,"enrollment":1232,"conditions":1233,"interventions":1235},"NCT00100815","Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer",[90],"2008-08","2004-08",50,[1234],"Pancreatic Cancer",[499,1052,1236],"gemcitabine hydrochloride",{"nctId":332,"briefTitle":333,"status":133,"phases":1238,"primaryCompletion":335,"completion":336,"start":337,"enrollment":159,"conditions":1239,"interventions":1240},[90],[215,216,339,217,219,220,340,221,225,226,227,228,341,342],[230,57,71],{"nctId":1242,"briefTitle":1243,"status":259,"phases":1244,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":263,"conditions":1247,"interventions":1250},"NCT01684397","Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer",[89,90],"2026-08-20","2012-11-21",[1248,1249],"Clear Cell Renal Cell Carcinoma","Stage IV Renal Cell Cancer",[230,1251],"Pazopanib Hydrochloride",{"nctId":394,"briefTitle":395,"status":113,"phases":1253,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":1254,"interventions":1255},[90],[219,401,402,226,403,404,227,405,406,407,408,228,409,410,411],[413,230,71],{"trials":1257,"activeCount":101},[],{"trials":1259,"activeCount":101},[],{"trials":1261,"activeCount":101},[1262],{"nctId":1263,"briefTitle":1264,"status":235,"phases":1265,"primaryCompletion":1266,"start":1267,"enrollment":101,"conditions":1268,"interventions":1269},"NCT00524069","Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery",[93],"2007-11","2007-01",[1234],[499,1052,1236],{"intervention":86,"totalTrials":1271,"cells":1272},4,{"EARLY_PHASE1":1273,"PHASE1":1294,"PHASE2":1296,"PHASE3":1313,"PHASE4":1315,"NA":1317},{"trials":1274,"activeCount":97,"soonestReadout":85},[1275,1290],{"nctId":1276,"briefTitle":1277,"status":133,"phases":1278,"primaryCompletion":1279,"completion":1280,"start":1281,"enrollment":21,"conditions":1282,"interventions":1289},"NCT04298606","A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence",[88],"2025-12-05","2026-02-06","2021-11-22",[1283,266,1284,1285,1286,1287,1288,272],"Chronic Obstructive Pulmonary Disease","Pneumonia","Stage IB Lung Cancer AJCC v8","Stage II Lung Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8","Stage IIB Lung Cancer AJCC v8",[86],{"nctId":83,"briefTitle":84,"status":259,"phases":1291,"primaryCompletion":85,"completion":438,"start":439,"enrollment":440,"conditions":1292,"interventions":1293},[88],[442],[86,174,175,173,230,444,312,445],{"trials":1295,"activeCount":101},[],{"trials":1297,"activeCount":440,"soonestReadout":80},[1298,1302],{"nctId":78,"briefTitle":79,"status":259,"phases":1299,"primaryCompletion":80,"completion":261,"start":262,"enrollment":263,"conditions":1300,"interventions":1301},[89,90],[265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280],[81,71,86],{"nctId":1303,"briefTitle":1304,"status":1305,"phases":1306,"primaryCompletion":196,"completion":196,"start":1307,"enrollment":1308,"conditions":1309,"interventions":1310},"NCT07543172","CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer","NOT_YET_RECRUITING",[90],"2026-06-01",29,[328,271,276],[1311,86,1312],"Adagrasib","Sotorasib",{"trials":1314,"activeCount":101},[],{"trials":1316,"activeCount":101},[],{"trials":1318,"activeCount":101},[],{"intervention":1320,"totalTrials":1271,"cells":1321},"Carfilzomib",{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1359,"PHASE3":1372,"PHASE4":1374,"NA":1376},{"trials":1323,"activeCount":101},[],{"trials":1325,"activeCount":440,"soonestReadout":51},[1326,1340,1350],{"nctId":49,"briefTitle":50,"status":259,"phases":1327,"primaryCompletion":51,"completion":1328,"start":1329,"enrollment":1308,"conditions":1330,"interventions":1336},[89],"2026-12-01","2014-04-17",[1331,603,610,1332,1333,1334,1335],"CD20 Positive","Stage I Diffuse Large B-Cell Lymphoma","Stage II Diffuse Large B-Cell Lymphoma","Stage III Diffuse Large B-Cell Lymphoma","Stage IV Diffuse Large B-Cell Lymphoma",[52,1320,1337,1338,1339],"Etoposide","Ifosfamide","Rituximab",{"nctId":1341,"briefTitle":1342,"status":235,"phases":1343,"primaryCompletion":1344,"completion":1344,"start":325,"enrollment":101,"conditions":1345,"interventions":1347},"NCT07082270","Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed\u002FRefractory Multiple Myeloma",[89],"2028-02-01",[1346,1022],"Recurrent Multiple Myeloma",[1320,1348,830,1349],"Daratumumab and Recombinant Human Hyaluronidase","Selvigaltin",{"nctId":1351,"briefTitle":1352,"status":113,"phases":1353,"primaryCompletion":1354,"completion":1355,"start":75,"enrollment":863,"conditions":1356,"interventions":1357},"NCT06622005","SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",[89],"2027-04-10","2030-04-10",[1346,1022],[1358,1348,1320,830],"Cxcr1\u002F2 Inhibitor SX-682",{"trials":1360,"activeCount":97,"soonestReadout":1365},[1361],{"nctId":1362,"briefTitle":1363,"status":113,"phases":1364,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":326,"conditions":1368,"interventions":1370},"NCT06627751","Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease",[90],"2027-05-01","2030-05-01","2025-05-01",[1369,1346,1022],"Extramedullary Disease in Multiple Myeloma",[1371,1320,830],"Mezigdomide",{"trials":1373,"activeCount":101},[],{"trials":1375,"activeCount":101},[],{"trials":1377,"activeCount":101},[],{"intervention":1379,"totalTrials":1271,"cells":1380},"SVN53-67\u002FM57-KLH Peptide Vaccine",{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1406,"PHASE3":1431,"PHASE4":1433,"NA":1435},{"trials":1382,"activeCount":101},[],{"trials":1384,"activeCount":97,"soonestReadout":61},[1385,1394],{"nctId":59,"briefTitle":60,"status":259,"phases":1386,"primaryCompletion":61,"completion":1387,"start":1388,"enrollment":24,"conditions":1389,"interventions":1391},[89],"2026-12-19","2017-04-13",[1390,745],"Partial Response of Multiple Myeloma or Plasma Cell Leukemia",[62,1392,1393,1379],"Lenalidomide","Sargramostim",{"nctId":1395,"briefTitle":1396,"status":133,"phases":1397,"primaryCompletion":1398,"completion":70,"start":518,"enrollment":1399,"conditions":1400,"interventions":1404},"NCT03879694","Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors",[89],"2025-02-15",19,[1401,1402,1403],"Lung Atypical Carcinoid Tumor","Lung Typical Carcinoid Tumor","Metastatic Pancreatic Neuroendocrine Tumor",[62,1405,1393,1379],"Octreotide Acetate",{"trials":1407,"activeCount":440,"soonestReadout":41},[1408,1422],{"nctId":1409,"briefTitle":1410,"status":113,"phases":1411,"primaryCompletion":1412,"completion":1413,"start":1414,"enrollment":212,"conditions":1415,"interventions":1419},"NCT06202066","Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas",[90],"2027-10-15","2028-10-15","2026-07-15",[1416,1417,32,1418],"Digestive System Neuroendocrine Neoplasm","Lung Neuroendocrine Neoplasm","Pancreatic Neuroendocrine Neoplasm",[1420,1393,1379,1421],"Incomplete Freund''s Adjuvant","Temozolomide",{"nctId":39,"briefTitle":40,"status":259,"phases":1423,"primaryCompletion":41,"completion":1424,"start":1425,"enrollment":1426,"conditions":1427,"interventions":1430},[90],"2026-06-02","2015-05-04",66,[1428,1429],"Glioblastoma","Gliosarcoma",[42,1393,1379,1421],{"trials":1432,"activeCount":101},[],{"trials":1434,"activeCount":101},[],{"trials":1436,"activeCount":101},[],{"intervention":808,"totalTrials":33,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1467,"PHASE3":1516,"PHASE4":1522,"NA":1524},{"trials":1440,"activeCount":101},[],{"trials":1442,"activeCount":97,"soonestReadout":51},[1443,1447,1457],{"nctId":49,"briefTitle":50,"status":259,"phases":1444,"primaryCompletion":51,"completion":1328,"start":1329,"enrollment":1308,"conditions":1445,"interventions":1446},[89],[1331,603,610,1332,1333,1334,1335],[52,1320,1337,1338,1339],{"nctId":1448,"briefTitle":1449,"status":133,"phases":1450,"primaryCompletion":1218,"completion":1218,"start":1451,"enrollment":97,"conditions":1452,"interventions":1456},"NCT00053118","Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer",[89],"2002-03",[1453,23,1454,1455],"Brain and Central Nervous System Tumors","Neuroblastoma","Retinoblastoma",[711,808,858],{"nctId":1458,"briefTitle":1459,"status":133,"phases":1460,"primaryCompletion":1461,"completion":1462,"start":1463,"enrollment":687,"conditions":1464,"interventions":1465},"NCT00003294","Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer",[89],"1999-04","2004-05","1997-05",[15,23,18],[711,1466,808,809],"amifostine trihydrate",{"trials":1468,"activeCount":440,"soonestReadout":1473},[1469,1480,1490,1494,1505,1512],{"nctId":1470,"briefTitle":1471,"status":113,"phases":1472,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":326,"conditions":1475,"interventions":1477},"NCT04696575","Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer",[90],"2027-07-01","2021-07-02",[1476],"Extensive Stage Lung Small Cell Carcinoma",[1478,52,1337,1479],"Atezolizumab","Lamivudine",{"nctId":1481,"briefTitle":1482,"status":365,"phases":1483,"primaryCompletion":1484,"completion":1104,"start":1485,"enrollment":317,"conditions":1486,"interventions":1488},"NCT00470067","Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer",[90],"2008-05","2007-02",[1487],"Endometrial Cancer",[808,1489],"pegylated liposomal doxorubicin hydrochloride",{"nctId":798,"briefTitle":799,"status":133,"phases":1491,"primaryCompletion":801,"completion":802,"start":803,"enrollment":804,"conditions":1492,"interventions":1493},[89,90],[806],[711,808,639,809,810],{"nctId":1495,"briefTitle":1496,"status":113,"phases":1497,"primaryCompletion":1498,"completion":1498,"start":1499,"enrollment":1500,"conditions":1501,"interventions":1503},"NCT04682158","Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma",[90],"2029-04-01","2021-04-01",106,[1502],"Esophageal Adenocarcinoma",[52,1504,667],"Propranolol",{"nctId":1506,"briefTitle":1507,"status":365,"phases":1508,"primaryCompletion":494,"completion":1133,"start":1509,"enrollment":1219,"conditions":1510,"interventions":1511},"NCT00526890","Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",[90],"2006-10",[20],[808,809],{"nctId":846,"briefTitle":847,"status":133,"phases":1513,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":1514,"interventions":1515},[90],[806,15,23,707,854,18,855],[712,808,857,639,858,844,810],{"trials":1517,"activeCount":101},[1518],{"nctId":929,"briefTitle":930,"status":133,"phases":1519,"primaryCompletion":932,"completion":932,"start":933,"enrollment":934,"conditions":1520,"interventions":1521},[90,91],[787,15,23,708,788,936,18,855],[710,712,808,639,858,794,844,810],{"trials":1523,"activeCount":101},[],{"trials":1525,"activeCount":101},[1526],{"nctId":965,"briefTitle":966,"status":133,"phases":1527,"primaryCompletion":968,"completion":968,"start":969,"enrollment":970,"conditions":1528,"interventions":1529},[93],[972,973,974,975,976,977,978,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998,999,1000,1001,1002,1003,1004,1005,1006,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,606,1018,1019,1020,1021,609,1022,1023,1024,1025,18,855,1026],[858,639,857,844,712,808,810],{"intervention":792,"totalTrials":36,"cells":1531},{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1606,"PHASE3":1629,"PHASE4":1631,"NA":1633},{"trials":1533,"activeCount":101},[],{"trials":1535,"activeCount":97,"soonestReadout":61},[1536,1551,1566,1598,1602],{"nctId":1537,"briefTitle":1538,"status":133,"phases":1539,"primaryCompletion":1540,"completion":453,"start":1541,"enrollment":24,"conditions":1542,"interventions":1546},"NCT01673217","Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer",[89],"2011-10","2009-04",[1543,1544,1545],"Recurrent Fallopian Tube Cancer","Recurrent Ovarian Epithelial Cancer","Recurrent Primary Peritoneal Cavity Cancer",[1547,1548,1489,792,1549,1090,1550],"decitabine","NY-ESO-1 peptide vaccine","incomplete Freund's adjuvant","DNA methylation analysis",{"nctId":1552,"briefTitle":1553,"status":133,"phases":1554,"primaryCompletion":1555,"completion":1555,"start":1556,"enrollment":317,"conditions":1557,"interventions":1564},"NCT01250470","Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma",[89],"2014-05-29","2012-09-05",[1558,1559,1560,1561,1428,1429,1562,1563],"Anaplastic Astrocytoma","Anaplastic Oligoastrocytoma","Anaplastic Oligodendroglioma","Giant Cell Glioblastoma","Mixed Glioma","Recurrent Brain Neoplasm",[1565,1393],"Montanide ISA-51\u002FSurvivin Peptide Vaccine",{"nctId":1567,"briefTitle":1568,"status":133,"phases":1569,"primaryCompletion":1570,"completion":1570,"start":1571,"enrollment":1572,"conditions":1573,"interventions":1595},"NCT01536054","Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer",[89],"2015-04-21","2012-08-20",7,[1543,1544,1545,1574,1575,1576,1577,1578,1579,1580,1581,1582,1583,1584,1585,1586,1587,1588,1589,1590,1591,1592,1593,1594],"Stage IIA Fallopian Tube Cancer","Stage IIA Ovarian Epithelial Cancer","Stage IIA Primary Peritoneal Cavity Cancer","Stage IIB Fallopian Tube Cancer","Stage IIB Ovarian Epithelial Cancer","Stage IIB Primary Peritoneal Cavity Cancer","Stage IIC Fallopian Tube Cancer","Stage IIC Ovarian Epithelial Cancer","Stage IIC Primary Peritoneal Cavity Cancer","Stage IIIA Fallopian Tube Cancer","Stage IIIA Ovarian Epithelial Cancer","Stage IIIA Primary Peritoneal Cavity Cancer","Stage IIIB Fallopian Tube Cancer","Stage IIIB Ovarian Epithelial Cancer","Stage IIIB Primary Peritoneal Cavity Cancer","Stage IIIC Fallopian Tube Cancer","Stage IIIC Ovarian Epithelial Cancer","Stage IIIC Primary Peritoneal Cavity Cancer","Stage IV Fallopian Tube Cancer","Stage IV Ovarian Epithelial Cancer","Stage IV Primary Peritoneal Cavity Cancer",[1596,1597,792],"ALVAC(2)-NY-ESO-1 (M)\u002FTRICOM vaccine","sirolimus",{"nctId":59,"briefTitle":60,"status":259,"phases":1599,"primaryCompletion":61,"completion":1387,"start":1388,"enrollment":24,"conditions":1600,"interventions":1601},[89],[1390,745],[62,1392,1393,1379],{"nctId":1395,"briefTitle":1396,"status":133,"phases":1603,"primaryCompletion":1398,"completion":70,"start":518,"enrollment":1399,"conditions":1604,"interventions":1605},[89],[1401,1402,1403],[62,1405,1393,1379],{"trials":1607,"activeCount":440,"soonestReadout":41},[1608,1612,1616,1620],{"nctId":780,"briefTitle":781,"status":133,"phases":1609,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":1610,"interventions":1611},[90],[787,15,23,707,708,788,789,728],[710,791,792,793,639,794,714,795,796],{"nctId":1409,"briefTitle":1410,"status":113,"phases":1613,"primaryCompletion":1412,"completion":1413,"start":1414,"enrollment":212,"conditions":1614,"interventions":1615},[90],[1416,1417,32,1418],[1420,1393,1379,1421],{"nctId":39,"briefTitle":40,"status":259,"phases":1617,"primaryCompletion":41,"completion":1424,"start":1425,"enrollment":1426,"conditions":1618,"interventions":1619},[90],[1428,1429],[42,1393,1379,1421],{"nctId":1621,"briefTitle":1622,"status":133,"phases":1623,"primaryCompletion":1624,"completion":1624,"start":1625,"conditions":1626,"interventions":1627},"NCT00053131","Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia",[90],"2004-02","1999-01",[15],[711,792,949,1628],"mitoxantrone hydrochloride",{"trials":1630,"activeCount":101},[],{"trials":1632,"activeCount":101},[],{"trials":1634,"activeCount":101},[1635],{"nctId":1636,"briefTitle":1637,"status":133,"phases":1638,"primaryCompletion":1231,"start":1639,"enrollment":36,"conditions":1640,"interventions":1642},"NCT00053157","Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia",[93],"2002-06",[787,706,15,23,708,1641],"Myelodysplastic\u002FMyeloproliferative Neoplasms",[792],{"intervention":624,"totalTrials":1572,"cells":1644},{"EARLY_PHASE1":1645,"PHASE1":1647,"PHASE2":1682,"PHASE3":1727,"PHASE4":1729,"NA":1731},{"trials":1646,"activeCount":101},[],{"trials":1648,"activeCount":97,"soonestReadout":46},[1649,1653,1667,1671],{"nctId":44,"briefTitle":45,"status":259,"phases":1650,"primaryCompletion":46,"completion":620,"start":621,"enrollment":317,"conditions":1651,"interventions":1652},[89],[226,227,228],[47,57,624,625],{"nctId":1654,"briefTitle":1655,"status":133,"phases":1656,"primaryCompletion":1657,"completion":1658,"start":1659,"enrollment":138,"conditions":1660,"interventions":1664},"NCT03358719","DEC-205\u002FNY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia",[89],"2020-02-27","2021-08-25","2018-03-27",[725,1661,734,1662,741,1663],"Blasts 30 Percent or Less of Bone Marrow Nucleated Cells","High Risk Myelodysplastic Syndrome","Refractory Anemia",[1665,624,81,1666],"DEC-205\u002FNY-ESO-1 Fusion Protein CDX-1401","Poly ICLC",{"nctId":1537,"briefTitle":1538,"status":133,"phases":1668,"primaryCompletion":1540,"completion":453,"start":1541,"enrollment":24,"conditions":1669,"interventions":1670},[89],[1543,1544,1545],[1547,1548,1489,792,1549,1090,1550],{"nctId":1672,"briefTitle":1673,"status":133,"phases":1674,"primaryCompletion":1675,"completion":1676,"start":1677,"enrollment":317,"conditions":1678,"interventions":1681},"NCT01834248","DEC-205\u002FNY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia",[89],"2015-06-09","2016-03-21","2013-07-30",[725,1679,734,741,1680],"Alkylating Agent-Related Acute Myeloid Leukemia","Refractory Anemia With Excess Blasts in Transformation",[1665,624,1666],{"trials":1683,"activeCount":97,"soonestReadout":56},[1684,1704,1723],{"nctId":1685,"briefTitle":1686,"status":365,"phases":1687,"primaryCompletion":1132,"completion":1688,"start":1689,"enrollment":440,"conditions":1690,"interventions":1702},"NCT02029417","Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",[90],"2015-12","2014-07",[1691,1692,1693,1694,1695,1696,1697,974,975,976,978,979,1698,1699,1700,749,1701],"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome","Adult Acute Megakaryoblastic Leukemia (M7)","Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myelomonocytic Leukemia (M4)","Adult Erythroleukemia (M6a)","Adult Pure Erythroid Leukemia (M6b)","Untreated Adult Acute Myeloid Leukemia",[949,1703,1547],"omacetaxine mepesuccinate",{"nctId":1705,"briefTitle":1706,"status":235,"phases":1707,"primaryCompletion":1708,"completion":1709,"start":1710,"enrollment":101,"conditions":1711,"interventions":1721},"NCT03709550","Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer",[89,90],"2023-04-15","2024-04-15","2021-04-15",[1712,1713,1714,1715,1716,1717,1718,1719,1720],"Castration Levels of Testosterone","Castration-Resistant Prostate Carcinoma","Metastatic Prostate Carcinoma in the Soft Tissue","Prostate Carcinoma Metastatic in the Bone","PSA Level Greater Than or Equal to Two","PSA Progression","Stage IV Prostate Cancer AJCC v8","Stage IVA Prostate Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8",[624,1722],"Enzalutamide",{"nctId":54,"briefTitle":55,"status":259,"phases":1724,"primaryCompletion":56,"completion":861,"start":862,"enrollment":863,"conditions":1725,"interventions":1726},[89,90],[865,866,867,868,869,870,871,872,873,874,875,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,891,892,893,894,895,896,897,898,899,900,901,902,903,904,905,906,907,908,909,910,911,912,913,914],[57,624,916],{"trials":1728,"activeCount":101},[],{"trials":1730,"activeCount":101},[],{"trials":1732,"activeCount":101},[],{"intervention":461,"totalTrials":1572,"cells":1734},{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1747,"PHASE3":1774,"PHASE4":1776,"NA":1778},{"trials":1736,"activeCount":101},[],{"trials":1738,"activeCount":101},[1739,1743],{"nctId":449,"briefTitle":450,"status":133,"phases":1740,"primaryCompletion":452,"completion":453,"start":454,"enrollment":184,"conditions":1741,"interventions":1742},[89],[35,456,457],[459,460,461,462],{"nctId":473,"briefTitle":474,"status":365,"phases":1744,"primaryCompletion":476,"completion":477,"start":478,"enrollment":184,"conditions":1745,"interventions":1746},[89],[35,456],[459,460,461,481],{"trials":1748,"activeCount":440,"soonestReadout":505},[1749,1753,1762,1766,1770],{"nctId":489,"briefTitle":490,"status":365,"phases":1750,"primaryCompletion":492,"completion":493,"start":494,"enrollment":36,"conditions":1751,"interventions":1752},[90],[496,497],[461,499,459,500],{"nctId":1754,"briefTitle":1755,"status":133,"phases":1756,"primaryCompletion":1267,"start":1757,"enrollment":537,"conditions":1758,"interventions":1759},"NCT00002578","Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma",[90],"1994-08",[23],[949,1760,461,1761],"gallium nitrate","methotrexate",{"nctId":502,"briefTitle":503,"status":113,"phases":1763,"primaryCompletion":505,"completion":505,"start":506,"enrollment":21,"conditions":1764,"interventions":1765},[90],[508],[173,510,511,175],{"nctId":531,"briefTitle":532,"status":113,"phases":1767,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":1768,"interventions":1769},[89,90],[539,540],[173,444,511,175,231],{"nctId":569,"briefTitle":570,"status":133,"phases":1771,"primaryCompletion":572,"completion":573,"start":574,"enrollment":575,"conditions":1772,"interventions":1773},[90],[577,578,579,580,496,497],[459,461,462],{"trials":1775,"activeCount":101},[],{"trials":1777,"activeCount":101},[],{"trials":1779,"activeCount":101},[],{"intervention":174,"totalTrials":582,"cells":1781},{"EARLY_PHASE1":1782,"PHASE1":1788,"PHASE2":1790,"PHASE3":1800,"PHASE4":1802,"NA":1804},{"trials":1783,"activeCount":97,"soonestReadout":85},[1784],{"nctId":83,"briefTitle":84,"status":259,"phases":1785,"primaryCompletion":85,"completion":438,"start":439,"enrollment":440,"conditions":1786,"interventions":1787},[88],[442],[86,174,175,173,230,444,312,445],{"trials":1789,"activeCount":101},[],{"trials":1791,"activeCount":97,"soonestReadout":157},[1792,1796],{"nctId":154,"briefTitle":155,"status":113,"phases":1793,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":1794,"interventions":1795},[90],[161,162,163,164,165,166,167,168,169,170,171],[173,174,175,71,176],{"nctId":513,"briefTitle":514,"status":365,"phases":1797,"primaryCompletion":516,"completion":517,"start":518,"enrollment":33,"conditions":1798,"interventions":1799},[90],[520,521,522,523,524,525,526,527],[173,174,529],{"trials":1801,"activeCount":101},[],{"trials":1803,"activeCount":101},[],{"trials":1805,"activeCount":101},[],{"intervention":444,"totalTrials":582,"cells":1807},{"EARLY_PHASE1":1808,"PHASE1":1814,"PHASE2":1816,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1809,"activeCount":97,"soonestReadout":85},[1810],{"nctId":83,"briefTitle":84,"status":259,"phases":1811,"primaryCompletion":85,"completion":438,"start":439,"enrollment":440,"conditions":1812,"interventions":1813},[88],[442],[86,174,175,173,230,444,312,445],{"trials":1815,"activeCount":101},[],{"trials":1817,"activeCount":97,"soonestReadout":534},[1818,1822],{"nctId":1182,"briefTitle":1183,"status":133,"phases":1819,"primaryCompletion":1185,"completion":1185,"start":1186,"enrollment":1187,"conditions":1820,"interventions":1821},[90],[1189,1190,1191,1192,1193,1194,1195,253,1196,1197,355,356,1198,1199,357,1200,358,1201,1202,359,1203,1204,360,1205,1206,255,1207],[444,230,1081],{"nctId":531,"briefTitle":532,"status":113,"phases":1823,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":1824,"interventions":1825},[89,90],[539,540],[173,444,511,175,231],{"trials":1827,"activeCount":101},[],{"trials":1829,"activeCount":101},[],{"trials":1831,"activeCount":101},[],{"intervention":231,"totalTrials":440,"cells":1833},{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1848,"PHASE4":1850,"NA":1852},{"trials":1835,"activeCount":101},[],{"trials":1837,"activeCount":101},[],{"trials":1839,"activeCount":440,"soonestReadout":534},[1840,1844],{"nctId":207,"briefTitle":208,"status":113,"phases":1841,"primaryCompletion":210,"completion":210,"start":211,"enrollment":212,"conditions":1842,"interventions":1843},[90],[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228],[230,231,71],{"nctId":531,"briefTitle":532,"status":113,"phases":1845,"primaryCompletion":534,"completion":535,"start":536,"enrollment":537,"conditions":1846,"interventions":1847},[89,90],[539,540],[173,444,511,175,231],{"trials":1849,"activeCount":101},[],{"trials":1851,"activeCount":101},[],{"trials":1853,"activeCount":101},[],{"intervention":1421,"totalTrials":440,"cells":1855},{"EARLY_PHASE1":1856,"PHASE1":1858,"PHASE2":1860,"PHASE3":1870,"PHASE4":1872,"NA":1874},{"trials":1857,"activeCount":101},[],{"trials":1859,"activeCount":101},[],{"trials":1861,"activeCount":440,"soonestReadout":41},[1862,1866],{"nctId":1409,"briefTitle":1410,"status":113,"phases":1863,"primaryCompletion":1412,"completion":1413,"start":1414,"enrollment":212,"conditions":1864,"interventions":1865},[90],[1416,1417,32,1418],[1420,1393,1379,1421],{"nctId":39,"briefTitle":40,"status":259,"phases":1867,"primaryCompletion":41,"completion":1424,"start":1425,"enrollment":1426,"conditions":1868,"interventions":1869},[90],[1428,1429],[42,1393,1379,1421],{"trials":1871,"activeCount":101},[],{"trials":1873,"activeCount":101},[],{"trials":1875,"activeCount":101},[],{"intervention":1877,"totalTrials":1878,"cells":1879},"dexamethasone",13,{"EARLY_PHASE1":1880,"PHASE1":1882,"PHASE2":1909,"PHASE3":1978,"PHASE4":1980,"NA":1982},{"trials":1881,"activeCount":101},[],{"trials":1883,"activeCount":97,"soonestReadout":1354},[1884,1888,1896,1905],{"nctId":1341,"briefTitle":1342,"status":235,"phases":1885,"primaryCompletion":1344,"completion":1344,"start":325,"enrollment":101,"conditions":1886,"interventions":1887},[89],[1346,1022],[1320,1348,830,1349],{"nctId":1889,"briefTitle":1890,"status":133,"phases":1891,"primaryCompletion":1509,"completion":478,"start":1892,"enrollment":1893,"conditions":1894,"interventions":1895},"NCT00084708","Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors",[89],"2002-11",53,[18],[1877,1053],{"nctId":1897,"briefTitle":1898,"status":133,"phases":1899,"primaryCompletion":1900,"start":1901,"enrollment":863,"conditions":1902,"interventions":1903},"NCT00238225","Calcitriol, Ketoconazole, and Dexamethasone in Treating Patients With Metastatic or Unresectable Solid Tumors",[89],"2006-06","2004-11",[18],[1877,1904],"ketoconazole",{"nctId":1351,"briefTitle":1352,"status":113,"phases":1906,"primaryCompletion":1354,"completion":1355,"start":75,"enrollment":863,"conditions":1907,"interventions":1908},[89],[1346,1022],[1358,1348,1320,830],{"trials":1910,"activeCount":97,"soonestReadout":1365},[1911,1919,1928,1941,1952,1956,1966,1970],{"nctId":1912,"briefTitle":1913,"status":365,"phases":1914,"primaryCompletion":1915,"completion":1112,"start":467,"enrollment":1916,"conditions":1917,"interventions":1918},"NCT00084864","Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate",[90],"2010-02",25,[26],[1877],{"nctId":1920,"briefTitle":1921,"status":133,"phases":1922,"primaryCompletion":1923,"completion":1924,"start":1925,"enrollment":863,"conditions":1926,"interventions":1927},"NCT00054522","Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer Who Have Undergone Surgery or Radiation Therapy",[90],"2006-01","2006-03","2002-04",[26],[1877],{"nctId":1929,"briefTitle":1930,"status":365,"phases":1931,"primaryCompletion":1932,"completion":1933,"start":1934,"enrollment":863,"conditions":1935,"interventions":1938},"NCT03457142","Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy",[90],"2022-11-21","2024-11-06","2018-09-11",[1936,1937],"Recurrent Plasma Cell Myeloma","Refractory Plasma Cell Myeloma",[1939,830,1940],"Abatacept","Ixazomib Citrate",{"nctId":1942,"briefTitle":1943,"status":365,"phases":1944,"primaryCompletion":1945,"completion":1945,"start":1946,"enrollment":863,"conditions":1947,"interventions":1949},"NCT04027348","Palliative Management of Inoperable Malignant Bowel Obstruction",[90],"2021-09-03","2019-06-26",[1948],"Malignant Bowel Obstruction",[830,1950,1951],"Metoclopramide","Octreotide",{"nctId":1362,"briefTitle":1363,"status":113,"phases":1953,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":326,"conditions":1954,"interventions":1955},[90],[1369,1346,1022],[1371,1320,830],{"nctId":1957,"briefTitle":1958,"status":133,"phases":1959,"primaryCompletion":1960,"start":1231,"enrollment":687,"conditions":1961,"interventions":1962},"NCT00054158","Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma",[90],"2006-04",[707],[1877,1963,1964,1965],"doxorubicin hydrochloride","thalidomide","vincristine sulfate",{"nctId":816,"briefTitle":817,"status":133,"phases":1967,"primaryCompletion":819,"completion":820,"start":821,"enrollment":380,"conditions":1968,"interventions":1969},[90],[823,824,825,826,827],[57,829,830,666,831,832,833],{"nctId":1971,"briefTitle":1972,"status":365,"phases":1973,"primaryCompletion":1974,"completion":1133,"start":1960,"enrollment":24,"conditions":1975,"interventions":1976},"NCT00524589","Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy",[90],"2010-07",[26],[1877,1977],"protein expression analysis",{"trials":1979,"activeCount":101},[],{"trials":1981,"activeCount":101},[],{"trials":1983,"activeCount":101},[1984],{"nctId":1985,"briefTitle":1986,"status":235,"phases":1987,"primaryCompletion":1988,"start":1989,"enrollment":101,"conditions":1990,"interventions":1991},"NCT00559481","Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy",[93],"2008-09","2007-10",[26],[1877,1904,1992],"therapeutic hydrocortisone",{"intervention":794,"totalTrials":33,"cells":1994},{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":2007,"PHASE3":2072,"PHASE4":2078,"NA":2080},{"trials":1996,"activeCount":101},[],{"trials":1998,"activeCount":97,"soonestReadout":672},[1999,2003],{"nctId":596,"briefTitle":597,"status":365,"phases":2000,"primaryCompletion":599,"completion":599,"start":600,"enrollment":97,"conditions":2001,"interventions":2002},[89],[602,603,604,605,606,607,608,609,610,611,612,613,614,615],[57,617,298],{"nctId":669,"briefTitle":670,"status":113,"phases":2004,"primaryCompletion":672,"completion":672,"start":506,"enrollment":673,"conditions":2005,"interventions":2006},[89],[675,676],[678,57,298,679],{"trials":2008,"activeCount":97,"soonestReadout":66},[2009,2013,2017,2021,2025,2035,2068],{"nctId":716,"briefTitle":717,"status":365,"phases":2010,"primaryCompletion":719,"completion":719,"start":379,"enrollment":720,"conditions":2011,"interventions":2012},[90],[722,723,724,725,726,727,728,729,730,731,732,203,733,734,735,736,737,738,739,740,741,742,743,744,745,746,747,748,749,750,751,752,753,754,755,756,757],[57,298],{"nctId":283,"briefTitle":284,"status":235,"phases":2014,"primaryCompletion":286,"completion":287,"start":288,"enrollment":101,"conditions":2015,"interventions":2016},[90],[290,291,292,293,294,295],[57,297,298,71,299,47],{"nctId":64,"briefTitle":65,"status":259,"phases":2018,"primaryCompletion":66,"completion":765,"start":766,"enrollment":537,"conditions":2019,"interventions":2020},[89,90],[768,769,770,771,706,772,773,741,743,774,745,751,756],[57,298,776,777,778],{"nctId":780,"briefTitle":781,"status":133,"phases":2022,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":2023,"interventions":2024},[90],[787,15,23,707,708,788,789,728],[710,791,792,793,639,794,714,795,796],{"nctId":2026,"briefTitle":2027,"status":133,"phases":2028,"primaryCompletion":2029,"completion":2030,"start":2031,"enrollment":2032,"conditions":2033,"interventions":2034},"NCT00096018","Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia",[89,90],"2010-11","2012-05","2002-05",43,[15],[794,1964],{"nctId":2036,"briefTitle":2037,"status":133,"phases":2038,"primaryCompletion":2039,"completion":2040,"start":2041,"enrollment":2042,"conditions":2043,"interventions":2067},"NCT01529827","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",[90],"2015-05-28","2019-08-29","2012-02-28",94,[2044,972,973,974,975,976,977,978,979,2045,980,2046,2047,728,2048,981,982,2049,984,2050,985,2051,986,734,2052,736,2053,988,989,2054,2055,991,744,992,746,2056,2057,2058,995,996,997,998,999,1000,1001,1002,1003,1004,2059,1005,1006,1007,1008,1009,1010,1011,1012,1014,1015,1016,606,1018,2060,1020,1021,609,2061,1022,749,2062,2063,2064,2065,752,1024,2066,756,757],"Accelerated Phase Chronic Myelogenous Leukemia","Adult Grade III Lymphomatoid Granulomatosis","Anaplastic Large Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Burkitt Lymphoma","Childhood Chronic Myelogenous Leukemia","Childhood Grade III Lymphomatoid Granulomatosis","Childhood Myelodysplastic Syndromes","Chronic Phase Chronic Myelogenous Leukemia","Diamond-Blackfan Anemia","Juvenile Myelomonocytic Leukemia","Myelodysplastic\u002FMyeloproliferative Neoplasm, Unclassifiable","Post-transplant Lymphoproliferative Disorder","Previously Treated Myelodysplastic Syndromes","Primary Myelofibrosis","Recurrent Adult T-cell Leukemia\u002FLymphoma","Recurrent Mycosis Fungoides\u002FSezary Syndrome","Refractory Hairy Cell Leukemia","Secondary Myelodysplastic Syndromes","Secondary Myelofibrosis","Severe Combined Immunodeficiency","Severe Congenital Neutropenia","T-cell Large Granular Lymphocyte Leukemia",[794,844,796,795,1761],{"nctId":918,"briefTitle":919,"status":133,"phases":2069,"primaryCompletion":921,"completion":922,"start":468,"conditions":2070,"interventions":2071},[90],[15,23,708,924],[710,711,712,639,713,794,844,714],{"trials":2073,"activeCount":101},[2074],{"nctId":929,"briefTitle":930,"status":133,"phases":2075,"primaryCompletion":932,"completion":932,"start":933,"enrollment":934,"conditions":2076,"interventions":2077},[90,91],[787,15,23,708,788,936,18,855],[710,712,808,639,858,794,844,810],{"trials":2079,"activeCount":101},[],{"trials":2081,"activeCount":101},[2082],{"nctId":2083,"briefTitle":2084,"status":133,"phases":2085,"primaryCompletion":2086,"completion":2087,"start":2088,"enrollment":2089,"conditions":2090,"interventions":2125},"NCT00856388","Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders",[93],"2012-08-09","2019-03-13","2009-01-14",62,[2044,1691,972,973,974,975,976,977,978,979,980,2046,2047,728,2091,981,982,2049,984,985,2051,986,2092,734,2093,2052,2094,988,789,2054,2055,991,2095,2096,2097,2098,2099,2100,2101,2102,2103,2104,2105,2106,744,2057,2058,995,996,997,998,999,1000,1001,1002,1003,1004,2059,1005,1006,1007,1008,1009,1010,1011,1012,1014,1015,1016,606,1018,2060,1020,1021,609,1022,2107,749,2062,1024,2108,2109,2110,2111,2112,2113,826,2114,2115,2116,2117,2118,2119,2120,2121,2122,827,2123,2124,1026],"Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative","Chronic Eosinophilic Leukemia","Chronic Neutrophilic Leukemia","de Novo Myelodysplastic Syndromes","Noncontiguous Stage II Adult Burkitt Lymphoma","Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma","Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma","Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma","Noncontiguous Stage II Adult Lymphoblastic Lymphoma","Noncontiguous Stage II Grade 1 Follicular Lymphoma","Noncontiguous Stage II Grade 2 Follicular Lymphoma","Noncontiguous Stage II Grade 3 Follicular Lymphoma","Noncontiguous Stage II Mantle Cell Lymphoma","Noncontiguous Stage II Marginal Zone Lymphoma","Noncontiguous Stage II Small Lymphocytic Lymphoma","Relapsing Chronic Myelogenous Leukemia","Stage III Adult Diffuse Small Cleaved Cell Lymphoma","Stage III Adult Immunoblastic Large Cell Lymphoma","Stage III Adult Lymphoblastic Lymphoma","Stage III Grade 1 Follicular Lymphoma","Stage III Grade 2 Follicular Lymphoma","Stage III Grade 3 Follicular Lymphoma","Stage III Marginal Zone Lymphoma","Stage III Small Lymphocytic Lymphoma","Stage IV Adult Burkitt Lymphoma","Stage IV Adult Diffuse Small Cleaved Cell Lymphoma","Stage IV Adult Immunoblastic Large Cell Lymphoma","Stage IV Adult Lymphoblastic Lymphoma","Stage IV Grade 1 Follicular Lymphoma","Stage IV Grade 2 Follicular Lymphoma","Stage IV Grade 3 Follicular Lymphoma","Stage IV Marginal Zone Lymphoma","Stage IV Small Lymphocytic Lymphoma",[794,844,710],{"intervention":858,"totalTrials":138,"cells":2127},{"EARLY_PHASE1":2128,"PHASE1":2130,"PHASE2":2149,"PHASE3":2159,"PHASE4":2169,"NA":2171},{"trials":2129,"activeCount":101},[],{"trials":2131,"activeCount":97,"soonestReadout":51},[2132,2136,2140],{"nctId":49,"briefTitle":50,"status":259,"phases":2133,"primaryCompletion":51,"completion":1328,"start":1329,"enrollment":1308,"conditions":2134,"interventions":2135},[89],[1331,603,610,1332,1333,1334,1335],[52,1320,1337,1338,1339],{"nctId":1448,"briefTitle":1449,"status":133,"phases":2137,"primaryCompletion":1218,"completion":1218,"start":1451,"enrollment":97,"conditions":2138,"interventions":2139},[89],[1453,23,1454,1455],[711,808,858],{"nctId":2141,"briefTitle":2142,"status":133,"phases":2143,"primaryCompletion":1267,"start":2144,"conditions":2145,"interventions":2147},"NCT00002936","Altretamine and Etoposide in Treating Patients With HIV-Related Cancer",[89],"1996-07",[23,2146],"Sarcoma",[2148,858],"altretamine",{"trials":2150,"activeCount":97,"soonestReadout":1473},[2151,2155],{"nctId":1470,"briefTitle":1471,"status":113,"phases":2152,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":326,"conditions":2153,"interventions":2154},[90],[1476],[1478,52,1337,1479],{"nctId":846,"briefTitle":847,"status":133,"phases":2156,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":2157,"interventions":2158},[90],[806,15,23,707,854,18,855],[712,808,857,639,858,844,810],{"trials":2160,"activeCount":101},[2161,2165],{"nctId":929,"briefTitle":930,"status":133,"phases":2162,"primaryCompletion":932,"completion":932,"start":933,"enrollment":934,"conditions":2163,"interventions":2164},[90,91],[787,15,23,708,788,936,18,855],[710,712,808,639,858,794,844,810],{"nctId":939,"briefTitle":940,"status":133,"phases":2166,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":2167,"interventions":2168},[91],[15],[948,711,639,949,858,950,844],{"trials":2170,"activeCount":101},[],{"trials":2172,"activeCount":101},[2173],{"nctId":965,"briefTitle":966,"status":133,"phases":2174,"primaryCompletion":968,"completion":968,"start":969,"enrollment":970,"conditions":2175,"interventions":2176},[93],[972,973,974,975,976,977,978,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998,999,1000,1001,1002,1003,1004,1005,1006,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,606,1018,1019,1020,1021,609,1022,1023,1024,1025,18,855,1026],[858,639,857,844,712,808,810],{"intervention":2178,"totalTrials":370,"cells":2179},"lenalidomide",{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2197,"PHASE3":2217,"PHASE4":2219,"NA":2221},{"trials":2181,"activeCount":101},[],{"trials":2183,"activeCount":97,"soonestReadout":61},[2184,2193],{"nctId":2185,"briefTitle":2186,"status":133,"phases":2187,"primaryCompletion":2188,"completion":2189,"start":2190,"enrollment":199,"conditions":2191,"interventions":2192},"NCT01246622","Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[89],"2014-05-15","2019-06-05","2011-02-07",[974,975,976,977,978,979,996],[949,2178],{"nctId":59,"briefTitle":60,"status":259,"phases":2194,"primaryCompletion":61,"completion":1387,"start":1388,"enrollment":24,"conditions":2195,"interventions":2196},[89],[1390,745],[62,1392,1393,1379],{"trials":2198,"activeCount":97,"soonestReadout":2203},[2199,2209],{"nctId":2200,"briefTitle":2201,"status":259,"phases":2202,"primaryCompletion":2203,"completion":2204,"start":2205,"enrollment":1271,"conditions":2206,"interventions":2207},"NCT04876248","Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant",[90],"2026-09-01","2027-09-01","2024-08-19",[745],[2208,1392],"Belantamab Mafodotin",{"nctId":2210,"briefTitle":2211,"status":133,"phases":2212,"primaryCompletion":2213,"completion":2213,"start":1165,"enrollment":307,"conditions":2214,"interventions":2215},"NCT00096044","Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia",[90],"2015-06",[15],[2216,2178],"rituximab",{"trials":2218,"activeCount":101},[],{"trials":2220,"activeCount":101},[],{"trials":2222,"activeCount":101},[2223],{"nctId":2224,"briefTitle":2225,"status":365,"phases":2226,"primaryCompletion":2030,"completion":2227,"start":2228,"enrollment":138,"conditions":2229,"interventions":2234},"NCT01649791","Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia",[93],"2014-10","2010-01",[2230,203,2231,2232,2233],"B-cell Chronic Lymphocytic Leukemia","Stage 0 Chronic Lymphocytic Leukemia","Stage I Chronic Lymphocytic Leukemia","Stage II Chronic Lymphocytic Leukemia",[2178],{"intervention":1504,"totalTrials":582,"cells":2236},{"EARLY_PHASE1":2237,"PHASE1":2239,"PHASE2":2250,"PHASE3":2256,"PHASE4":2258,"NA":2260},{"trials":2238,"activeCount":101},[],{"trials":2240,"activeCount":101},[2241],{"nctId":2242,"briefTitle":2243,"status":235,"phases":2244,"primaryCompletion":2245,"completion":2245,"start":2246,"enrollment":101,"conditions":2247,"interventions":2249},"NCT06670976","Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma",[89],"2029-11-15","2026-05-15",[2248],"Soft Tissue Sarcoma",[1504],{"trials":2251,"activeCount":97,"soonestReadout":1498},[2252],{"nctId":1495,"briefTitle":1496,"status":113,"phases":2253,"primaryCompletion":1498,"completion":1498,"start":1499,"enrollment":1500,"conditions":2254,"interventions":2255},[90],[1502],[52,1504,667],{"trials":2257,"activeCount":101},[],{"trials":2259,"activeCount":101},[],{"trials":2261,"activeCount":97,"soonestReadout":2266},[2262],{"nctId":2263,"briefTitle":2264,"status":113,"phases":2265,"primaryCompletion":2266,"completion":2266,"start":2267,"enrollment":2268,"conditions":2269,"interventions":2271},"NCT05312255","Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma",[93],"2027-06-28","2022-06-28",175,[745,1936,1937,2270],"Smoldering Plasma Cell Myeloma",[2272,1504],"Beta-Adrenergic Antagonist",{"intervention":1489,"totalTrials":138,"cells":2274},{"EARLY_PHASE1":2275,"PHASE1":2277,"PHASE2":2283,"PHASE3":2333,"PHASE4":2343,"NA":2345},{"trials":2276,"activeCount":101},[],{"trials":2278,"activeCount":101},[2279],{"nctId":1537,"briefTitle":1538,"status":133,"phases":2280,"primaryCompletion":1540,"completion":453,"start":1541,"enrollment":24,"conditions":2281,"interventions":2282},[89],[1543,1544,1545],[1547,1548,1489,792,1549,1090,1550],{"trials":2284,"activeCount":97,"soonestReadout":2319},[2285,2297,2301,2308,2315,2326],{"nctId":2286,"briefTitle":2287,"status":365,"phases":2288,"primaryCompletion":2289,"completion":2289,"start":2290,"enrollment":317,"conditions":2291,"interventions":2292},"NCT00851552","Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment",[90],"2011-09","2009-01",[23],[2216,2293,1489,1088,2294,2295,2296],"bortezomib","polymerase chain reaction","polymorphism analysis","proteomic profiling",{"nctId":1481,"briefTitle":1482,"status":365,"phases":2298,"primaryCompletion":1484,"completion":1104,"start":1485,"enrollment":317,"conditions":2299,"interventions":2300},[90],[1487],[808,1489],{"nctId":2302,"briefTitle":2303,"status":365,"phases":2304,"primaryCompletion":1230,"start":478,"enrollment":9,"conditions":2305,"interventions":2306},"NCT00524459","Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery",[90],[806],[2307,1489],"docetaxel",{"nctId":2309,"briefTitle":2310,"status":133,"phases":2311,"primaryCompletion":2289,"completion":452,"start":1900,"enrollment":2312,"conditions":2313,"interventions":2314},"NCT00523848","Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma",[90],46,[707],[2293,1489,1964],{"nctId":2316,"briefTitle":2317,"status":113,"phases":2318,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":804,"conditions":2321,"interventions":2323},"NCT06434064","Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer",[90],"2028-11-30","2026-03-03",[240,186,2322,188],"Locally Advanced Unresectable Triple-Negative Breast Carcinoma",[2324,2325],"Pegylated Liposomal Doxorubicin Hydrochloride","Tamoxifen",{"nctId":2327,"briefTitle":2328,"status":133,"phases":2329,"primaryCompletion":1230,"completion":2330,"start":922,"enrollment":1187,"conditions":2331,"interventions":2332},"NCT00244985","Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[89,90],"2012-12",[23],[2216,1489],{"trials":2334,"activeCount":101},[2335],{"nctId":2336,"briefTitle":2337,"status":133,"phases":2338,"primaryCompletion":1267,"start":2339,"conditions":2340,"interventions":2341},"NCT00002985","Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma",[91],"1996-11",[2146],[2342,1489],"daunorubicin hydrochloride",{"trials":2344,"activeCount":101},[],{"trials":2346,"activeCount":101},[],{"intervention":148,"totalTrials":138,"cells":2348},{"EARLY_PHASE1":2349,"PHASE1":2355,"PHASE2":2361,"PHASE3":2423,"PHASE4":2425,"NA":2427},{"trials":2350,"activeCount":101},[2351],{"nctId":131,"briefTitle":132,"status":133,"phases":2352,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":2353,"interventions":2354},[88],[140,141,142,143,144],[146,147,148,71],{"trials":2356,"activeCount":101},[2357],{"nctId":641,"briefTitle":642,"status":133,"phases":2358,"primaryCompletion":644,"completion":645,"start":646,"enrollment":317,"conditions":2359,"interventions":2360},[89],[648,649,650,651,652,653,654,655,141,142,144,656,657,658,659,660,661,662,663],[146,57,665,666,667,147,148],{"trials":2362,"activeCount":97,"soonestReadout":2410},[2363,2373,2386,2398,2402,2406],{"nctId":2364,"briefTitle":2365,"status":365,"phases":2366,"primaryCompletion":2367,"completion":2367,"start":2368,"enrollment":1271,"conditions":2369,"interventions":2372},"NCT04379518","Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients",[89,90],"2023-03-15","2020-11-17",[2370,32,2371],"Hematopoietic and Lymphoid Cell Neoplasm","Symptomatic COVID-19 Infection Laboratory-Confirmed",[147,148],{"nctId":2374,"briefTitle":2375,"status":133,"phases":2376,"primaryCompletion":2377,"completion":2378,"start":2379,"enrollment":1399,"conditions":2380,"interventions":2385},"NCT03403634","Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver",[90],"2020-12-23","2021-08-29","2018-04-19",[2381,252,2382,2383,2384],"Metastatic Carcinoma in the Liver","Stage IV Colorectal Cancer AJCC v7","Stage IVA Colorectal Cancer AJCC v7","Stage IVB Colorectal Cancer AJCC v7",[146,147,148],{"nctId":2387,"briefTitle":2388,"status":365,"phases":2389,"primaryCompletion":2390,"completion":368,"start":2391,"enrollment":97,"conditions":2392,"interventions":2395},"NCT04093323","Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma",[90],"2025-04-03","2024-11-13",[2393,2394],"HLA-A2 Positive Cells Present","Refractory Melanoma",[243,146,2396,2397,147,148],"PD-1 Ligand Inhibitor","PD1 Inhibitor",{"nctId":345,"briefTitle":346,"status":235,"phases":2399,"primaryCompletion":348,"completion":348,"start":349,"enrollment":101,"conditions":2400,"interventions":2401},[90],[351,352,353,354,253,355,356,357,254,358,359,360,255],[71,148],{"nctId":363,"briefTitle":364,"status":365,"phases":2403,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":2404,"interventions":2405},[89,90],[186,188,241],[146,373,71,148],{"nctId":2407,"briefTitle":2408,"status":259,"phases":2409,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":2412,"conditions":2413,"interventions":2421},"NCT03899987","Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery",[90],"2027-04-30","2019-11-29",12,[2414,120,121,2415,2416,2417,122,2418,2419,2420],"Prostate Adenocarcinoma","Stage IIA Prostate Cancer AJCC v8","Stage IIB Prostate Cancer AJCC v8","Stage IIC Prostate Cancer AJCC v8","Stage IIIA Prostate Cancer AJCC v8","Stage IIIB Prostate Cancer AJCC v8","Stage IIIC Prostate Cancer AJCC v8",[2422,147,148],"EC Aspirin",{"trials":2424,"activeCount":101},[],{"trials":2426,"activeCount":101},[],{"trials":2428,"activeCount":101},[],{"intervention":147,"totalTrials":9,"cells":2430},{"EARLY_PHASE1":2431,"PHASE1":2437,"PHASE2":2443,"PHASE3":2461,"PHASE4":2463,"NA":2465},{"trials":2432,"activeCount":101},[2433],{"nctId":131,"briefTitle":132,"status":133,"phases":2434,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":2435,"interventions":2436},[88],[140,141,142,143,144],[146,147,148,71],{"trials":2438,"activeCount":101},[2439],{"nctId":641,"briefTitle":642,"status":133,"phases":2440,"primaryCompletion":644,"completion":645,"start":646,"enrollment":317,"conditions":2441,"interventions":2442},[89],[648,649,650,651,652,653,654,655,141,142,144,656,657,658,659,660,661,662,663],[146,57,665,666,667,147,148],{"trials":2444,"activeCount":97,"soonestReadout":2410},[2445,2449,2453,2457],{"nctId":2364,"briefTitle":2365,"status":365,"phases":2446,"primaryCompletion":2367,"completion":2367,"start":2368,"enrollment":1271,"conditions":2447,"interventions":2448},[89,90],[2370,32,2371],[147,148],{"nctId":2374,"briefTitle":2375,"status":133,"phases":2450,"primaryCompletion":2377,"completion":2378,"start":2379,"enrollment":1399,"conditions":2451,"interventions":2452},[90],[2381,252,2382,2383,2384],[146,147,148],{"nctId":2387,"briefTitle":2388,"status":365,"phases":2454,"primaryCompletion":2390,"completion":368,"start":2391,"enrollment":97,"conditions":2455,"interventions":2456},[90],[2393,2394],[243,146,2396,2397,147,148],{"nctId":2407,"briefTitle":2408,"status":259,"phases":2458,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":2412,"conditions":2459,"interventions":2460},[90],[2414,120,121,2415,2416,2417,122,2418,2419,2420],[2422,147,148],{"trials":2462,"activeCount":101},[],{"trials":2464,"activeCount":101},[],{"trials":2466,"activeCount":101},[],{"intervention":81,"totalTrials":1271,"cells":2468},{"EARLY_PHASE1":2469,"PHASE1":2471,"PHASE2":2502,"PHASE3":2508,"PHASE4":2510,"NA":2512},{"trials":2470,"activeCount":101},[],{"trials":2472,"activeCount":101},[2473,2484,2488],{"nctId":2474,"briefTitle":2475,"status":365,"phases":2476,"primaryCompletion":2477,"completion":2477,"start":2478,"enrollment":370,"conditions":2479,"interventions":2482},"NCT03727061","Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer",[89],"2024-10-22","2019-07-10",[2480,2481],"Recurrent Head and Neck Carcinoma","Locally Advanced Head and Neck Carcinoma",[81,2483],"Porfimer Sodium",{"nctId":1654,"briefTitle":1655,"status":133,"phases":2485,"primaryCompletion":1657,"completion":1658,"start":1659,"enrollment":138,"conditions":2486,"interventions":2487},[89],[725,1661,734,1662,741,1663],[1665,624,81,1666],{"nctId":2489,"briefTitle":2490,"status":133,"phases":2491,"primaryCompletion":1710,"completion":2492,"start":2493,"enrollment":1572,"conditions":2494,"interventions":2500},"NCT02947386","Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer",[89],"2022-09-08","2017-06-29",[2495,2496,2497,2498,2499],"EGFR Gene Mutation","Recurrent Non-Small Cell Lung Carcinoma","Stage IIIA Non-Small Cell Lung Cancer","Stage IIIB Non-Small Cell Lung Cancer","Stage IV Non-Small Cell Lung Cancer",[2501,81],"Nimotuzumab",{"trials":2503,"activeCount":97,"soonestReadout":80},[2504],{"nctId":78,"briefTitle":79,"status":259,"phases":2505,"primaryCompletion":80,"completion":261,"start":262,"enrollment":263,"conditions":2506,"interventions":2507},[89,90],[265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280],[81,71,86],{"trials":2509,"activeCount":101},[],{"trials":2511,"activeCount":101},[],{"trials":2513,"activeCount":101},[],{"intervention":778,"totalTrials":1271,"cells":2515},{"EARLY_PHASE1":2516,"PHASE1":2518,"PHASE2":2600,"PHASE3":2606,"PHASE4":2608,"NA":2610},{"trials":2517,"activeCount":101},[],{"trials":2519,"activeCount":101},[2520,2583,2596],{"nctId":2521,"briefTitle":2522,"status":133,"phases":2523,"primaryCompletion":2524,"completion":2524,"start":2525,"enrollment":24,"conditions":2526,"interventions":2582},"NCT01522820","Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors",[89],"2016-07","2012-03",[1558,1559,1560,141,2527,1428,2528,2529,2530,2531,2532,2533,252,2534,1141,691,2535,2536,227,2537,2538,2539,2540,2146,2541,2542,2543,2544,2545,2546,2547,2548,2549,2550,2551,2552,2553,2554,2555,2556,2557,2558,2559,2560,2561,2562,2563,2564,2565,2566,2567,2568,2569,2570,2571,2572,2573,2574,2575,2576,2577,2578,2579,2580,2581],"Estrogen Receptor Positive","Hormone-Resistant Prostate Cancer","Metastatic Prostate Carcinoma","Metastatic Renal Cell Cancer","Recurrent Adult Brain Neoplasm","Recurrent Bladder Carcinoma","Recurrent Breast Carcinoma","Recurrent Esophageal Carcinoma","Recurrent Lung Carcinoma","Recurrent Melanoma","Recurrent Prostate Carcinoma","Recurrent Renal Cell Carcinoma","Recurrent Uterine Corpus Carcinoma","Resectable Hepatocellular Carcinoma","Stage IA Breast Cancer","Stage IA Ovarian Cancer","Stage IA Uterine Corpus Cancer","Stage IB Breast Cancer","Stage IB Ovarian Cancer","Stage IB Uterine Corpus Cancer","Stage IC Ovarian Cancer","Stage II Uterine Corpus Cancer","Stage IIA Breast Cancer","Stage IIA Lung Carcinoma","Stage IIA Ovarian Cancer","Stage IIB Breast Cancer","Stage IIB Esophageal Cancer","Stage IIB Lung Carcinoma","Stage IIB Ovarian Cancer","Stage IIB Skin Melanoma","Stage IIC Ovarian Cancer","Stage IIC Skin Melanoma","Stage IIIA Breast Cancer","Stage IIIA Esophageal Cancer","Stage IIIA Lung Carcinoma","Stage IIIA Ovarian Cancer","Stage IIIA Skin Melanoma","Stage IIIA Uterine Corpus Cancer","Stage IIIB Breast Cancer","Stage IIIB Esophageal Cancer","Stage IIIB Ovarian Cancer","Stage IIIB Skin Melanoma","Stage IIIB Uterine Corpus Cancer","Stage IIIC Breast Cancer","Stage IIIC Esophageal Cancer","Stage IIIC Ovarian Cancer","Stage IIIC Skin Melanoma","Stage IIIC Uterine Corpus Cancer","Stage IV Bladder Urothelial Carcinoma","Stage IV Esophageal Cancer","Stage IV Ovarian Cancer","Stage IV Prostate Cancer","Stage IV Skin Melanoma","Stage IVA Uterine Corpus Cancer","Stage IVB Uterine Corpus Cancer",[1665,778],{"nctId":2584,"briefTitle":2585,"status":235,"phases":2586,"primaryCompletion":2587,"completion":2588,"start":621,"enrollment":101,"conditions":2589,"interventions":2594},"NCT02833506","Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[89],"2018-08-15","2019-08-15",[226,227,228,1574,2551,1577,2555,1580,2557,1583,2562,2590,1586,2567,2591,1589,2572,2592,1592,2577,2593],"Stage IIIA Primary Peritoneal Cancer","Stage IIIB Primary Peritoneal Cancer","Stage IIIC Primary Peritoneal Cancer","Stage IV Primary Peritoneal Cancer",[2595,778],"Recombinant NY-ESO-1 Protein",{"nctId":1567,"briefTitle":1568,"status":133,"phases":2597,"primaryCompletion":1570,"completion":1570,"start":1571,"enrollment":1572,"conditions":2598,"interventions":2599},[89],[1543,1544,1545,1574,1575,1576,1577,1578,1579,1580,1581,1582,1583,1584,1585,1586,1587,1588,1589,1590,1591,1592,1593,1594],[1596,1597,792],{"trials":2601,"activeCount":97,"soonestReadout":66},[2602],{"nctId":64,"briefTitle":65,"status":259,"phases":2603,"primaryCompletion":66,"completion":765,"start":766,"enrollment":537,"conditions":2604,"interventions":2605},[89,90],[768,769,770,771,706,772,773,741,743,774,745,751,756],[57,298,776,777,778],{"trials":2607,"activeCount":101},[],{"trials":2609,"activeCount":101},[],{"trials":2611,"activeCount":101},[],{"intervention":795,"totalTrials":582,"cells":2613},{"EARLY_PHASE1":2614,"PHASE1":2616,"PHASE2":2618,"PHASE3":2632,"PHASE4":2634,"NA":2636},{"trials":2615,"activeCount":101},[],{"trials":2617,"activeCount":101},[],{"trials":2619,"activeCount":97,"soonestReadout":66},[2620,2624,2628],{"nctId":64,"briefTitle":65,"status":259,"phases":2621,"primaryCompletion":66,"completion":765,"start":766,"enrollment":537,"conditions":2622,"interventions":2623},[89,90],[768,769,770,771,706,772,773,741,743,774,745,751,756],[57,298,776,777,778],{"nctId":780,"briefTitle":781,"status":133,"phases":2625,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":2626,"interventions":2627},[90],[787,15,23,707,708,788,789,728],[710,791,792,793,639,794,714,795,796],{"nctId":2036,"briefTitle":2037,"status":133,"phases":2629,"primaryCompletion":2039,"completion":2040,"start":2041,"enrollment":2042,"conditions":2630,"interventions":2631},[90],[2044,972,973,974,975,976,977,978,979,2045,980,2046,2047,728,2048,981,982,2049,984,2050,985,2051,986,734,2052,736,2053,988,989,2054,2055,991,744,992,746,2056,2057,2058,995,996,997,998,999,1000,1001,1002,1003,1004,2059,1005,1006,1007,1008,1009,1010,1011,1012,1014,1015,1016,606,1018,2060,1020,1021,609,2061,1022,749,2062,2063,2064,2065,752,1024,2066,756,757],[794,844,796,795,1761],{"trials":2633,"activeCount":101},[],{"trials":2635,"activeCount":101},[],{"trials":2637,"activeCount":101},[],{"intervention":176,"totalTrials":440,"cells":2639},{"EARLY_PHASE1":2640,"PHASE1":2642,"PHASE2":2644,"PHASE3":2654,"PHASE4":2656,"NA":2658},{"trials":2641,"activeCount":101},[],{"trials":2643,"activeCount":101},[],{"trials":2645,"activeCount":97,"soonestReadout":157},[2646,2650],{"nctId":154,"briefTitle":155,"status":113,"phases":2647,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":2648,"interventions":2649},[90],[161,162,163,164,165,166,167,168,169,170,171],[173,174,175,71,176],{"nctId":415,"briefTitle":416,"status":417,"phases":2651,"primaryCompletion":419,"completion":419,"start":420,"enrollment":421,"conditions":2652,"interventions":2653},[89,90],[423,424],[71,176],{"trials":2655,"activeCount":101},[],{"trials":2657,"activeCount":101},[],{"trials":2659,"activeCount":101},[],{"intervention":1478,"totalTrials":97,"cells":2661},{"EARLY_PHASE1":2662,"PHASE1":2664,"PHASE2":2666,"PHASE3":2672,"PHASE4":2674,"NA":2676},{"trials":2663,"activeCount":101},[],{"trials":2665,"activeCount":101},[],{"trials":2667,"activeCount":97,"soonestReadout":1473},[2668],{"nctId":1470,"briefTitle":1471,"status":113,"phases":2669,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":326,"conditions":2670,"interventions":2671},[90],[1476],[1478,52,1337,1479],{"trials":2673,"activeCount":101},[],{"trials":2675,"activeCount":101},[],{"trials":2677,"activeCount":101},[],{"intervention":1479,"totalTrials":97,"cells":2679},{"EARLY_PHASE1":2680,"PHASE1":2682,"PHASE2":2684,"PHASE3":2690,"PHASE4":2692,"NA":2694},{"trials":2681,"activeCount":101},[],{"trials":2683,"activeCount":101},[],{"trials":2685,"activeCount":97,"soonestReadout":1473},[2686],{"nctId":1470,"briefTitle":1471,"status":113,"phases":2687,"primaryCompletion":1473,"completion":1473,"start":1474,"enrollment":326,"conditions":2688,"interventions":2689},[90],[1476],[1478,52,1337,1479],{"trials":2691,"activeCount":101},[],{"trials":2693,"activeCount":101},[],{"trials":2695,"activeCount":101},[],{"intervention":191,"totalTrials":97,"cells":2697},{"EARLY_PHASE1":2698,"PHASE1":2700,"PHASE2":2702,"PHASE3":2708,"PHASE4":2710,"NA":2712},{"trials":2699,"activeCount":101},[],{"trials":2701,"activeCount":101},[],{"trials":2703,"activeCount":97,"soonestReadout":181},[2704],{"nctId":178,"briefTitle":179,"status":113,"phases":2705,"primaryCompletion":181,"completion":182,"start":183,"enrollment":184,"conditions":2706,"interventions":2707},[90],[186,187,188,189],[191,71],{"trials":2709,"activeCount":101},[],{"trials":2711,"activeCount":101},[],{"trials":2713,"activeCount":101},[],{"intervention":205,"totalTrials":97,"cells":2715},{"EARLY_PHASE1":2716,"PHASE1":2718,"PHASE2":2720,"PHASE3":2726,"PHASE4":2728,"NA":2730},{"trials":2717,"activeCount":101},[],{"trials":2719,"activeCount":101},[],{"trials":2721,"activeCount":97,"soonestReadout":196},[2722],{"nctId":193,"briefTitle":194,"status":113,"phases":2723,"primaryCompletion":196,"completion":197,"start":198,"enrollment":199,"conditions":2724,"interventions":2725},[90],[201,202,203],[205,71],{"trials":2727,"activeCount":101},[],{"trials":2729,"activeCount":101},[],{"trials":2731,"activeCount":101},[],{"intervention":76,"totalTrials":97,"cells":2733},{"EARLY_PHASE1":2734,"PHASE1":2736,"PHASE2":2738,"PHASE3":2750,"PHASE4":2752,"NA":2754},{"trials":2735,"activeCount":101},[],{"trials":2737,"activeCount":101},[],{"trials":2739,"activeCount":97,"soonestReadout":75},[2740],{"nctId":73,"briefTitle":74,"status":259,"phases":2741,"primaryCompletion":75,"completion":2742,"start":2743,"enrollment":2744,"conditions":2745,"interventions":2749},[90],"2027-01-29","2021-07-29",21,[2746,2747,749,2748],"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Acute Myeloid Leukemia With Myelodysplasia-Related Changes","Therapy-Related Acute Myeloid Leukemia",[76],{"trials":2751,"activeCount":101},[],{"trials":2753,"activeCount":101},[],{"trials":2755,"activeCount":101},[],{"intervention":2208,"totalTrials":97,"cells":2757},{"EARLY_PHASE1":2758,"PHASE1":2760,"PHASE2":2762,"PHASE3":2768,"PHASE4":2770,"NA":2772},{"trials":2759,"activeCount":101},[],{"trials":2761,"activeCount":101},[],{"trials":2763,"activeCount":97,"soonestReadout":2203},[2764],{"nctId":2200,"briefTitle":2201,"status":259,"phases":2765,"primaryCompletion":2203,"completion":2204,"start":2205,"enrollment":1271,"conditions":2766,"interventions":2767},[90],[745],[2208,1392],{"trials":2769,"activeCount":101},[],{"trials":2771,"activeCount":101},[],{"trials":2773,"activeCount":101},[],{"intervention":776,"totalTrials":97,"cells":2775},{"EARLY_PHASE1":2776,"PHASE1":2778,"PHASE2":2780,"PHASE3":2786,"PHASE4":2788,"NA":2790},{"trials":2777,"activeCount":101},[],{"trials":2779,"activeCount":101},[],{"trials":2781,"activeCount":97,"soonestReadout":66},[2782],{"nctId":64,"briefTitle":65,"status":259,"phases":2783,"primaryCompletion":66,"completion":765,"start":766,"enrollment":537,"conditions":2784,"interventions":2785},[89,90],[768,769,770,771,706,772,773,741,743,774,745,751,756],[57,298,776,777,778],{"trials":2787,"activeCount":101},[],{"trials":2789,"activeCount":101},[],{"trials":2791,"activeCount":101},[],{"intervention":330,"totalTrials":97,"cells":2793},{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2798,"PHASE3":2804,"PHASE4":2806,"NA":2808},{"trials":2795,"activeCount":101},[],{"trials":2797,"activeCount":101},[],{"trials":2799,"activeCount":97,"soonestReadout":324},[2800],{"nctId":321,"briefTitle":322,"status":113,"phases":2801,"primaryCompletion":324,"completion":324,"start":325,"enrollment":326,"conditions":2802,"interventions":2803},[90],[328,267,271,276],[330,71],{"trials":2805,"activeCount":101},[],{"trials":2807,"activeCount":101},[],{"trials":2809,"activeCount":101},[],{"intervention":1371,"totalTrials":97,"cells":2811},{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2816,"PHASE3":2822,"PHASE4":2824,"NA":2826},{"trials":2813,"activeCount":101},[],{"trials":2815,"activeCount":101},[],{"trials":2817,"activeCount":97,"soonestReadout":1365},[2818],{"nctId":1362,"briefTitle":1363,"status":113,"phases":2819,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":326,"conditions":2820,"interventions":2821},[90],[1369,1346,1022],[1371,1320,830],{"trials":2823,"activeCount":101},[],{"trials":2825,"activeCount":101},[],{"trials":2827,"activeCount":101},[],{"intervention":510,"totalTrials":97,"cells":2829},{"EARLY_PHASE1":2830,"PHASE1":2832,"PHASE2":2834,"PHASE3":2840,"PHASE4":2842,"NA":2844},{"trials":2831,"activeCount":101},[],{"trials":2833,"activeCount":101},[],{"trials":2835,"activeCount":97,"soonestReadout":505},[2836],{"nctId":502,"briefTitle":503,"status":113,"phases":2837,"primaryCompletion":505,"completion":505,"start":506,"enrollment":21,"conditions":2838,"interventions":2839},[90],[508],[173,510,511,175],{"trials":2841,"activeCount":101},[],{"trials":2843,"activeCount":101},[],{"trials":2845,"activeCount":101},[],{"intervention":2847,"totalTrials":97,"cells":2848},"Olanzapine",{"EARLY_PHASE1":2849,"PHASE1":2851,"PHASE2":2853,"PHASE3":2867,"PHASE4":2869,"NA":2871},{"trials":2850,"activeCount":101},[],{"trials":2852,"activeCount":101},[],{"trials":2854,"activeCount":97,"soonestReadout":2859},[2855],{"nctId":2856,"briefTitle":2857,"status":113,"phases":2858,"primaryCompletion":2859,"completion":2860,"start":2861,"enrollment":1426,"conditions":2862,"interventions":2866},"NCT06995508","Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial",[90],"2030-11-15","2031-11-15","2025-12-24",[2863,2864,2865],"Cancer-Associated Anorexia","Head and Neck Squamous Cell Carcinoma","Neck Squamous Cell Carcinoma of Unknown Primary",[2847],{"trials":2868,"activeCount":101},[],{"trials":2870,"activeCount":101},[],{"trials":2872,"activeCount":101},[],{"intervention":2874,"totalTrials":97,"cells":2875},"Cemiplimab",{"EARLY_PHASE1":2876,"PHASE1":2878,"PHASE2":2880,"PHASE3":2892,"PHASE4":2894,"NA":2896},{"trials":2877,"activeCount":101},[],{"trials":2879,"activeCount":101},[],{"trials":2881,"activeCount":97,"soonestReadout":1365},[2882],{"nctId":2883,"briefTitle":2884,"status":1305,"phases":2885,"primaryCompletion":1365,"completion":2886,"start":2246,"enrollment":2887,"conditions":2888,"interventions":2890},"NCT06943664","Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer",[90],"2028-05-01",27,[266,267,2889,273,274,276],"Refractory Lung Non-Small Cell Carcinoma",[2874,2891],"Cetuximab Sarotalocan Sodium",{"trials":2893,"activeCount":101},[],{"trials":2895,"activeCount":101},[],{"trials":2897,"activeCount":101},[],{"intervention":2891,"totalTrials":97,"cells":2899},{"EARLY_PHASE1":2900,"PHASE1":2902,"PHASE2":2904,"PHASE3":2910,"PHASE4":2912,"NA":2914},{"trials":2901,"activeCount":101},[],{"trials":2903,"activeCount":101},[],{"trials":2905,"activeCount":97,"soonestReadout":1365},[2906],{"nctId":2883,"briefTitle":2884,"status":1305,"phases":2907,"primaryCompletion":1365,"completion":2886,"start":2246,"enrollment":2887,"conditions":2908,"interventions":2909},[90],[266,267,2889,273,274,276],[2874,2891],{"trials":2911,"activeCount":101},[],{"trials":2913,"activeCount":101},[],{"trials":2915,"activeCount":101},[],{"intervention":2917,"totalTrials":97,"cells":2918},"Verteporfin",{"EARLY_PHASE1":2919,"PHASE1":2921,"PHASE2":2923,"PHASE3":2932,"PHASE4":2934,"NA":2936},{"trials":2920,"activeCount":101},[],{"trials":2922,"activeCount":101},[],{"trials":2924,"activeCount":97,"soonestReadout":2929},[2925],{"nctId":2926,"briefTitle":2927,"status":113,"phases":2928,"primaryCompletion":2929,"completion":2929,"start":249,"enrollment":1187,"conditions":2930,"interventions":2931},"NCT06306638","Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction",[89,90],"2029-10-01",[32],[2917],{"trials":2933,"activeCount":101},[],{"trials":2935,"activeCount":101},[],{"trials":2937,"activeCount":101},[],{"intervention":1420,"totalTrials":97,"cells":2939},{"EARLY_PHASE1":2940,"PHASE1":2942,"PHASE2":2944,"PHASE3":2950,"PHASE4":2952,"NA":2954},{"trials":2941,"activeCount":101},[],{"trials":2943,"activeCount":101},[],{"trials":2945,"activeCount":97,"soonestReadout":1412},[2946],{"nctId":1409,"briefTitle":1410,"status":113,"phases":2947,"primaryCompletion":1412,"completion":1413,"start":1414,"enrollment":212,"conditions":2948,"interventions":2949},[90],[1416,1417,32,1418],[1420,1393,1379,1421],{"trials":2951,"activeCount":101},[],{"trials":2953,"activeCount":101},[],{"trials":2955,"activeCount":101},[],{"intervention":1311,"totalTrials":97,"cells":2957},{"EARLY_PHASE1":2958,"PHASE1":2960,"PHASE2":2962,"PHASE3":2968,"PHASE4":2970,"NA":2972},{"trials":2959,"activeCount":101},[],{"trials":2961,"activeCount":101},[],{"trials":2963,"activeCount":97,"soonestReadout":196},[2964],{"nctId":1303,"briefTitle":1304,"status":1305,"phases":2965,"primaryCompletion":196,"completion":196,"start":1307,"enrollment":1308,"conditions":2966,"interventions":2967},[90],[328,271,276],[1311,86,1312],{"trials":2969,"activeCount":101},[],{"trials":2971,"activeCount":101},[],{"trials":2973,"activeCount":101},[],{"intervention":1312,"totalTrials":97,"cells":2975},{"EARLY_PHASE1":2976,"PHASE1":2978,"PHASE2":2980,"PHASE3":2986,"PHASE4":2988,"NA":2990},{"trials":2977,"activeCount":101},[],{"trials":2979,"activeCount":101},[],{"trials":2981,"activeCount":97,"soonestReadout":196},[2982],{"nctId":1303,"briefTitle":1304,"status":1305,"phases":2983,"primaryCompletion":196,"completion":196,"start":1307,"enrollment":1308,"conditions":2984,"interventions":2985},[90],[328,271,276],[1311,86,1312],{"trials":2987,"activeCount":101},[],{"trials":2989,"activeCount":101},[],{"trials":2991,"activeCount":101},[],{"intervention":1251,"totalTrials":97,"cells":2993},{"EARLY_PHASE1":2994,"PHASE1":2996,"PHASE2":2998,"PHASE3":3004,"PHASE4":3006,"NA":3008},{"trials":2995,"activeCount":101},[],{"trials":2997,"activeCount":101},[],{"trials":2999,"activeCount":97,"soonestReadout":1245},[3000],{"nctId":1242,"briefTitle":1243,"status":259,"phases":3001,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":263,"conditions":3002,"interventions":3003},[89,90],[1248,1249],[230,1251],{"trials":3005,"activeCount":101},[],{"trials":3007,"activeCount":101},[],{"trials":3009,"activeCount":101},[],{"intervention":42,"totalTrials":97,"cells":3011},{"EARLY_PHASE1":3012,"PHASE1":3014,"PHASE2":3016,"PHASE3":3022,"PHASE4":3024,"NA":3026},{"trials":3013,"activeCount":101},[],{"trials":3015,"activeCount":101},[],{"trials":3017,"activeCount":97,"soonestReadout":41},[3018],{"nctId":39,"briefTitle":40,"status":259,"phases":3019,"primaryCompletion":41,"completion":1424,"start":1425,"enrollment":1426,"conditions":3020,"interventions":3021},[90],[1428,1429],[42,1393,1379,1421],{"trials":3023,"activeCount":101},[],{"trials":3025,"activeCount":101},[],{"trials":3027,"activeCount":101},[],{"intervention":413,"totalTrials":97,"cells":3029},{"EARLY_PHASE1":3030,"PHASE1":3032,"PHASE2":3034,"PHASE3":3040,"PHASE4":3042,"NA":3044},{"trials":3031,"activeCount":101},[],{"trials":3033,"activeCount":101},[],{"trials":3035,"activeCount":97,"soonestReadout":397},[3036],{"nctId":394,"briefTitle":395,"status":113,"phases":3037,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":3038,"interventions":3039},[90],[219,401,402,226,403,404,227,405,406,407,408,228,409,410,411],[413,230,71],{"trials":3041,"activeCount":101},[],{"trials":3043,"activeCount":101},[],{"trials":3045,"activeCount":101},[],{"intervention":2422,"totalTrials":97,"cells":3047},{"EARLY_PHASE1":3048,"PHASE1":3050,"PHASE2":3052,"PHASE3":3058,"PHASE4":3060,"NA":3062},{"trials":3049,"activeCount":101},[],{"trials":3051,"activeCount":101},[],{"trials":3053,"activeCount":97,"soonestReadout":2410},[3054],{"nctId":2407,"briefTitle":2408,"status":259,"phases":3055,"primaryCompletion":2410,"completion":2410,"start":2411,"enrollment":2412,"conditions":3056,"interventions":3057},[90],[2414,120,121,2415,2416,2417,122,2418,2419,2420],[2422,147,148],{"trials":3059,"activeCount":101},[],{"trials":3061,"activeCount":101},[],{"trials":3063,"activeCount":101},[],{"intervention":916,"totalTrials":97,"cells":3065},{"EARLY_PHASE1":3066,"PHASE1":3068,"PHASE2":3070,"PHASE3":3076,"PHASE4":3078,"NA":3080},{"trials":3067,"activeCount":101},[],{"trials":3069,"activeCount":101},[],{"trials":3071,"activeCount":97,"soonestReadout":56},[3072],{"nctId":54,"briefTitle":55,"status":259,"phases":3073,"primaryCompletion":56,"completion":861,"start":862,"enrollment":863,"conditions":3074,"interventions":3075},[89,90],[865,866,867,868,869,870,871,872,873,874,875,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,891,892,893,894,895,896,897,898,899,900,901,902,903,904,905,906,907,908,909,910,911,912,913,914],[57,624,916],{"trials":3077,"activeCount":101},[],{"trials":3079,"activeCount":101},[],{"trials":3081,"activeCount":101},[],{"intervention":3083,"totalTrials":97,"cells":3084},"Psilocybine",{"EARLY_PHASE1":3085,"PHASE1":3087,"PHASE2":3089,"PHASE3":3099,"PHASE4":3101,"NA":3103},{"trials":3086,"activeCount":101},[],{"trials":3088,"activeCount":101},[],{"trials":3090,"activeCount":97,"soonestReadout":3095},[3091],{"nctId":3092,"briefTitle":3093,"status":1305,"phases":3094,"primaryCompletion":3095,"completion":3095,"start":2246,"enrollment":21,"conditions":3096,"interventions":3098},"NCT06827054","Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids",[90],"2027-05-05",[3097,32],"Hematopoietic and Lymphatic System Neoplasm",[3083],{"trials":3100,"activeCount":101},[],{"trials":3102,"activeCount":101},[],{"trials":3104,"activeCount":101},[],{"intervention":3106,"totalTrials":36,"cells":3107},"Cisplatin",{"EARLY_PHASE1":3108,"PHASE1":3110,"PHASE2":3208,"PHASE3":3248,"PHASE4":3250,"NA":3252},{"trials":3109,"activeCount":101},[],{"trials":3111,"activeCount":101},[3112,3123,3171,3179,3186,3195],{"nctId":3113,"briefTitle":3114,"status":133,"phases":3115,"primaryCompletion":3116,"completion":3117,"start":3118,"enrollment":33,"conditions":3119,"interventions":3122},"NCT01014598","Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis",[89],"2013-10-23","2017-05-01","2007-12-04",[3120,2498,3121,2499],"Metastatic Malignant Neoplasm in the Lung","Stage IV Adult Soft Tissue Sarcoma",[3106],{"nctId":3124,"briefTitle":3125,"status":235,"phases":3126,"primaryCompletion":3127,"start":3128,"enrollment":101,"conditions":3129,"interventions":3168},"NCT01728480","Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy",[89],"2015-10","2014-01",[3130,3131,3132,3133,3134,3135,3136,3137,3138,3139,3140,3141,3142,3143,3144,3145,3146,3147,3148,3149,3150,3151,3152,3153,3154,3155,3156,3157,3158,3159,3160,3161,3162,3163,3164,3165,3166,3167],"Mucositis","Recurrent Squamous Cell Carcinoma of the Hypopharynx","Recurrent Squamous Cell Carcinoma of the Larynx","Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity","Recurrent Squamous Cell Carcinoma of the Nasopharynx","Recurrent Squamous Cell Carcinoma of the Oropharynx","Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Recurrent Verrucous Carcinoma of the Larynx","Recurrent Verrucous Carcinoma of the Oral Cavity","Stage III Squamous Cell Carcinoma of the Hypopharynx","Stage III Squamous Cell Carcinoma of the Larynx","Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage III Squamous Cell Carcinoma of the Nasopharynx","Stage III Squamous Cell Carcinoma of the Oropharynx","Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage III Verrucous Carcinoma of the Larynx","Stage III Verrucous Carcinoma of the Oral Cavity","Stage IV Squamous Cell Carcinoma of the Hypopharynx","Stage IV Squamous Cell Carcinoma of the Nasopharynx","Stage IVA Squamous Cell Carcinoma of the Larynx","Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVA Squamous Cell Carcinoma of the Oropharynx","Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVA Verrucous Carcinoma of the Larynx","Stage IVA Verrucous Carcinoma of the Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Larynx","Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVB Squamous Cell Carcinoma of the Oropharynx","Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVB Verrucous Carcinoma of the Larynx","Stage IVB Verrucous Carcinoma of the Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Larynx","Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IVC Squamous Cell Carcinoma of the Oropharynx","Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage IVC Verrucous Carcinoma of the Larynx","Stage IVC Verrucous Carcinoma of the Oral Cavity","Tongue Cancer",[3169,3170],"entolimod","cisplatin",{"nctId":3172,"briefTitle":3173,"status":365,"phases":3174,"primaryCompletion":2213,"completion":1132,"start":2289,"enrollment":30,"conditions":3175,"interventions":3177},"NCT01093092","Calcitriol, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery",[89],[3176],"Adult Solid Neoplasm",[3106,3178],"Gemcitabine Hydrochloride",{"nctId":3180,"briefTitle":3181,"status":133,"phases":3182,"primaryCompletion":3183,"completion":1104,"start":2031,"enrollment":945,"conditions":3184,"interventions":3185},"NCT00084734","Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors",[89],"2009-11",[18],[1052,3170,2307],{"nctId":3187,"briefTitle":3188,"status":235,"phases":3189,"primaryCompletion":3190,"start":3191,"enrollment":101,"conditions":3192,"interventions":3193},"NCT01971489","Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors",[89],"2016-08","2015-09",[3176,2496,2497,2498,2499],[3194,3106,3178],"Buparlisib",{"nctId":3196,"briefTitle":3197,"status":133,"phases":3198,"primaryCompletion":3199,"completion":3200,"start":3201,"enrollment":3202,"conditions":3203,"interventions":3205},"NCT02227940","Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer",[89],"2018-12-27","2019-02-12","2015-01-08",38,[866,3204,549,553,560],"ALK Positive",[3206,3106,3178,3207],"Ceritinib","Paclitaxel Albumin-Stabilized Nanoparticle Formulation",{"trials":3209,"activeCount":97,"soonestReadout":3214},[3210,3224,3238],{"nctId":3211,"briefTitle":3212,"status":113,"phases":3213,"primaryCompletion":3214,"completion":3215,"start":3216,"enrollment":3217,"conditions":3218,"interventions":3223},"NCT03965234","Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases",[89,90],"2029-05-25","2030-05-25","2020-07-16",99,[3219,3120,3220,3221,3222,29],"Metastatic Bone Sarcoma","Metastatic Soft Tissue Sarcoma","Metastatic Unresectable Sarcoma","Resectable Sarcoma",[3106],{"nctId":3225,"briefTitle":3226,"status":365,"phases":3227,"primaryCompletion":492,"completion":493,"start":3228,"enrollment":24,"conditions":3229,"interventions":3237},"NCT01682031","Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy",[90],"2009-06",[3230,3130,3231,3139,3140,3141,3142,3143,3144,3147,3232,3233,3148,3234,3235,3236],"Chemotherapeutic Agent Toxicity","Radiation Toxicity","Stage IV Squamous Cell Carcinoma of the Larynx","Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage IV Squamous Cell Carcinoma of the Oropharynx","Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Xerostomia",[3170],{"nctId":3239,"briefTitle":3240,"status":133,"phases":3241,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":3202,"conditions":3245,"interventions":3246},"NCT00248495","Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",[90],"2011-04-29","2017-04-05","2005-06-08",[20],[3170,3247],"pemetrexed disodium",{"trials":3249,"activeCount":101},[],{"trials":3251,"activeCount":101},[],{"trials":3253,"activeCount":101},[3254],{"nctId":3255,"briefTitle":3256,"status":133,"phases":3257,"primaryCompletion":3258,"start":3259,"enrollment":440,"conditions":3260,"interventions":3264},"NCT00003569","Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel",[],"2003-06","1998-03",[3261,20,3262,3263],"Head and Neck Cancer","Neurotoxicity","Ovarian Cancer",[3170,3265,809],"dimesna",{"intervention":3267,"totalTrials":317,"cells":3268},"Photodynamic Therapy",{"EARLY_PHASE1":3269,"PHASE1":3271,"PHASE2":3376,"PHASE3":3416,"PHASE4":3418,"NA":3420},{"trials":3270,"activeCount":101},[],{"trials":3272,"activeCount":101},[3273,3284,3293,3351,3363],{"nctId":3274,"briefTitle":3275,"status":133,"phases":3276,"primaryCompletion":3277,"completion":3277,"start":3278,"enrollment":138,"conditions":3279,"interventions":3282},"NCT01854684","Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery",[89],"2018-09-04","2014-02-21",[2496,3280,3281,2497,2498],"Stage IIA Non-Small Cell Lung Carcinoma","Stage IIB Non-Small Cell Lung Carcinoma",[3283,3267],"Temoporfin",{"nctId":3285,"briefTitle":3286,"status":365,"phases":3287,"primaryCompletion":3288,"completion":599,"start":3289,"enrollment":370,"conditions":3290,"interventions":3292},"NCT04836429","Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease",[89],"2024-02-03","2022-03-10",[266,3291],"Pleural Disorder",[2483,3267],{"nctId":3294,"briefTitle":3295,"status":133,"phases":3296,"primaryCompletion":3297,"completion":3298,"start":3299,"enrollment":863,"conditions":3300,"interventions":3348},"NCT00470496","Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer",[89],"2011-10-28","2018-08-30","2006-10-19",[3301,3302,3303,3304,3305,3306,3307,3308,3309,3310,3131,3132,3133,3134,3135,3136,3311,3137,3138,3312,3313,3314,3315,3316,3317,3318,3319,3320,3321,3322,3323,3324,3325,3326,3327,3328,3329,3330,3331,3332,3333,3334,3335,3336,3337,3338,3339,3340,3341,3342,3343,3344,3345,3346,3347],"Recurrent Adenoid Cystic Carcinoma of the Oral Cavity","Recurrent Basal Cell Carcinoma of the Lip","Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Recurrent Lymphoepithelioma of the Nasopharynx","Recurrent Lymphoepithelioma of the Oropharynx","Recurrent Metastatic Squamous Neck Cancer With Occult Primary","Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Recurrent Mucoepidermoid Carcinoma of the Oral Cavity","Recurrent Salivary Gland Cancer","Recurrent Thyroid Cancer","Stage I Adenoid Cystic Carcinoma of the Oral Cavity","Stage I Basal Cell Carcinoma of the Lip","Stage I Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage I Follicular Thyroid Cancer","Stage I Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage I Lymphoepithelioma of the Nasopharynx","Stage I Lymphoepithelioma of the Oropharynx","Stage I Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage I Mucoepidermoid Carcinoma of the Oral Cavity","Stage I Papillary Thyroid Cancer","Stage I Salivary Gland Cancer","Stage I Squamous Cell Carcinoma of the Hypopharynx","Stage I Squamous Cell Carcinoma of the Larynx","Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage I Squamous Cell Carcinoma of the Oropharynx","Stage I Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage I Verrucous Carcinoma of the Larynx","Stage I Verrucous Carcinoma of the Oral Cavity","Stage II Adenoid Cystic Carcinoma of the Oral Cavity","Stage II Basal Cell Carcinoma of the Lip","Stage II Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity","Stage II Follicular Thyroid Cancer","Stage II Inverted Papilloma of the Paranasal Sinus and Nasal Cavity","Stage II Lymphoepithelioma of the Nasopharynx","Stage II Lymphoepithelioma of the Oropharynx","Stage II Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity","Stage II Mucoepidermoid Carcinoma of the Oral Cavity","Stage II Papillary Thyroid Cancer","Stage II Salivary Gland Cancer","Stage II Squamous Cell Carcinoma of the Hypopharynx","Stage II Squamous Cell Carcinoma of the Larynx","Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity","Stage II Squamous Cell Carcinoma of the Oropharynx","Stage II Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity","Stage II Verrucous Carcinoma of the Larynx","Stage II Verrucous Carcinoma of the Oral Cavity",[3349,3350],"HPPH","photodynamic therapy",{"nctId":3352,"briefTitle":3353,"status":133,"phases":3354,"primaryCompletion":453,"completion":3355,"start":1624,"enrollment":27,"conditions":3356,"interventions":3362},"NCT01668823","Photodynamic Therapy in Treating Patients With Lung Cancer",[89],"2014-06",[3357,3358,3359,3360,3361],"Adenocarcinoma of the Lung","Large Cell Lung Cancer","Recurrent Non-small Cell Lung Cancer","Squamous Cell Lung Cancer","Stage 0 Non-small Cell Lung Cancer",[3349,3350],{"nctId":3364,"briefTitle":3365,"status":133,"phases":3366,"primaryCompletion":3367,"completion":3368,"start":3369,"enrollment":2744,"conditions":3370,"interventions":3374},"NCT01292668","Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer",[89],"2012-07","2014-09","2011-03",[3371,3372,3373],"Basal Cell Carcinoma of the Skin","Pain","Recurrent Skin Cancer",[3375,3350],"methyl-5-aminolevulinate hydrochloride cream",{"trials":3377,"activeCount":97,"soonestReadout":3382},[3378,3389,3400],{"nctId":3379,"briefTitle":3380,"status":113,"phases":3381,"primaryCompletion":3382,"completion":3382,"start":3383,"enrollment":2744,"conditions":3384,"interventions":3387},"NCT06307548","Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer",[89,90],"2027-06-01","2024-07-30",[3385,252,3386],"Locally Advanced Colorectal Carcinoma","Stage III Colorectal Cancer",[3388,3267],"Aminolevulinic Acid",{"nctId":3390,"briefTitle":3391,"status":365,"phases":3392,"primaryCompletion":3393,"completion":3394,"start":3395,"enrollment":440,"conditions":3396,"interventions":3399},"NCT03090412","Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer",[90],"2021-08-01","2021-08-06","2018-03-07",[3397,3398],"Stage I Oral Cavity Squamous Cell Carcinoma","Stage II Oral Cavity Squamous Cell Carcinoma",[3349,3267],{"nctId":3401,"briefTitle":3402,"status":365,"phases":3403,"primaryCompletion":3404,"completion":3405,"start":3406,"enrollment":582,"conditions":3407,"interventions":3415},"NCT02068157","Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer",[90],"2016-10-13","2016-11-04","2014-04-01",[3408,3409,3410,3411,3412,3413,3414],"Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Laryngeal Verrucous Carcinoma","Recurrent Lip and Oral Cavity Squamous Cell Carcinoma","Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary","Recurrent Oral Cavity Verrucous Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Tongue Carcinoma",[3267,2483],{"trials":3417,"activeCount":101},[],{"trials":3419,"activeCount":101},[],{"trials":3421,"activeCount":101},[3422],{"nctId":3423,"briefTitle":3424,"status":235,"phases":3425,"primaryCompletion":3426,"completion":3426,"start":3427,"enrollment":101,"conditions":3428,"interventions":3429},"NCT01718223","Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer",[93],"2014-08","2013-12",[3133,3135,3138,3325,3326,3329,3343,3344,3347,3167],[3350,3430],"temoporfin",{"intervention":809,"totalTrials":9,"cells":3432},{"EARLY_PHASE1":3433,"PHASE1":3435,"PHASE2":3445,"PHASE3":3459,"PHASE4":3461,"NA":3463},{"trials":3434,"activeCount":101},[],{"trials":3436,"activeCount":101},[3437,3441],{"nctId":641,"briefTitle":642,"status":133,"phases":3438,"primaryCompletion":644,"completion":645,"start":646,"enrollment":317,"conditions":3439,"interventions":3440},[89],[648,649,650,651,652,653,654,655,141,142,144,656,657,658,659,660,661,662,663],[146,57,665,666,667,147,148],{"nctId":1458,"briefTitle":1459,"status":133,"phases":3442,"primaryCompletion":1461,"completion":1462,"start":1463,"enrollment":687,"conditions":3443,"interventions":3444},[89],[15,23,18],[711,1466,808,809],{"trials":3446,"activeCount":97,"soonestReadout":1498},[3447,3451,3455],{"nctId":798,"briefTitle":799,"status":133,"phases":3448,"primaryCompletion":801,"completion":802,"start":803,"enrollment":804,"conditions":3449,"interventions":3450},[89,90],[806],[711,808,639,809,810],{"nctId":1495,"briefTitle":1496,"status":113,"phases":3452,"primaryCompletion":1498,"completion":1498,"start":1499,"enrollment":1500,"conditions":3453,"interventions":3454},[90],[1502],[52,1504,667],{"nctId":1506,"briefTitle":1507,"status":365,"phases":3456,"primaryCompletion":494,"completion":1133,"start":1509,"enrollment":1219,"conditions":3457,"interventions":3458},[90],[20],[808,809],{"trials":3460,"activeCount":101},[],{"trials":3462,"activeCount":101},[],{"trials":3464,"activeCount":101},[3465],{"nctId":3255,"briefTitle":3256,"status":133,"phases":3466,"primaryCompletion":3258,"start":3259,"enrollment":440,"conditions":3467,"interventions":3468},[],[3261,20,3262,3263],[3170,3265,809],{"intervention":3470,"totalTrials":582,"cells":3471},"aminolevulinic acid",{"EARLY_PHASE1":3472,"PHASE1":3474,"PHASE2":3476,"PHASE3":3493,"PHASE4":3495,"NA":3497},{"trials":3473,"activeCount":101},[],{"trials":3475,"activeCount":101},[],{"trials":3477,"activeCount":97,"soonestReadout":3382},[3478,3482],{"nctId":3379,"briefTitle":3380,"status":113,"phases":3479,"primaryCompletion":3382,"completion":3382,"start":3383,"enrollment":2744,"conditions":3480,"interventions":3481},[89,90],[3385,252,3386],[3388,3267],{"nctId":3483,"briefTitle":3484,"status":133,"phases":3485,"primaryCompletion":1541,"completion":3486,"start":3487,"enrollment":3488,"conditions":3489,"interventions":3492},"NCT00002975","Photodynamic Therapy in Treating Patients With Skin Cancer",[90],"2010-04","1997-02",180,[3490,3491],"Non-melanomatous Skin Cancer","Precancerous Condition",[3470],{"trials":3494,"activeCount":101},[],{"trials":3496,"activeCount":101},[],{"trials":3498,"activeCount":101},[3499],{"nctId":3500,"briefTitle":3501,"status":365,"phases":3502,"primaryCompletion":2290,"completion":3503,"start":3504,"enrollment":2412,"conditions":3505,"interventions":3507},"NCT00524485","Photodynamic Therapy Using Topical Aminolevulinic Acid in Treating Patients With Actinic Keratosis",[93],"2009-05","2005-05",[3506],"Precancerous\u002FNonmalignant Condition",[3470],{"intervention":2325,"totalTrials":440,"cells":3509},{"EARLY_PHASE1":3510,"PHASE1":3512,"PHASE2":3514,"PHASE3":3520,"PHASE4":3522,"NA":3524},{"trials":3511,"activeCount":101},[],{"trials":3513,"activeCount":101},[],{"trials":3515,"activeCount":97,"soonestReadout":2319},[3516],{"nctId":2316,"briefTitle":2317,"status":113,"phases":3517,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":804,"conditions":3518,"interventions":3519},[90],[240,186,2322,188],[2324,2325],{"trials":3521,"activeCount":101},[],{"trials":3523,"activeCount":101},[],{"trials":3525,"activeCount":101},[3526],{"nctId":3527,"briefTitle":3528,"status":133,"phases":3529,"primaryCompletion":1688,"completion":1688,"start":3530,"enrollment":3531,"conditions":3532,"interventions":3533},"NCT01027416","Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients",[93],"2009-12-14",59,[806],[2325],{"intervention":47,"totalTrials":9,"cells":3535},{"EARLY_PHASE1":3536,"PHASE1":3538,"PHASE2":3569,"PHASE3":3583,"PHASE4":3589,"NA":3591},{"trials":3537,"activeCount":101},[],{"trials":3539,"activeCount":97,"soonestReadout":46},[3540,3544,3560],{"nctId":44,"briefTitle":45,"status":259,"phases":3541,"primaryCompletion":46,"completion":620,"start":621,"enrollment":317,"conditions":3542,"interventions":3543},[89],[226,227,228],[47,57,624,625],{"nctId":3545,"briefTitle":3546,"status":365,"phases":3547,"primaryCompletion":3548,"completion":3549,"start":3550,"enrollment":1271,"conditions":3551,"interventions":3557},"NCT03691376","Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[89],"2021-01-30","2024-06-24","2019-03-08",[884,885,886,3552,401,3553,226,227,228,3554,3555,3556],"Platinum-Sensitive Fallopian Tube Carcinoma","Platinum-Sensitive Primary Peritoneal Carcinoma","Refractory Fallopian Tube Carcinoma","Refractory Ovarian Carcinoma","Refractory Primary Peritoneal Carcinoma",[47,3558,3559],"Autologous NY-ESO-1-specific CD8-positive T Lymphocytes","Melphalan",{"nctId":3561,"briefTitle":3562,"status":133,"phases":3563,"primaryCompletion":3564,"start":3565,"enrollment":97,"conditions":3566,"interventions":3567},"NCT00058045","Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer",[89],"2003-11","2002-08",[23],[948,3568],"recombinant human stem cell factor",{"trials":3570,"activeCount":101},[3571,3575],{"nctId":283,"briefTitle":284,"status":235,"phases":3572,"primaryCompletion":286,"completion":287,"start":288,"enrollment":101,"conditions":3573,"interventions":3574},[90],[290,291,292,293,294,295],[57,297,298,71,299,47],{"nctId":3576,"briefTitle":3577,"status":133,"phases":3578,"primaryCompletion":3579,"completion":469,"start":3580,"enrollment":687,"conditions":3581,"interventions":3582},"NCT00004248","Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",[90],"2000-06","1999-07",[457],[948,1963],{"trials":3584,"activeCount":101},[3585],{"nctId":939,"briefTitle":940,"status":133,"phases":3586,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":3587,"interventions":3588},[91],[15],[948,711,639,949,858,950,844],{"trials":3590,"activeCount":101},[],{"trials":3592,"activeCount":101},[],{"intervention":2216,"totalTrials":370,"cells":3594},{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3603,"PHASE3":3637,"PHASE4":3639,"NA":3641},{"trials":3596,"activeCount":101},[],{"trials":3598,"activeCount":97,"soonestReadout":51},[3599],{"nctId":49,"briefTitle":50,"status":259,"phases":3600,"primaryCompletion":51,"completion":1328,"start":1329,"enrollment":1308,"conditions":3601,"interventions":3602},[89],[1331,603,610,1332,1333,1334,1335],[52,1320,1337,1338,1339],{"trials":3604,"activeCount":101},[3605,3609,3613,3617],{"nctId":2286,"briefTitle":2287,"status":365,"phases":3606,"primaryCompletion":2289,"completion":2289,"start":2290,"enrollment":317,"conditions":3607,"interventions":3608},[90],[23],[2216,2293,1489,1088,2294,2295,2296],{"nctId":2327,"briefTitle":2328,"status":133,"phases":3610,"primaryCompletion":1230,"completion":2330,"start":922,"enrollment":1187,"conditions":3611,"interventions":3612},[89,90],[23],[2216,1489],{"nctId":2210,"briefTitle":2211,"status":133,"phases":3614,"primaryCompletion":2213,"completion":2213,"start":1165,"enrollment":307,"conditions":3615,"interventions":3616},[90],[15],[2216,2178],{"nctId":3618,"briefTitle":3619,"status":133,"phases":3620,"primaryCompletion":3621,"completion":262,"start":3622,"enrollment":21,"conditions":3623,"interventions":3634},"NCT01682044","Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma",[90],"2013-11-22","2007-04-17",[3624,3625,3626,3627,3628,988,991,2101,2102,2103,2105,2106,1014,1015,1016,1018,1020,1024,3629,3630,3631,3632,3633,2111,2112,2113,2114,2115,2120,2121,2122,2123,2124],"Contiguous Stage II Grade 1 Follicular Lymphoma","Contiguous Stage II Grade 2 Follicular Lymphoma","Contiguous Stage II Grade 3 Follicular Lymphoma","Contiguous Stage II Marginal Zone Lymphoma","Contiguous Stage II Small Lymphocytic Lymphoma","Stage I Grade 1 Follicular Lymphoma","Stage I Grade 2 Follicular Lymphoma","Stage I Grade 3 Follicular Lymphoma","Stage I Marginal Zone Lymphoma","Stage I Small Lymphocytic Lymphoma",[3635,2216,3636],"pegfilgrastim","western blotting",{"trials":3638,"activeCount":101},[],{"trials":3640,"activeCount":101},[],{"trials":3642,"activeCount":101},[],{"intervention":1081,"totalTrials":582,"cells":3644},{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3674,"PHASE3":3684,"PHASE4":3686,"NA":3688},{"trials":3646,"activeCount":101},[],{"trials":3648,"activeCount":97,"soonestReadout":3653},[3649],{"nctId":3650,"briefTitle":3651,"status":113,"phases":3652,"primaryCompletion":3653,"completion":1498,"start":3654,"enrollment":307,"conditions":3655,"interventions":3672},"NCT04511039","Trifluridine\u002FTipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer",[89],"2028-09-01","2021-06-08",[866,3656,3657,3658,3659,3385,167,351,169,3660,3661,3662,3663,3664,3665,3666,3667,3668,3669,3670,3671,253,355,356,357,254,358,359,360],"Clinical Stage III Gastroesophageal Junction Adenocarcinoma","Clinical Stage IV Gastroesophageal Junction Adenocarcinoma","Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma","Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A","Pathologic Stage III Gastroesophageal Junction Adenocarcinoma","Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma","Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma","Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma","Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma","Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma","Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8","Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",[1081,3673],"Talazoparib Tosylate",{"trials":3675,"activeCount":101},[3676,3680],{"nctId":1182,"briefTitle":1183,"status":133,"phases":3677,"primaryCompletion":1185,"completion":1185,"start":1186,"enrollment":1187,"conditions":3678,"interventions":3679},[90],[1189,1190,1191,1192,1193,1194,1195,253,1196,1197,355,356,1198,1199,357,1200,358,1201,1202,359,1203,1204,360,1205,1206,255,1207],[444,230,1081],{"nctId":1059,"briefTitle":1060,"status":133,"phases":3681,"primaryCompletion":1062,"completion":1063,"start":1064,"enrollment":16,"conditions":3682,"interventions":3683},[90],[1066,1067,162,163,1068,1069,1070,1071,1072,1073,1074,1075,1076,1077,1078,1079],[1081,175],{"trials":3685,"activeCount":101},[],{"trials":3687,"activeCount":101},[],{"trials":3689,"activeCount":101},[],{"intervention":62,"totalTrials":582,"cells":3691},{"EARLY_PHASE1":3692,"PHASE1":3694,"PHASE2":3708,"PHASE3":3710,"PHASE4":3712,"NA":3714},{"trials":3693,"activeCount":101},[],{"trials":3695,"activeCount":97,"soonestReadout":61},[3696,3700,3704],{"nctId":1537,"briefTitle":1538,"status":133,"phases":3697,"primaryCompletion":1540,"completion":453,"start":1541,"enrollment":24,"conditions":3698,"interventions":3699},[89],[1543,1544,1545],[1547,1548,1489,792,1549,1090,1550],{"nctId":59,"briefTitle":60,"status":259,"phases":3701,"primaryCompletion":61,"completion":1387,"start":1388,"enrollment":24,"conditions":3702,"interventions":3703},[89],[1390,745],[62,1392,1393,1379],{"nctId":1395,"briefTitle":1396,"status":133,"phases":3705,"primaryCompletion":1398,"completion":70,"start":518,"enrollment":1399,"conditions":3706,"interventions":3707},[89],[1401,1402,1403],[62,1405,1393,1379],{"trials":3709,"activeCount":101},[],{"trials":3711,"activeCount":101},[],{"trials":3713,"activeCount":101},[],{"trials":3715,"activeCount":101},[],{"intervention":3673,"totalTrials":440,"cells":3717},{"EARLY_PHASE1":3718,"PHASE1":3720,"PHASE2":3737,"PHASE3":3739,"PHASE4":3741,"NA":3743},{"trials":3719,"activeCount":101},[],{"trials":3721,"activeCount":97,"soonestReadout":3653},[3722,3726],{"nctId":3650,"briefTitle":3651,"status":113,"phases":3723,"primaryCompletion":3653,"completion":1498,"start":3654,"enrollment":307,"conditions":3724,"interventions":3725},[89],[866,3656,3657,3658,3659,3385,167,351,169,3660,3661,3662,3663,3664,3665,3666,3667,3668,3669,3670,3671,253,355,356,357,254,358,359,360],[1081,3673],{"nctId":3727,"briefTitle":3728,"status":133,"phases":3729,"primaryCompletion":3730,"completion":3731,"start":3732,"enrollment":687,"conditions":3733,"interventions":3734},"NCT04207190","Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia",[89],"2024-05-26","2024-06-29","2020-10-23",[675,676],[3735,3736,3673],"Gemtuzumab Ozogamicin","Talazoparib",{"trials":3738,"activeCount":101},[],{"trials":3740,"activeCount":101},[],{"trials":3742,"activeCount":101},[],{"trials":3744,"activeCount":101},[],{"intervention":1348,"totalTrials":440,"cells":3746},{"EARLY_PHASE1":3747,"PHASE1":3749,"PHASE2":3759,"PHASE3":3761,"PHASE4":3763,"NA":3765},{"trials":3748,"activeCount":101},[],{"trials":3750,"activeCount":97,"soonestReadout":1354},[3751,3755],{"nctId":1341,"briefTitle":1342,"status":235,"phases":3752,"primaryCompletion":1344,"completion":1344,"start":325,"enrollment":101,"conditions":3753,"interventions":3754},[89],[1346,1022],[1320,1348,830,1349],{"nctId":1351,"briefTitle":1352,"status":113,"phases":3756,"primaryCompletion":1354,"completion":1355,"start":75,"enrollment":863,"conditions":3757,"interventions":3758},[89],[1346,1022],[1358,1348,1320,830],{"trials":3760,"activeCount":101},[],{"trials":3762,"activeCount":101},[],{"trials":3764,"activeCount":101},[],{"trials":3766,"activeCount":101},[],{"intervention":625,"totalTrials":97,"cells":3768},{"EARLY_PHASE1":3769,"PHASE1":3771,"PHASE2":3777,"PHASE3":3779,"PHASE4":3781,"NA":3783},{"trials":3770,"activeCount":101},[],{"trials":3772,"activeCount":97,"soonestReadout":46},[3773],{"nctId":44,"briefTitle":45,"status":259,"phases":3774,"primaryCompletion":46,"completion":620,"start":621,"enrollment":317,"conditions":3775,"interventions":3776},[89],[226,227,228],[47,57,624,625],{"trials":3778,"activeCount":101},[],{"trials":3780,"activeCount":101},[],{"trials":3782,"activeCount":101},[],{"trials":3784,"activeCount":101},[],{"intervention":3786,"totalTrials":97,"cells":3787},"Marijuana via vape device",{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3801,"PHASE3":3803,"PHASE4":3805,"NA":3807},{"trials":3789,"activeCount":101},[],{"trials":3791,"activeCount":97,"soonestReadout":397},[3792],{"nctId":3793,"briefTitle":3794,"status":1305,"phases":3795,"primaryCompletion":397,"completion":3796,"start":686,"enrollment":159,"conditions":3797,"interventions":3799},"NCT06055231","PK\u002FPD of Vaping THC-containing Liquids vs. Smoked Cannabis",[89],"2027-09-15",[3798],"Cigarette Smoking-Related Carcinoma",[3786,3800],"Marijuana via joint",{"trials":3802,"activeCount":101},[],{"trials":3804,"activeCount":101},[],{"trials":3806,"activeCount":101},[],{"trials":3808,"activeCount":101},[],{"intervention":3800,"totalTrials":97,"cells":3810},{"EARLY_PHASE1":3811,"PHASE1":3813,"PHASE2":3819,"PHASE3":3821,"PHASE4":3823,"NA":3825},{"trials":3812,"activeCount":101},[],{"trials":3814,"activeCount":97,"soonestReadout":397},[3815],{"nctId":3793,"briefTitle":3794,"status":1305,"phases":3816,"primaryCompletion":397,"completion":3796,"start":686,"enrollment":159,"conditions":3817,"interventions":3818},[89],[3798],[3786,3800],{"trials":3820,"activeCount":101},[],{"trials":3822,"activeCount":101},[],{"trials":3824,"activeCount":101},[],{"trials":3826,"activeCount":101},[],{"intervention":1338,"totalTrials":97,"cells":3828},{"EARLY_PHASE1":3829,"PHASE1":3831,"PHASE2":3837,"PHASE3":3839,"PHASE4":3841,"NA":3843},{"trials":3830,"activeCount":101},[],{"trials":3832,"activeCount":97,"soonestReadout":51},[3833],{"nctId":49,"briefTitle":50,"status":259,"phases":3834,"primaryCompletion":51,"completion":1328,"start":1329,"enrollment":1308,"conditions":3835,"interventions":3836},[89],[1331,603,610,1332,1333,1334,1335],[52,1320,1337,1338,1339],{"trials":3838,"activeCount":101},[],{"trials":3840,"activeCount":101},[],{"trials":3842,"activeCount":101},[],{"trials":3844,"activeCount":101},[],{"intervention":3846,"totalTrials":97,"cells":3847},"Leuprolide Acetate",{"EARLY_PHASE1":3848,"PHASE1":3850,"PHASE2":3861,"PHASE3":3863,"PHASE4":3865,"NA":3867},{"trials":3849,"activeCount":101},[],{"trials":3851,"activeCount":97,"soonestReadout":3856},[3852],{"nctId":3853,"briefTitle":3854,"status":113,"phases":3855,"primaryCompletion":3856,"completion":3856,"start":3857,"enrollment":30,"conditions":3858,"interventions":3859},"NCT06305598","Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer",[89],"2029-12-15","2024-12-19",[1713,2529,1720],[3846,3860],"Testosterone Cypionate",{"trials":3862,"activeCount":101},[],{"trials":3864,"activeCount":101},[],{"trials":3866,"activeCount":101},[],{"trials":3868,"activeCount":101},[],{"intervention":3860,"totalTrials":97,"cells":3870},{"EARLY_PHASE1":3871,"PHASE1":3873,"PHASE2":3879,"PHASE3":3881,"PHASE4":3883,"NA":3885},{"trials":3872,"activeCount":101},[],{"trials":3874,"activeCount":97,"soonestReadout":3856},[3875],{"nctId":3853,"briefTitle":3854,"status":113,"phases":3876,"primaryCompletion":3856,"completion":3856,"start":3857,"enrollment":30,"conditions":3877,"interventions":3878},[89],[1713,2529,1720],[3846,3860],{"trials":3880,"activeCount":101},[],{"trials":3882,"activeCount":101},[],{"trials":3884,"activeCount":101},[],{"trials":3886,"activeCount":101},[],{"intervention":678,"totalTrials":97,"cells":3888},{"EARLY_PHASE1":3889,"PHASE1":3891,"PHASE2":3897,"PHASE3":3899,"PHASE4":3901,"NA":3903},{"trials":3890,"activeCount":101},[],{"trials":3892,"activeCount":97,"soonestReadout":672},[3893],{"nctId":669,"briefTitle":670,"status":113,"phases":3894,"primaryCompletion":672,"completion":672,"start":506,"enrollment":673,"conditions":3895,"interventions":3896},[89],[675,676],[678,57,298,679],{"trials":3898,"activeCount":101},[],{"trials":3900,"activeCount":101},[],{"trials":3902,"activeCount":101},[],{"trials":3904,"activeCount":101},[],{"intervention":679,"totalTrials":97,"cells":3906},{"EARLY_PHASE1":3907,"PHASE1":3909,"PHASE2":3915,"PHASE3":3917,"PHASE4":3919,"NA":3921},{"trials":3908,"activeCount":101},[],{"trials":3910,"activeCount":97,"soonestReadout":672},[3911],{"nctId":669,"briefTitle":670,"status":113,"phases":3912,"primaryCompletion":672,"completion":672,"start":506,"enrollment":673,"conditions":3913,"interventions":3914},[89],[675,676],[678,57,298,679],{"trials":3916,"activeCount":101},[],{"trials":3918,"activeCount":101},[],{"trials":3920,"activeCount":101},[],{"trials":3922,"activeCount":101},[],{"intervention":1358,"totalTrials":97,"cells":3924},{"EARLY_PHASE1":3925,"PHASE1":3927,"PHASE2":3933,"PHASE3":3935,"PHASE4":3937,"NA":3939},{"trials":3926,"activeCount":101},[],{"trials":3928,"activeCount":97,"soonestReadout":1354},[3929],{"nctId":1351,"briefTitle":1352,"status":113,"phases":3930,"primaryCompletion":1354,"completion":1355,"start":75,"enrollment":863,"conditions":3931,"interventions":3932},[89],[1346,1022],[1358,1348,1320,830],{"trials":3934,"activeCount":101},[],{"trials":3936,"activeCount":101},[],{"trials":3938,"activeCount":101},[],{"trials":3940,"activeCount":101},[],{"intervention":3942,"totalTrials":97,"cells":3943},"GB-5267 - IV only",{"EARLY_PHASE1":3944,"PHASE1":3946,"PHASE2":3958,"PHASE3":3960,"PHASE4":3962,"NA":3964},{"trials":3945,"activeCount":101},[],{"trials":3947,"activeCount":97,"soonestReadout":3952},[3948],{"nctId":3949,"briefTitle":3950,"status":1305,"phases":3951,"primaryCompletion":3952,"completion":3953,"start":198,"enrollment":24,"conditions":3954,"interventions":3956},"NCT07489287","GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer",[89],"2028-01-15","2030-01-15",[3955],"Platinum-resistant Ovarian Cancer",[3942,3957],"GB-5267 -Combined IV and IP",{"trials":3959,"activeCount":101},[],{"trials":3961,"activeCount":101},[],{"trials":3963,"activeCount":101},[],{"trials":3965,"activeCount":101},[],{"intervention":3957,"totalTrials":97,"cells":3967},{"EARLY_PHASE1":3968,"PHASE1":3970,"PHASE2":3976,"PHASE3":3978,"PHASE4":3980,"NA":3982},{"trials":3969,"activeCount":101},[],{"trials":3971,"activeCount":97,"soonestReadout":3952},[3972],{"nctId":3949,"briefTitle":3950,"status":1305,"phases":3973,"primaryCompletion":3952,"completion":3953,"start":198,"enrollment":24,"conditions":3974,"interventions":3975},[89],[3955],[3942,3957],{"trials":3977,"activeCount":101},[],{"trials":3979,"activeCount":101},[],{"trials":3981,"activeCount":101},[],{"trials":3983,"activeCount":101},[],{"intervention":3985,"totalTrials":97,"cells":3986},"Cannabis sativa Extract",{"EARLY_PHASE1":3987,"PHASE1":3998,"PHASE2":4000,"PHASE3":4002,"PHASE4":4004,"NA":4006},{"trials":3988,"activeCount":97,"soonestReadout":3993},[3989],{"nctId":3990,"briefTitle":3991,"status":1305,"phases":3992,"primaryCompletion":3993,"completion":3993,"start":2246,"enrollment":212,"conditions":3994,"interventions":3996},"NCT06334016","Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream",[88],"2028-03-01",[3995],"Cannabis Dependence",[3985,3997],"Nicotine",{"trials":3999,"activeCount":101},[],{"trials":4001,"activeCount":101},[],{"trials":4003,"activeCount":101},[],{"trials":4005,"activeCount":101},[],{"trials":4007,"activeCount":101},[],{"intervention":445,"totalTrials":97,"cells":4009},{"EARLY_PHASE1":4010,"PHASE1":4016,"PHASE2":4018,"PHASE3":4020,"PHASE4":4022,"NA":4024},{"trials":4011,"activeCount":97,"soonestReadout":85},[4012],{"nctId":83,"briefTitle":84,"status":259,"phases":4013,"primaryCompletion":85,"completion":438,"start":439,"enrollment":440,"conditions":4014,"interventions":4015},[88],[442],[86,174,175,173,230,444,312,445],{"trials":4017,"activeCount":101},[],{"trials":4019,"activeCount":101},[],{"trials":4021,"activeCount":101},[],{"trials":4023,"activeCount":101},[],{"trials":4025,"activeCount":101},[],{"intervention":312,"totalTrials":582,"cells":4027},{"EARLY_PHASE1":4028,"PHASE1":4034,"PHASE2":4036,"PHASE3":4042,"PHASE4":4044,"NA":4046},{"trials":4029,"activeCount":97,"soonestReadout":85},[4030],{"nctId":83,"briefTitle":84,"status":259,"phases":4031,"primaryCompletion":85,"completion":438,"start":439,"enrollment":440,"conditions":4032,"interventions":4033},[88],[442],[86,174,175,173,230,444,312,445],{"trials":4035,"activeCount":101},[],{"trials":4037,"activeCount":101},[4038],{"nctId":301,"briefTitle":302,"status":133,"phases":4039,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":4040,"interventions":4041},[89,90],[252,309,310],[312,71],{"trials":4043,"activeCount":101},[],{"trials":4045,"activeCount":101},[],{"trials":4047,"activeCount":101},[4048],{"nctId":4049,"briefTitle":4050,"status":365,"phases":4051,"primaryCompletion":4052,"start":1541,"enrollment":440,"conditions":4053,"interventions":4054},"NCT00891904","Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer",[93],"2011-07",[3261],[4055],"cetuximab",{"intervention":3997,"totalTrials":440,"cells":4057},{"EARLY_PHASE1":4058,"PHASE1":4064,"PHASE2":4066,"PHASE3":4068,"PHASE4":4070,"NA":4072},{"trials":4059,"activeCount":97,"soonestReadout":3993},[4060],{"nctId":3990,"briefTitle":3991,"status":1305,"phases":4061,"primaryCompletion":3993,"completion":3993,"start":2246,"enrollment":212,"conditions":4062,"interventions":4063},[88],[3995],[3985,3997],{"trials":4065,"activeCount":101},[],{"trials":4067,"activeCount":101},[],{"trials":4069,"activeCount":101},[],{"trials":4071,"activeCount":101},[],{"trials":4073,"activeCount":101},[4074],{"nctId":4075,"briefTitle":4076,"status":133,"phases":4077,"primaryCompletion":4078,"completion":4078,"start":4079,"enrollment":863,"conditions":4080,"interventions":4082},"NCT04231539","Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study",[93],"2024-07-10","2020-02-18",[4081],"Nicotine Dependence",[3997,4083,4084,4085],"Salt-HIgh Nicotine Unflavored","Free-Low Nicotine Tobacco Flavored","Salt-High Nicotine Tobacco Flavored",{"intervention":2272,"totalTrials":97,"cells":4087},{"EARLY_PHASE1":4088,"PHASE1":4090,"PHASE2":4092,"PHASE3":4094,"PHASE4":4096,"NA":4098},{"trials":4089,"activeCount":101},[],{"trials":4091,"activeCount":101},[],{"trials":4093,"activeCount":101},[],{"trials":4095,"activeCount":101},[],{"trials":4097,"activeCount":101},[],{"trials":4099,"activeCount":97,"soonestReadout":2266},[4100],{"nctId":2263,"briefTitle":2264,"status":113,"phases":4101,"primaryCompletion":2266,"completion":2266,"start":2267,"enrollment":2268,"conditions":4102,"interventions":4103},[93],[745,1936,1937,2270],[2272,1504],{"intervention":4105,"totalTrials":97,"cells":4106},"Clindamycin",{"EARLY_PHASE1":4107,"PHASE1":4109,"PHASE2":4111,"PHASE3":4113,"PHASE4":4115,"NA":4132},{"trials":4108,"activeCount":101},[],{"trials":4110,"activeCount":101},[],{"trials":4112,"activeCount":101},[],{"trials":4114,"activeCount":101},[],{"trials":4116,"activeCount":101},[4117],{"nctId":4118,"briefTitle":4119,"status":133,"phases":4120,"primaryCompletion":4121,"completion":4121,"start":135,"enrollment":4122,"conditions":4123,"interventions":4127},"NCT04502095","Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy",[92],"2025-03-13",89,[4124,4125,4126],"Bladder Carcinoma","Refractory Bladder Carcinoma","Urinary Tract Infection",[4105,4128,4129,4130,4131],"Ertapenem","Levofloxacin","Nitrofurantoin","Trimethoprim-Sulfamethoxazole",{"trials":4133,"activeCount":101},[],{"intervention":4128,"totalTrials":97,"cells":4135},{"EARLY_PHASE1":4136,"PHASE1":4138,"PHASE2":4140,"PHASE3":4142,"PHASE4":4144,"NA":4150},{"trials":4137,"activeCount":101},[],{"trials":4139,"activeCount":101},[],{"trials":4141,"activeCount":101},[],{"trials":4143,"activeCount":101},[],{"trials":4145,"activeCount":101},[4146],{"nctId":4118,"briefTitle":4119,"status":133,"phases":4147,"primaryCompletion":4121,"completion":4121,"start":135,"enrollment":4122,"conditions":4148,"interventions":4149},[92],[4124,4125,4126],[4105,4128,4129,4130,4131],{"trials":4151,"activeCount":101},[],{"intervention":4129,"totalTrials":97,"cells":4153},{"EARLY_PHASE1":4154,"PHASE1":4156,"PHASE2":4158,"PHASE3":4160,"PHASE4":4162,"NA":4168},{"trials":4155,"activeCount":101},[],{"trials":4157,"activeCount":101},[],{"trials":4159,"activeCount":101},[],{"trials":4161,"activeCount":101},[],{"trials":4163,"activeCount":101},[4164],{"nctId":4118,"briefTitle":4119,"status":133,"phases":4165,"primaryCompletion":4121,"completion":4121,"start":135,"enrollment":4122,"conditions":4166,"interventions":4167},[92],[4124,4125,4126],[4105,4128,4129,4130,4131],{"trials":4169,"activeCount":101},[],{"intervention":4130,"totalTrials":97,"cells":4171},{"EARLY_PHASE1":4172,"PHASE1":4174,"PHASE2":4176,"PHASE3":4178,"PHASE4":4180,"NA":4186},{"trials":4173,"activeCount":101},[],{"trials":4175,"activeCount":101},[],{"trials":4177,"activeCount":101},[],{"trials":4179,"activeCount":101},[],{"trials":4181,"activeCount":101},[4182],{"nctId":4118,"briefTitle":4119,"status":133,"phases":4183,"primaryCompletion":4121,"completion":4121,"start":135,"enrollment":4122,"conditions":4184,"interventions":4185},[92],[4124,4125,4126],[4105,4128,4129,4130,4131],{"trials":4187,"activeCount":101},[],{"intervention":4131,"totalTrials":97,"cells":4189},{"EARLY_PHASE1":4190,"PHASE1":4192,"PHASE2":4194,"PHASE3":4196,"PHASE4":4198,"NA":4204},{"trials":4191,"activeCount":101},[],{"trials":4193,"activeCount":101},[],{"trials":4195,"activeCount":101},[],{"trials":4197,"activeCount":101},[],{"trials":4199,"activeCount":101},[4200],{"nctId":4118,"briefTitle":4119,"status":133,"phases":4201,"primaryCompletion":4121,"completion":4121,"start":135,"enrollment":4122,"conditions":4202,"interventions":4203},[92],[4124,4125,4126],[4105,4128,4129,4130,4131],{"trials":4205,"activeCount":101},[],{"intervention":949,"totalTrials":317,"cells":4207},{"EARLY_PHASE1":4208,"PHASE1":4210,"PHASE2":4242,"PHASE3":4260,"PHASE4":4266,"NA":4268},{"trials":4209,"activeCount":101},[],{"trials":4211,"activeCount":101},[4212,4219,4229,4233],{"nctId":4213,"briefTitle":4214,"status":133,"phases":4215,"primaryCompletion":3183,"completion":1104,"start":1925,"enrollment":945,"conditions":4216,"interventions":4217},"NCT00093483","Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia",[89],[15],[711,4218,949,950],"arsenic trioxide",{"nctId":4220,"briefTitle":4221,"status":133,"phases":4222,"primaryCompletion":4223,"completion":4224,"start":4225,"enrollment":687,"conditions":4226,"interventions":4227},"NCT01555268","Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia",[89],"2013-09-24","2016-08-03","2011-10-31",[1692,1693,1694,1695,1696,1697,974,975,976,978,979,1698,1699,1700,996,1701],[4228,949],"trebananib",{"nctId":2185,"briefTitle":2186,"status":133,"phases":4230,"primaryCompletion":2188,"completion":2189,"start":2190,"enrollment":199,"conditions":4231,"interventions":4232},[89],[974,975,976,977,978,979,996],[949,2178],{"nctId":4234,"briefTitle":4235,"status":133,"phases":4236,"primaryCompletion":4237,"completion":4238,"start":4239,"conditions":4240,"interventions":4241},"NCT00053144","Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia",[89],"2003-02","2003-03","1999-11",[15],[949,460],{"trials":4243,"activeCount":101},[4244,4248,4252,4256],{"nctId":1685,"briefTitle":1686,"status":365,"phases":4245,"primaryCompletion":1132,"completion":1688,"start":1689,"enrollment":440,"conditions":4246,"interventions":4247},[90],[1691,1692,1693,1694,1695,1696,1697,974,975,976,978,979,1698,1699,1700,749,1701],[949,1703,1547],{"nctId":1754,"briefTitle":1755,"status":133,"phases":4249,"primaryCompletion":1267,"start":1757,"enrollment":537,"conditions":4250,"interventions":4251},[90],[23],[949,1760,461,1761],{"nctId":816,"briefTitle":817,"status":133,"phases":4253,"primaryCompletion":819,"completion":820,"start":821,"enrollment":380,"conditions":4254,"interventions":4255},[90],[823,824,825,826,827],[57,829,830,666,831,832,833],{"nctId":1621,"briefTitle":1622,"status":133,"phases":4257,"primaryCompletion":1624,"completion":1624,"start":1625,"conditions":4258,"interventions":4259},[90],[15],[711,792,949,1628],{"trials":4261,"activeCount":101},[4262],{"nctId":939,"briefTitle":940,"status":133,"phases":4263,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":4264,"interventions":4265},[91],[15],[948,711,639,949,858,950,844],{"trials":4267,"activeCount":101},[],{"trials":4269,"activeCount":101},[],{"intervention":711,"totalTrials":138,"cells":4271},{"EARLY_PHASE1":4272,"PHASE1":4274,"PHASE2":4288,"PHASE3":4306,"PHASE4":4312,"NA":4314},{"trials":4273,"activeCount":101},[],{"trials":4275,"activeCount":101},[4276,4280,4284],{"nctId":4213,"briefTitle":4214,"status":133,"phases":4277,"primaryCompletion":3183,"completion":1104,"start":1925,"enrollment":945,"conditions":4278,"interventions":4279},[89],[15],[711,4218,949,950],{"nctId":1448,"briefTitle":1449,"status":133,"phases":4281,"primaryCompletion":1218,"completion":1218,"start":1451,"enrollment":97,"conditions":4282,"interventions":4283},[89],[1453,23,1454,1455],[711,808,858],{"nctId":1458,"briefTitle":1459,"status":133,"phases":4285,"primaryCompletion":1461,"completion":1462,"start":1463,"enrollment":687,"conditions":4286,"interventions":4287},[89],[15,23,18],[711,1466,808,809],{"trials":4289,"activeCount":101},[4290,4294,4298,4302],{"nctId":700,"briefTitle":701,"status":133,"phases":4291,"primaryCompletion":703,"completion":703,"start":704,"enrollment":21,"conditions":4292,"interventions":4293},[90],[706,15,23,707,708],[710,711,712,639,713,714],{"nctId":798,"briefTitle":799,"status":133,"phases":4295,"primaryCompletion":801,"completion":802,"start":803,"enrollment":804,"conditions":4296,"interventions":4297},[89,90],[806],[711,808,639,809,810],{"nctId":1621,"briefTitle":1622,"status":133,"phases":4299,"primaryCompletion":1624,"completion":1624,"start":1625,"conditions":4300,"interventions":4301},[90],[15],[711,792,949,1628],{"nctId":918,"briefTitle":919,"status":133,"phases":4303,"primaryCompletion":921,"completion":922,"start":468,"conditions":4304,"interventions":4305},[90],[15,23,708,924],[710,711,712,639,713,794,844,714],{"trials":4307,"activeCount":101},[4308],{"nctId":939,"briefTitle":940,"status":133,"phases":4309,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":4310,"interventions":4311},[91],[15],[948,711,639,949,858,950,844],{"trials":4313,"activeCount":101},[],{"trials":4315,"activeCount":101},[],{"intervention":950,"totalTrials":440,"cells":4317},{"EARLY_PHASE1":4318,"PHASE1":4320,"PHASE2":4326,"PHASE3":4328,"PHASE4":4334,"NA":4336},{"trials":4319,"activeCount":101},[],{"trials":4321,"activeCount":101},[4322],{"nctId":4213,"briefTitle":4214,"status":133,"phases":4323,"primaryCompletion":3183,"completion":1104,"start":1925,"enrollment":945,"conditions":4324,"interventions":4325},[89],[15],[711,4218,949,950],{"trials":4327,"activeCount":101},[],{"trials":4329,"activeCount":101},[4330],{"nctId":939,"briefTitle":940,"status":133,"phases":4331,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":4332,"interventions":4333},[91],[15],[948,711,639,949,858,950,844],{"trials":4335,"activeCount":101},[],{"trials":4337,"activeCount":101},[],{"intervention":2342,"totalTrials":440,"cells":4339},{"EARLY_PHASE1":4340,"PHASE1":4342,"PHASE2":4344,"PHASE3":4355,"PHASE4":4361,"NA":4363},{"trials":4341,"activeCount":101},[],{"trials":4343,"activeCount":101},[],{"trials":4345,"activeCount":101},[4346],{"nctId":4347,"briefTitle":4348,"status":365,"phases":4349,"primaryCompletion":453,"completion":476,"start":4350,"enrollment":2744,"conditions":4351,"interventions":4352},"NCT00814164","Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",[90],"2008-12",[15],[4353,2342,4354,1977],"clofarabine","cytogenetic analysis",{"trials":4356,"activeCount":101},[4357],{"nctId":2336,"briefTitle":2337,"status":133,"phases":4358,"primaryCompletion":1267,"start":2339,"conditions":4359,"interventions":4360},[91],[2146],[2342,1489],{"trials":4362,"activeCount":101},[],{"trials":4364,"activeCount":101},[],{"intervention":4366,"totalTrials":97,"cells":4367},"hydromorphone hydrochloride",{"EARLY_PHASE1":4368,"PHASE1":4370,"PHASE2":4372,"PHASE3":4374,"PHASE4":4383,"NA":4385},{"trials":4369,"activeCount":101},[],{"trials":4371,"activeCount":101},[],{"trials":4373,"activeCount":101},[],{"trials":4375,"activeCount":101},[4376],{"nctId":4377,"briefTitle":4378,"status":133,"phases":4379,"primaryCompletion":468,"completion":1624,"start":4380,"enrollment":159,"conditions":4381,"interventions":4382},"NCT00003115","Epidural Hydromorphone Compared With Hydromorphone Infusion in Treating Patients With Prostate Cancer Undergoing Radical Prostatectomy",[91],"1996-06",[3372,26],[4366],{"trials":4384,"activeCount":101},[],{"trials":4386,"activeCount":101},[],{"intervention":3349,"totalTrials":863,"cells":4388},{"EARLY_PHASE1":4389,"PHASE1":4391,"PHASE2":4474,"PHASE3":4509,"PHASE4":4511,"NA":4513},{"trials":4390,"activeCount":101},[],{"trials":4392,"activeCount":101},[4393,4402,4406,4410,4417,4426,4434,4445,4454,4466],{"nctId":4394,"briefTitle":4395,"status":365,"phases":4396,"primaryCompletion":4397,"completion":4398,"start":4399,"enrollment":33,"conditions":4400,"interventions":4401},"NCT00670397","Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer",[89],"2011-11","2015-07","2010-06",[3261],[3349],{"nctId":3294,"briefTitle":3295,"status":133,"phases":4403,"primaryCompletion":3297,"completion":3298,"start":3299,"enrollment":863,"conditions":4404,"interventions":4405},[89],[3301,3302,3303,3304,3305,3306,3307,3308,3309,3310,3131,3132,3133,3134,3135,3136,3311,3137,3138,3312,3313,3314,3315,3316,3317,3318,3319,3320,3321,3322,3323,3324,3325,3326,3327,3328,3329,3330,3331,3332,3333,3334,3335,3336,3337,3338,3339,3340,3341,3342,3343,3344,3345,3346,3347],[3349,3350],{"nctId":3352,"briefTitle":3353,"status":133,"phases":4407,"primaryCompletion":453,"completion":3355,"start":1624,"enrollment":27,"conditions":4408,"interventions":4409},[89],[3357,3358,3359,3360,3361],[3349,3350],{"nctId":4411,"briefTitle":4412,"status":133,"phases":4413,"primaryCompletion":453,"completion":4414,"start":1624,"enrollment":27,"conditions":4415,"interventions":4416},"NCT00526461","Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer",[89],"2014-04",[20],[3349],{"nctId":4418,"briefTitle":4419,"status":133,"phases":4420,"primaryCompletion":4421,"completion":4422,"start":4423,"enrollment":1308,"conditions":4424,"interventions":4425},"NCT00675233","Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx",[89],"2013-06-28","2018-09-27","2008-04-25",[3261],[3349],{"nctId":4427,"briefTitle":4428,"status":133,"phases":4429,"primaryCompletion":4430,"completion":1267,"start":4431,"enrollment":9,"conditions":4432,"interventions":4433},"NCT00017485","Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer",[89],"2006-12","2000-01",[3490],[3349],{"nctId":4435,"briefTitle":4436,"status":133,"phases":4437,"primaryCompletion":1124,"completion":4438,"start":4439,"enrollment":24,"conditions":4440,"interventions":4444},"NCT01236443","Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus",[89],"2013-04","2000-08",[4441,4442,4443],"Barrett's Esophagus","CIS","High Grade Dysplasia",[3349],{"nctId":4446,"briefTitle":4447,"status":133,"phases":4448,"primaryCompletion":4449,"completion":4450,"start":4238,"enrollment":24,"conditions":4451,"interventions":4453},"NCT01238042","Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus",[89],"2004-10","2014-11",[4441,4442,4452],"HGD",[3349],{"nctId":4455,"briefTitle":4456,"status":133,"phases":4457,"primaryCompletion":4458,"completion":4459,"start":4460,"enrollment":1308,"conditions":4461,"interventions":4465},"NCT01140178","A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and\u002For Oropharynx",[89],"2013-01-29","2018-10-01","2010-06-08",[4462,4463,4464],"Dysplasia","Carcinoma of the Oral Cavity","Carcinoma of the Oropharynx",[3349],{"nctId":4467,"briefTitle":4468,"status":133,"phases":4469,"primaryCompletion":4470,"completion":4449,"start":4471,"conditions":4472,"interventions":4473},"NCT00025571","Photodynamic Therapy With HPPH in Treating Patients With Non-Small Cell Lung Cancer",[89],"2002-10","2001-06",[20],[3349],{"trials":4475,"activeCount":101},[4476,4484,4488,4495,4502],{"nctId":4477,"briefTitle":4478,"status":133,"phases":4479,"primaryCompletion":921,"completion":4480,"start":4481,"enrollment":33,"conditions":4482,"interventions":4483},"NCT00060268","Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors",[89,90],"2004-06","1997-01",[35],[3349],{"nctId":3390,"briefTitle":3391,"status":365,"phases":4485,"primaryCompletion":3393,"completion":3394,"start":3395,"enrollment":440,"conditions":4486,"interventions":4487},[90],[3397,3398],[3349,3267],{"nctId":4489,"briefTitle":4490,"status":365,"phases":4491,"primaryCompletion":3183,"completion":4492,"start":955,"enrollment":9,"conditions":4493,"interventions":4494},"NCT00528775","Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages",[90],"2014-03",[20],[3349],{"nctId":4496,"briefTitle":4497,"status":235,"phases":4498,"primaryCompletion":4499,"enrollment":101,"conditions":4500,"interventions":4501},"NCT02119728","Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity",[90],"2017-01",[3133,3135,3138,3325,3326,3329,3343,3344,3347,3141,3143,3146,3150,3151,3154,3156,3157,3160,3162,3163,3166],[3349],{"nctId":4503,"briefTitle":4504,"status":133,"phases":4505,"primaryCompletion":4506,"completion":3427,"start":1624,"enrollment":212,"conditions":4507,"interventions":4508},"NCT00281736","Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer",[90],"2007-07",[35,3491],[3349],{"trials":4510,"activeCount":101},[],{"trials":4512,"activeCount":101},[],{"trials":4514,"activeCount":101},[],{"intervention":460,"totalTrials":36,"cells":4516},{"EARLY_PHASE1":4517,"PHASE1":4519,"PHASE2":4569,"PHASE3":4583,"PHASE4":4585,"NA":4587},{"trials":4518,"activeCount":101},[],{"trials":4520,"activeCount":101},[4521,4525,4531,4539,4543,4552,4556,4565],{"nctId":449,"briefTitle":450,"status":133,"phases":4522,"primaryCompletion":452,"completion":453,"start":454,"enrollment":184,"conditions":4523,"interventions":4524},[89],[35,456,457],[459,460,461,462],{"nctId":4526,"briefTitle":4527,"status":133,"phases":4528,"primaryCompletion":1124,"completion":3228,"start":942,"conditions":4529,"interventions":4530},"NCT00054288","Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors",[89],[18],[1236,460],{"nctId":4532,"briefTitle":4533,"status":133,"phases":4534,"primaryCompletion":4535,"completion":4536,"start":1892,"enrollment":2412,"conditions":4537,"interventions":4538},"NCT00083148","Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer",[89],"2005-03","2006-09",[806],[1052,460],{"nctId":464,"briefTitle":465,"status":133,"phases":4540,"primaryCompletion":467,"completion":468,"start":469,"conditions":4541,"interventions":4542},[89],[18],[459,460],{"nctId":4544,"briefTitle":4545,"status":133,"phases":4546,"primaryCompletion":4547,"completion":4548,"start":1231,"enrollment":4549,"conditions":4550,"interventions":4551},"NCT00112892","Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors",[89],"2007-09","2007-12",36,[18],[460],{"nctId":473,"briefTitle":474,"status":365,"phases":4553,"primaryCompletion":476,"completion":477,"start":478,"enrollment":184,"conditions":4554,"interventions":4555},[89],[35,456],[459,460,461,481],{"nctId":4557,"briefTitle":4558,"status":133,"phases":4559,"primaryCompletion":4560,"start":4535,"enrollment":440,"conditions":4561,"interventions":4563},"NCT00084721","Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer",[89],"2005-10",[29,4562],"Diarrhea",[4564,460],"celecoxib",{"nctId":4234,"briefTitle":4235,"status":133,"phases":4566,"primaryCompletion":4237,"completion":4238,"start":4239,"conditions":4567,"interventions":4568},[89],[15],[949,460],{"trials":4570,"activeCount":101},[4571,4579],{"nctId":4572,"briefTitle":4573,"status":133,"phases":4574,"primaryCompletion":4547,"completion":4575,"start":4576,"enrollment":3202,"conditions":4577,"interventions":4578},"NCT00182806","Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer",[90],"2008-07","2004-09",[20],[1236,460],{"nctId":543,"briefTitle":544,"status":235,"phases":4580,"primaryCompletion":546,"enrollment":101,"conditions":4581,"interventions":4582},[89,90],[548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564],[173,566,175,567],{"trials":4584,"activeCount":101},[],{"trials":4586,"activeCount":101},[],{"trials":4588,"activeCount":101},[],{"intervention":146,"totalTrials":9,"cells":4590},{"EARLY_PHASE1":4591,"PHASE1":4597,"PHASE2":4607,"PHASE3":4621,"PHASE4":4623,"NA":4625},{"trials":4592,"activeCount":101},[4593],{"nctId":131,"briefTitle":132,"status":133,"phases":4594,"primaryCompletion":135,"completion":136,"start":137,"enrollment":138,"conditions":4595,"interventions":4596},[88],[140,141,142,143,144],[146,147,148,71],{"trials":4598,"activeCount":101},[4599,4603],{"nctId":641,"briefTitle":642,"status":133,"phases":4600,"primaryCompletion":644,"completion":645,"start":646,"enrollment":317,"conditions":4601,"interventions":4602},[89],[648,649,650,651,652,653,654,655,141,142,144,656,657,658,659,660,661,662,663],[146,57,665,666,667,147,148],{"nctId":4557,"briefTitle":4558,"status":133,"phases":4604,"primaryCompletion":4560,"start":4535,"enrollment":440,"conditions":4605,"interventions":4606},[89],[29,4562],[4564,460],{"trials":4608,"activeCount":101},[4609,4613,4617],{"nctId":2374,"briefTitle":2375,"status":133,"phases":4610,"primaryCompletion":2377,"completion":2378,"start":2379,"enrollment":1399,"conditions":4611,"interventions":4612},[90],[2381,252,2382,2383,2384],[146,147,148],{"nctId":2387,"briefTitle":2388,"status":365,"phases":4614,"primaryCompletion":2390,"completion":368,"start":2391,"enrollment":97,"conditions":4615,"interventions":4616},[90],[2393,2394],[243,146,2396,2397,147,148],{"nctId":363,"briefTitle":364,"status":365,"phases":4618,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":4619,"interventions":4620},[89,90],[186,188,241],[146,373,71,148],{"trials":4622,"activeCount":101},[],{"trials":4624,"activeCount":101},[],{"trials":4626,"activeCount":101},[],{"intervention":714,"totalTrials":370,"cells":4628},{"EARLY_PHASE1":4629,"PHASE1":4631,"PHASE2":4633,"PHASE3":4656,"PHASE4":4658,"NA":4660},{"trials":4630,"activeCount":101},[],{"trials":4632,"activeCount":101},[],{"trials":4634,"activeCount":101},[4635,4639,4643,4648,4652],{"nctId":700,"briefTitle":701,"status":133,"phases":4636,"primaryCompletion":703,"completion":703,"start":704,"enrollment":21,"conditions":4637,"interventions":4638},[90],[706,15,23,707,708],[710,711,712,639,713,714],{"nctId":780,"briefTitle":781,"status":133,"phases":4640,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":4641,"interventions":4642},[90],[787,15,23,707,708,788,789,728],[710,791,792,793,639,794,714,795,796],{"nctId":4644,"briefTitle":701,"status":133,"phases":4645,"primaryCompletion":4239,"completion":1924,"start":630,"enrollment":582,"conditions":4646,"interventions":4647},"NCT00003661",[90],[706,15,23,708,1454],[710,712,713,844,714],{"nctId":835,"briefTitle":836,"status":133,"phases":4649,"primaryCompletion":838,"completion":838,"start":839,"enrollment":840,"conditions":4650,"interventions":4651},[90],[706,15,708,842],[710,712,639,713,844,714],{"nctId":918,"briefTitle":919,"status":133,"phases":4653,"primaryCompletion":921,"completion":922,"start":468,"conditions":4654,"interventions":4655},[90],[15,23,708,924],[710,711,712,639,713,794,844,714],{"trials":4657,"activeCount":101},[],{"trials":4659,"activeCount":101},[],{"trials":4661,"activeCount":101},[],{"intervention":1963,"totalTrials":370,"cells":4663},{"EARLY_PHASE1":4664,"PHASE1":4666,"PHASE2":4672,"PHASE3":4695,"PHASE4":4697,"NA":4699},{"trials":4665,"activeCount":101},[],{"trials":4667,"activeCount":101},[4668],{"nctId":641,"briefTitle":642,"status":133,"phases":4669,"primaryCompletion":644,"completion":645,"start":646,"enrollment":317,"conditions":4670,"interventions":4671},[89],[648,649,650,651,652,653,654,655,141,142,144,656,657,658,659,660,661,662,663],[146,57,665,666,667,147,148],{"trials":4673,"activeCount":101},[4674,4683,4687,4691],{"nctId":4675,"briefTitle":4676,"status":365,"phases":4677,"primaryCompletion":4678,"completion":4679,"start":4680,"enrollment":1219,"conditions":4681,"interventions":4682},"NCT00524316","Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",[90],"2010-12","2014-05","2007-04",[457],[1963,481],{"nctId":1957,"briefTitle":1958,"status":133,"phases":4684,"primaryCompletion":1960,"start":1231,"enrollment":687,"conditions":4685,"interventions":4686},[90],[707],[1877,1963,1964,1965],{"nctId":3576,"briefTitle":3577,"status":133,"phases":4688,"primaryCompletion":3579,"completion":469,"start":3580,"enrollment":687,"conditions":4689,"interventions":4690},[90],[457],[948,1963],{"nctId":816,"briefTitle":817,"status":133,"phases":4692,"primaryCompletion":819,"completion":820,"start":821,"enrollment":380,"conditions":4693,"interventions":4694},[90],[823,824,825,826,827],[57,829,830,666,831,832,833],{"trials":4696,"activeCount":101},[],{"trials":4698,"activeCount":101},[],{"trials":4700,"activeCount":101},[],{"intervention":1964,"totalTrials":370,"cells":4702},{"EARLY_PHASE1":4703,"PHASE1":4705,"PHASE2":4707,"PHASE3":4735,"PHASE4":4737,"NA":4739},{"trials":4704,"activeCount":101},[],{"trials":4706,"activeCount":101},[],{"trials":4708,"activeCount":101},[4709,4713,4717,4721,4728],{"nctId":2309,"briefTitle":2310,"status":133,"phases":4710,"primaryCompletion":2289,"completion":452,"start":1900,"enrollment":2312,"conditions":4711,"interventions":4712},[90],[707],[2293,1489,1964],{"nctId":2026,"briefTitle":2027,"status":133,"phases":4714,"primaryCompletion":2029,"completion":2030,"start":2031,"enrollment":2032,"conditions":4715,"interventions":4716},[89,90],[15],[794,1964],{"nctId":1957,"briefTitle":1958,"status":133,"phases":4718,"primaryCompletion":1960,"start":1231,"enrollment":687,"conditions":4719,"interventions":4720},[90],[707],[1877,1963,1964,1965],{"nctId":4722,"briefTitle":4723,"status":133,"phases":4724,"primaryCompletion":4431,"completion":1639,"start":4725,"enrollment":4549,"conditions":4726,"interventions":4727},"NCT00003894","Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant",[90],"1999-03",[706,18,855],[1964],{"nctId":4729,"briefTitle":4730,"status":133,"phases":4731,"primaryCompletion":3258,"start":4732,"conditions":4733,"interventions":4734},"NCT00030550","Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome",[90],"2001-09",[15,708,1641],[1964],{"trials":4736,"activeCount":101},[],{"trials":4738,"activeCount":101},[],{"trials":4740,"activeCount":101},[],{"intervention":713,"totalTrials":1271,"cells":4742},{"EARLY_PHASE1":4743,"PHASE1":4745,"PHASE2":4747,"PHASE3":4765,"PHASE4":4767,"NA":4769},{"trials":4744,"activeCount":101},[],{"trials":4746,"activeCount":101},[],{"trials":4748,"activeCount":101},[4749,4753,4757,4761],{"nctId":700,"briefTitle":701,"status":133,"phases":4750,"primaryCompletion":703,"completion":703,"start":704,"enrollment":21,"conditions":4751,"interventions":4752},[90],[706,15,23,707,708],[710,711,712,639,713,714],{"nctId":4644,"briefTitle":701,"status":133,"phases":4754,"primaryCompletion":4239,"completion":1924,"start":630,"enrollment":582,"conditions":4755,"interventions":4756},[90],[706,15,23,708,1454],[710,712,713,844,714],{"nctId":835,"briefTitle":836,"status":133,"phases":4758,"primaryCompletion":838,"completion":838,"start":839,"enrollment":840,"conditions":4759,"interventions":4760},[90],[706,15,708,842],[710,712,639,713,844,714],{"nctId":918,"briefTitle":919,"status":133,"phases":4762,"primaryCompletion":921,"completion":922,"start":468,"conditions":4763,"interventions":4764},[90],[15,23,708,924],[710,711,712,639,713,794,844,714],{"trials":4766,"activeCount":101},[],{"trials":4768,"activeCount":101},[],{"trials":4770,"activeCount":101},[],{"intervention":1665,"totalTrials":1271,"cells":4772},{"EARLY_PHASE1":4773,"PHASE1":4775,"PHASE2":4789,"PHASE3":4803,"PHASE4":4805,"NA":4807},{"trials":4774,"activeCount":101},[],{"trials":4776,"activeCount":101},[4777,4781,4785],{"nctId":1654,"briefTitle":1655,"status":133,"phases":4778,"primaryCompletion":1657,"completion":1658,"start":1659,"enrollment":138,"conditions":4779,"interventions":4780},[89],[725,1661,734,1662,741,1663],[1665,624,81,1666],{"nctId":2521,"briefTitle":2522,"status":133,"phases":4782,"primaryCompletion":2524,"completion":2524,"start":2525,"enrollment":24,"conditions":4783,"interventions":4784},[89],[1558,1559,1560,141,2527,1428,2528,2529,2530,2531,2532,2533,252,2534,1141,691,2535,2536,227,2537,2538,2539,2540,2146,2541,2542,2543,2544,2545,2546,2547,2548,2549,2550,2551,2552,2553,2554,2555,2556,2557,2558,2559,2560,2561,2562,2563,2564,2565,2566,2567,2568,2569,2570,2571,2572,2573,2574,2575,2576,2577,2578,2579,2580,2581],[1665,778],{"nctId":1672,"briefTitle":1673,"status":133,"phases":4786,"primaryCompletion":1675,"completion":1676,"start":1677,"enrollment":317,"conditions":4787,"interventions":4788},[89],[725,1679,734,741,1680],[1665,624,1666],{"trials":4790,"activeCount":101},[4791],{"nctId":4792,"briefTitle":4793,"status":133,"phases":4794,"primaryCompletion":4795,"completion":4795,"start":4796,"enrollment":159,"conditions":4797,"interventions":4801},"NCT02166905","DEC-205\u002FNY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",[89,90],"2020-08-20","2014-10-10",[4798,4799,4800],"Fallopian Tube Carcinoma","Ovarian Carcinoma","Primary Peritoneal Carcinoma",[1665,4802,1666],"Epacadostat",{"trials":4804,"activeCount":101},[],{"trials":4806,"activeCount":101},[],{"trials":4808,"activeCount":101},[],{"intervention":2307,"totalTrials":1271,"cells":4810},{"EARLY_PHASE1":4811,"PHASE1":4813,"PHASE2":4827,"PHASE3":4840,"PHASE4":4842,"NA":4844},{"trials":4812,"activeCount":101},[],{"trials":4814,"activeCount":101},[4815,4819],{"nctId":3180,"briefTitle":3181,"status":133,"phases":4816,"primaryCompletion":3183,"completion":1104,"start":2031,"enrollment":945,"conditions":4817,"interventions":4818},[89],[18],[1052,3170,2307],{"nctId":4820,"briefTitle":4821,"status":133,"phases":4822,"primaryCompletion":2213,"completion":4823,"start":2030,"enrollment":3202,"conditions":4824,"interventions":4825},"NCT01540253","PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic",[89],"2016-06",[18],[4826,2307],"PI3K inhibitor BKM120",{"trials":4828,"activeCount":101},[4829,4836],{"nctId":4830,"briefTitle":4831,"status":365,"phases":4832,"primaryCompletion":1541,"completion":3369,"start":1484,"enrollment":138,"conditions":4833,"interventions":4834},"NCT00683787","Docetaxel With or Without Vandetanib in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer",[90],[456],[2307,4835],"vandetanib",{"nctId":2302,"briefTitle":2303,"status":365,"phases":4837,"primaryCompletion":1230,"start":478,"enrollment":9,"conditions":4838,"interventions":4839},[90],[806],[2307,1489],{"trials":4841,"activeCount":101},[],{"trials":4843,"activeCount":101},[],{"trials":4845,"activeCount":101},[],{"intervention":4847,"totalTrials":1271,"cells":4848},"Nintedanib",{"EARLY_PHASE1":4849,"PHASE1":4851,"PHASE2":4853,"PHASE3":4908,"PHASE4":4910,"NA":4912},{"trials":4850,"activeCount":101},[],{"trials":4852,"activeCount":101},[],{"trials":4854,"activeCount":101},[4855,4867,4878,4890],{"nctId":4856,"briefTitle":4857,"status":133,"phases":4858,"primaryCompletion":4859,"completion":4860,"start":4861,"enrollment":1187,"conditions":4862,"interventions":4865},"NCT02393755","Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer",[89,90],"2017-11-01","2021-05-18","2015-05-08",[548,552,4863,4864,561,562,563,564],"Recurrent Colon Carcinoma","Recurrent Rectal Carcinoma",[4866,4847],"Capecitabine",{"nctId":4868,"briefTitle":4869,"status":133,"phases":4870,"primaryCompletion":4871,"completion":4871,"start":4872,"enrollment":9,"conditions":4873,"interventions":4876},"NCT01948141","Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens",[90],"2016-08-16","2014-01-30",[3359,3360,4874,4875],"Stage III Non-small Cell Lung Cancer","Stage IV Non-small Cell Lung Cancer",[4877],"nintedanib",{"nctId":4879,"briefTitle":4880,"status":133,"phases":4881,"primaryCompletion":4882,"completion":4883,"start":4884,"enrollment":199,"conditions":4885,"interventions":4889},"NCT02399215","Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors",[90],"2019-09-01","2022-08-31","2015-05-15",[4886,4887,4888],"Carcinoid Tumor","Metastatic Carcinoid Tumor","Neuroendocrine Neoplasm",[4847],{"nctId":4891,"briefTitle":4892,"status":365,"phases":4893,"primaryCompletion":4894,"completion":4894,"start":4895,"enrollment":138,"conditions":4896,"interventions":4906},"NCT02452463","Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy",[90],"2019-06-10","2015-06-29",[4897,4898,4899,4900,4901,4902,4903,4904,4905],"Lung Non-Squamous Non-Small Cell Carcinoma","Radiation-Induced Pneumonitis","Stage II Lung Non-Small Cell Cancer AJCC v7","Stage IIA Lung Non-Small Cell Carcinoma AJCC v7","Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","Stage III Lung Non-Small Cell Cancer AJCC v7","Stage IIIA Lung Non-Small Cell Cancer AJCC v7","Stage IIIB Lung Non-Small Cell Cancer AJCC v7","Stage IV Lung Non-Small Cell Cancer AJCC v7",[4907,4847],"Durvalumab",{"trials":4909,"activeCount":101},[],{"trials":4911,"activeCount":101},[],{"trials":4913,"activeCount":101},[],{"intervention":1722,"totalTrials":582,"cells":4915},{"EARLY_PHASE1":4916,"PHASE1":4918,"PHASE2":4939,"PHASE3":4945,"PHASE4":4947,"NA":4949},{"trials":4917,"activeCount":101},[],{"trials":4919,"activeCount":101},[4920,4929],{"nctId":4921,"briefTitle":4922,"status":365,"phases":4923,"primaryCompletion":4924,"completion":599,"start":4925,"enrollment":138,"conditions":4926,"interventions":4927},"NCT05037500","Decitabine\u002FCedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer",[89],"2024-12-17","2022-01-26",[1713,1718,1719,1720],[4928,1722],"Decitabine and Cedazuridine",{"nctId":4930,"briefTitle":4931,"status":133,"phases":4932,"primaryCompletion":4933,"completion":4934,"start":4935,"enrollment":36,"conditions":4936,"interventions":4937},"NCT03751436","Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer",[89],"2022-07-18","2023-08-11","2019-08-02",[1712,1713,2529,1714,1715,1717,1718,1719,1720],[1722,4938],"Venetoclax",{"trials":4940,"activeCount":101},[4941],{"nctId":1705,"briefTitle":1706,"status":235,"phases":4942,"primaryCompletion":1708,"completion":1709,"start":1710,"enrollment":101,"conditions":4943,"interventions":4944},[89,90],[1712,1713,1714,1715,1716,1717,1718,1719,1720],[624,1722],{"trials":4946,"activeCount":101},[],{"trials":4948,"activeCount":101},[],{"trials":4950,"activeCount":101},[],{"intervention":2293,"totalTrials":582,"cells":4952},{"EARLY_PHASE1":4953,"PHASE1":4955,"PHASE2":4957,"PHASE3":4974,"PHASE4":4976,"NA":4978},{"trials":4954,"activeCount":101},[],{"trials":4956,"activeCount":101},[],{"trials":4958,"activeCount":101},[4959,4963,4967],{"nctId":2286,"briefTitle":2287,"status":365,"phases":4960,"primaryCompletion":2289,"completion":2289,"start":2290,"enrollment":317,"conditions":4961,"interventions":4962},[90],[23],[2216,2293,1489,1088,2294,2295,2296],{"nctId":2309,"briefTitle":2310,"status":133,"phases":4964,"primaryCompletion":2289,"completion":452,"start":1900,"enrollment":2312,"conditions":4965,"interventions":4966},[90],[707],[2293,1489,1964],{"nctId":4968,"briefTitle":4969,"status":365,"phases":4970,"primaryCompletion":4414,"start":492,"enrollment":582,"conditions":4971,"interventions":4972},"NCT01536067","Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia",[90],[1026],[4973,2293],"ofatumumab",{"trials":4975,"activeCount":101},[],{"trials":4977,"activeCount":101},[],{"trials":4979,"activeCount":101},[],{"intervention":1088,"totalTrials":582,"cells":4981},{"EARLY_PHASE1":4982,"PHASE1":4984,"PHASE2":4996,"PHASE3":5006,"PHASE4":5008,"NA":5010},{"trials":4983,"activeCount":101},[],{"trials":4985,"activeCount":101},[4986],{"nctId":4987,"briefTitle":4988,"status":235,"phases":4989,"primaryCompletion":4052,"start":4678,"enrollment":101,"conditions":4990,"interventions":4993},"NCT01251250","Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia",[89],[609,2233,4991,4992],"Stage III Chronic Lymphocytic Leukemia","Stage IV Chronic Lymphocytic Leukemia",[3636,1088,4994,4995,1090],"fluorescence in situ hybridization","azadirachta indica",{"trials":4997,"activeCount":101},[4998,5002],{"nctId":2286,"briefTitle":2287,"status":365,"phases":4999,"primaryCompletion":2289,"completion":2289,"start":2290,"enrollment":317,"conditions":5000,"interventions":5001},[90],[23],[2216,2293,1489,1088,2294,2295,2296],{"nctId":1083,"briefTitle":1084,"status":133,"phases":5003,"primaryCompletion":452,"start":454,"enrollment":785,"conditions":5004,"interventions":5005},[90],[35],[1052,500,1088,1089,1090],{"trials":5007,"activeCount":101},[],{"trials":5009,"activeCount":101},[],{"trials":5011,"activeCount":101},[],{"intervention":1666,"totalTrials":582,"cells":5013},{"EARLY_PHASE1":5014,"PHASE1":5016,"PHASE2":5026,"PHASE3":5032,"PHASE4":5034,"NA":5036},{"trials":5015,"activeCount":101},[],{"trials":5017,"activeCount":101},[5018,5022],{"nctId":1654,"briefTitle":1655,"status":133,"phases":5019,"primaryCompletion":1657,"completion":1658,"start":1659,"enrollment":138,"conditions":5020,"interventions":5021},[89],[725,1661,734,1662,741,1663],[1665,624,81,1666],{"nctId":1672,"briefTitle":1673,"status":133,"phases":5023,"primaryCompletion":1675,"completion":1676,"start":1677,"enrollment":317,"conditions":5024,"interventions":5025},[89],[725,1679,734,741,1680],[1665,624,1666],{"trials":5027,"activeCount":101},[5028],{"nctId":4792,"briefTitle":4793,"status":133,"phases":5029,"primaryCompletion":4795,"completion":4795,"start":4796,"enrollment":159,"conditions":5030,"interventions":5031},[89,90],[4798,4799,4800],[1665,4802,1666],{"trials":5033,"activeCount":101},[],{"trials":5035,"activeCount":101},[],{"trials":5037,"activeCount":101},[],{"intervention":462,"totalTrials":582,"cells":5039},{"EARLY_PHASE1":5040,"PHASE1":5042,"PHASE2":5060,"PHASE3":5066,"PHASE4":5068,"NA":5070},{"trials":5041,"activeCount":101},[],{"trials":5043,"activeCount":101},[5044,5056],{"nctId":5045,"briefTitle":5046,"status":365,"phases":5047,"primaryCompletion":5048,"completion":3190,"start":5049,"enrollment":1878,"conditions":5050,"interventions":5054},"NCT01174199","Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer",[89],"2015-08","2012-02",[26,5051,5052,5053,2578],"Adenocarcinoma of the Prostate","Hormone-resistant Prostate Cancer","Recurrent Prostate Cancer",[462,5055],"temsirolimus",{"nctId":449,"briefTitle":450,"status":133,"phases":5057,"primaryCompletion":452,"completion":453,"start":454,"enrollment":184,"conditions":5058,"interventions":5059},[89],[35,456,457],[459,460,461,462],{"trials":5061,"activeCount":101},[5062],{"nctId":569,"briefTitle":570,"status":133,"phases":5063,"primaryCompletion":572,"completion":573,"start":574,"enrollment":575,"conditions":5064,"interventions":5065},[90],[577,578,579,580,496,497],[459,461,462],{"trials":5067,"activeCount":101},[],{"trials":5069,"activeCount":101},[],{"trials":5071,"activeCount":101},[],{"intervention":243,"totalTrials":582,"cells":5073},{"EARLY_PHASE1":5074,"PHASE1":5076,"PHASE2":5078,"PHASE3":5106,"PHASE4":5108,"NA":5110},{"trials":5075,"activeCount":101},[],{"trials":5077,"activeCount":101},[],{"trials":5079,"activeCount":101},[5080,5084,5088],{"nctId":233,"briefTitle":234,"status":235,"phases":5081,"primaryCompletion":237,"completion":237,"start":238,"enrollment":101,"conditions":5082,"interventions":5083},[90],[240,186,188,241],[243,71],{"nctId":2387,"briefTitle":2388,"status":365,"phases":5085,"primaryCompletion":2390,"completion":368,"start":2391,"enrollment":97,"conditions":5086,"interventions":5087},[90],[2393,2394],[243,146,2396,2397,147,148],{"nctId":5089,"briefTitle":5090,"status":235,"phases":5091,"primaryCompletion":5092,"completion":5092,"start":5093,"enrollment":101,"conditions":5094,"interventions":5104},"NCT03735589","Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",[89,90],"2025-12-01","2023-12-15",[5095,5096,5097,5098,5099,5100,5101,5102,5103,887,888,889,890,891,892,893,894,895,896,897,898,899,900,901,902,903,904,905,906,907,908,909,910,911],"Stage II Fallopian Tube Cancer AJCC v8","Stage II Ovarian Cancer AJCC v8","Stage II Primary Peritoneal Cancer AJCC v8","Stage IIA Fallopian Tube Cancer AJCC v8","Stage IIA Ovarian Cancer AJCC v8","Stage IIA Primary Peritoneal Cancer AJCC v8","Stage IIB Fallopian Tube Cancer AJCC v8","Stage IIB Ovarian Cancer AJCC v8","Stage IIB Primary Peritoneal Cancer AJCC v8",[243,5105],"Autologous Natural Killer Cell-like CTLs",{"trials":5107,"activeCount":101},[],{"trials":5109,"activeCount":101},[],{"trials":5111,"activeCount":101},[],{"intervention":1053,"totalTrials":582,"cells":5113},{"EARLY_PHASE1":5114,"PHASE1":5116,"PHASE2":5122,"PHASE3":5132,"PHASE4":5134,"NA":5136},{"trials":5115,"activeCount":101},[],{"trials":5117,"activeCount":101},[5118],{"nctId":1889,"briefTitle":1890,"status":133,"phases":5119,"primaryCompletion":1509,"completion":478,"start":1892,"enrollment":1893,"conditions":5120,"interventions":5121},[89],[18],[1877,1053],{"trials":5123,"activeCount":101},[5124,5128],{"nctId":1045,"briefTitle":1046,"status":365,"phases":5125,"primaryCompletion":1048,"start":1049,"enrollment":36,"conditions":5126,"interventions":5127},[89,90],[29],[1052,1053,500],{"nctId":1120,"briefTitle":1121,"status":365,"phases":5129,"primaryCompletion":1123,"start":1124,"conditions":5130,"interventions":5131},[89,90],[35],[1053,500],{"trials":5133,"activeCount":101},[],{"trials":5135,"activeCount":101},[],{"trials":5137,"activeCount":101},[],{"intervention":1761,"totalTrials":582,"cells":5139},{"EARLY_PHASE1":5140,"PHASE1":5142,"PHASE2":5144,"PHASE3":5158,"PHASE4":5160,"NA":5162},{"trials":5141,"activeCount":101},[],{"trials":5143,"activeCount":101},[],{"trials":5145,"activeCount":101},[5146,5150,5154],{"nctId":1754,"briefTitle":1755,"status":133,"phases":5147,"primaryCompletion":1267,"start":1757,"enrollment":537,"conditions":5148,"interventions":5149},[90],[23],[949,1760,461,1761],{"nctId":816,"briefTitle":817,"status":133,"phases":5151,"primaryCompletion":819,"completion":820,"start":821,"enrollment":380,"conditions":5152,"interventions":5153},[90],[823,824,825,826,827],[57,829,830,666,831,832,833],{"nctId":2036,"briefTitle":2037,"status":133,"phases":5155,"primaryCompletion":2039,"completion":2040,"start":2041,"enrollment":2042,"conditions":5156,"interventions":5157},[90],[2044,972,973,974,975,976,977,978,979,2045,980,2046,2047,728,2048,981,982,2049,984,2050,985,2051,986,734,2052,736,2053,988,989,2054,2055,991,744,992,746,2056,2057,2058,995,996,997,998,999,1000,1001,1002,1003,1004,2059,1005,1006,1007,1008,1009,1010,1011,1012,1014,1015,1016,606,1018,2060,1020,1021,609,2061,1022,749,2062,2063,2064,2065,752,1024,2066,756,757],[794,844,796,795,1761],{"trials":5159,"activeCount":101},[],{"trials":5161,"activeCount":101},[],{"trials":5163,"activeCount":101},[],{"intervention":1596,"totalTrials":440,"cells":5165},{"EARLY_PHASE1":5166,"PHASE1":5168,"PHASE2":5174,"PHASE3":5193,"PHASE4":5195,"NA":5197},{"trials":5167,"activeCount":101},[],{"trials":5169,"activeCount":101},[5170],{"nctId":1567,"briefTitle":1568,"status":133,"phases":5171,"primaryCompletion":1570,"completion":1570,"start":1571,"enrollment":1572,"conditions":5172,"interventions":5173},[89],[1543,1544,1545,1574,1575,1576,1577,1578,1579,1580,1581,1582,1583,1584,1585,1586,1587,1588,1589,1590,1591,1592,1593,1594],[1596,1597,792],{"trials":5175,"activeCount":101},[5176],{"nctId":5177,"briefTitle":5178,"status":235,"phases":5179,"primaryCompletion":5180,"start":3427,"enrollment":101,"conditions":5181,"interventions":5191},"NCT01982487","Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission",[89,90],"2017-09",[1543,1544,1545,5182,5183,5184,5185,5186,5187,5188,5189,5190,1574,1575,1576,1577,1578,1579,1580,1581,1582,1583,1584,1585,1586,1587,1588,1589,1590,1591,1592,1593,1594],"Stage IA Fallopian Tube Cancer","Stage IA Ovarian Epithelial Cancer","Stage IA Primary Peritoneal Cavity Cancer","Stage IB Fallopian Tube Cancer","Stage IB Ovarian Epithelial Cancer","Stage IB Primary Peritoneal Cavity Cancer","Stage IC Fallopian Tube Cancer","Stage IC Ovarian Epithelial Cancer","Stage IC Primary Peritoneal Cavity Cancer",[1596,5192],"IDO1 inhibitor INCB024360",{"trials":5194,"activeCount":101},[],{"trials":5196,"activeCount":101},[],{"trials":5198,"activeCount":101},[],{"intervention":5200,"totalTrials":440,"cells":5201},"everolimus",{"EARLY_PHASE1":5202,"PHASE1":5204,"PHASE2":5217,"PHASE3":5229,"PHASE4":5231,"NA":5233},{"trials":5203,"activeCount":101},[],{"trials":5205,"activeCount":101},[5206],{"nctId":5207,"briefTitle":5208,"status":133,"phases":5209,"primaryCompletion":943,"completion":2330,"start":5210,"enrollment":2412,"conditions":5211,"interventions":5215},"NCT00981162","Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride",[89],"2009-08",[5212,5213,5214,560,18],"Acinar Cell Adenocarcinoma of the Pancreas","Duct Cell Adenocarcinoma of the Pancreas","Recurrent Pancreatic Cancer",[5216,5200],"sorafenib tosylate",{"trials":5218,"activeCount":101},[5219],{"nctId":5220,"briefTitle":5221,"status":365,"phases":5222,"primaryCompletion":3127,"completion":1688,"start":5223,"enrollment":673,"conditions":5224,"interventions":5227},"NCT01582009","Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate",[89,90],"2010-03",[1248,5225,5226,1249],"Recurrent Renal Cell Cancer","Stage III Renal Cell Cancer",[5228,5200],"panobinostat",{"trials":5230,"activeCount":101},[],{"trials":5232,"activeCount":101},[],{"trials":5234,"activeCount":101},[],{"intervention":5236,"totalTrials":440,"cells":5237},"fulvestrant",{"EARLY_PHASE1":5238,"PHASE1":5240,"PHASE2":5242,"PHASE3":5256,"PHASE4":5258,"NA":5260},{"trials":5239,"activeCount":101},[],{"trials":5241,"activeCount":101},[],{"trials":5243,"activeCount":101},[5244,5250],{"nctId":5245,"briefTitle":5246,"status":365,"phases":5247,"primaryCompletion":1915,"completion":5223,"start":4480,"enrollment":27,"conditions":5248,"interventions":5249},"NCT00217464","Fulvestrant in Treating Patients With Recurrent Prostate Cancer",[90],[26],[5236],{"nctId":5251,"briefTitle":5252,"status":133,"phases":5253,"primaryCompletion":1509,"completion":493,"start":922,"enrollment":21,"conditions":5254,"interventions":5255},"NCT00244998","Fulvestrant in Treating Patients With Advanced Prostate Cancer",[90],[26],[5236],{"trials":5257,"activeCount":101},[],{"trials":5259,"activeCount":101},[],{"trials":5261,"activeCount":101},[],{"intervention":4353,"totalTrials":440,"cells":5263},{"EARLY_PHASE1":5264,"PHASE1":5266,"PHASE2":5276,"PHASE3":5282,"PHASE4":5284,"NA":5286},{"trials":5265,"activeCount":101},[],{"trials":5267,"activeCount":101},[5268],{"nctId":5269,"briefTitle":5270,"status":365,"phases":5271,"primaryCompletion":453,"completion":5272,"start":1103,"enrollment":1271,"conditions":5273,"interventions":5274},"NCT01003678","Safety and Tolerability of Oral Clofarabine in Intermediate to High Risk Myelodysplastic Patients",[89],"2013-10",[741],[5275],"Clofarabine",{"trials":5277,"activeCount":101},[5278],{"nctId":4347,"briefTitle":4348,"status":365,"phases":5279,"primaryCompletion":453,"completion":476,"start":4350,"enrollment":2744,"conditions":5280,"interventions":5281},[90],[15],[4353,2342,4354,1977],{"trials":5283,"activeCount":101},[],{"trials":5285,"activeCount":101},[],{"trials":5287,"activeCount":101},[],{"intervention":4354,"totalTrials":440,"cells":5289},{"EARLY_PHASE1":5290,"PHASE1":5292,"PHASE2":5294,"PHASE3":5309,"PHASE4":5311,"NA":5313},{"trials":5291,"activeCount":101},[],{"trials":5293,"activeCount":101},[],{"trials":5295,"activeCount":101},[5296,5300],{"nctId":4347,"briefTitle":4348,"status":365,"phases":5297,"primaryCompletion":453,"completion":476,"start":4350,"enrollment":2744,"conditions":5298,"interventions":5299},[90],[15],[4353,2342,4354,1977],{"nctId":5301,"briefTitle":5302,"status":133,"phases":5303,"primaryCompletion":1124,"completion":1217,"start":5304,"enrollment":2744,"conditions":5305,"interventions":5306},"NCT00057798","Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery",[90],"2000-03",[20],[1236,5307,4354,5308,1089],"vinorelbine ditartrate","loss of heterozygosity analysis",{"trials":5310,"activeCount":101},[],{"trials":5312,"activeCount":101},[],{"trials":5314,"activeCount":101},[],{"intervention":5316,"totalTrials":440,"cells":5317},"therapeutic autologous dendritic cells",{"EARLY_PHASE1":5318,"PHASE1":5320,"PHASE2":5330,"PHASE3":5336,"PHASE4":5338,"NA":5340},{"trials":5319,"activeCount":101},[],{"trials":5321,"activeCount":101},[5322],{"nctId":5323,"briefTitle":5324,"status":133,"phases":5325,"primaryCompletion":5326,"completion":1164,"start":838,"conditions":5327,"interventions":5328},"NCT00023985","Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer",[89],"2003-07",[20],[5329,5316],"autologous tumor cell vaccine",{"trials":5331,"activeCount":101},[5332],{"nctId":245,"briefTitle":246,"status":235,"phases":5333,"primaryCompletion":248,"completion":248,"start":249,"enrollment":101,"conditions":5334,"interventions":5335},[90],[251,252,253,254,255],[71,257],{"trials":5337,"activeCount":101},[],{"trials":5339,"activeCount":101},[],{"trials":5341,"activeCount":101},[],{"intervention":297,"totalTrials":440,"cells":5343},{"EARLY_PHASE1":5344,"PHASE1":5346,"PHASE2":5352,"PHASE3":5358,"PHASE4":5360,"NA":5362},{"trials":5345,"activeCount":101},[],{"trials":5347,"activeCount":101},[5348],{"nctId":681,"briefTitle":682,"status":417,"phases":5349,"primaryCompletion":684,"completion":685,"start":686,"enrollment":687,"conditions":5350,"interventions":5351},[89],[689,690,691,692,693,694],[696,57,297],{"trials":5353,"activeCount":101},[5354],{"nctId":283,"briefTitle":284,"status":235,"phases":5355,"primaryCompletion":286,"completion":287,"start":288,"enrollment":101,"conditions":5356,"interventions":5357},[90],[290,291,292,293,294,295],[57,297,298,71,299,47],{"trials":5359,"activeCount":101},[],{"trials":5361,"activeCount":101},[],{"trials":5363,"activeCount":101},[],{"intervention":796,"totalTrials":440,"cells":5365},{"EARLY_PHASE1":5366,"PHASE1":5368,"PHASE2":5370,"PHASE3":5380,"PHASE4":5382,"NA":5384},{"trials":5367,"activeCount":101},[],{"trials":5369,"activeCount":101},[],{"trials":5371,"activeCount":101},[5372,5376],{"nctId":780,"briefTitle":781,"status":133,"phases":5373,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":5374,"interventions":5375},[90],[787,15,23,707,708,788,789,728],[710,791,792,793,639,794,714,795,796],{"nctId":2036,"briefTitle":2037,"status":133,"phases":5377,"primaryCompletion":2039,"completion":2040,"start":2041,"enrollment":2042,"conditions":5378,"interventions":5379},[90],[2044,972,973,974,975,976,977,978,979,2045,980,2046,2047,728,2048,981,982,2049,984,2050,985,2051,986,734,2052,736,2053,988,989,2054,2055,991,744,992,746,2056,2057,2058,995,996,997,998,999,1000,1001,1002,1003,1004,2059,1005,1006,1007,1008,1009,1010,1011,1012,1014,1015,1016,606,1018,2060,1020,1021,609,2061,1022,749,2062,2063,2064,2065,752,1024,2066,756,757],[794,844,796,795,1761],{"trials":5381,"activeCount":101},[],{"trials":5383,"activeCount":101},[],{"trials":5385,"activeCount":101},[],{"intervention":4907,"totalTrials":440,"cells":5387},{"EARLY_PHASE1":5388,"PHASE1":5390,"PHASE2":5392,"PHASE3":5410,"PHASE4":5412,"NA":5414},{"trials":5389,"activeCount":101},[],{"trials":5391,"activeCount":101},[],{"trials":5393,"activeCount":101},[5394,5406],{"nctId":5395,"briefTitle":5396,"status":133,"phases":5397,"primaryCompletion":5398,"completion":5399,"start":2493,"enrollment":159,"conditions":5400,"interventions":5403},"NCT02953457","Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation",[90],"2021-09-15","2024-08-15",[5401,5402,221,226,227,228],"BRCA1 Gene Mutation","BRCA2 Gene Mutation",[4907,5404,5405],"Olaparib","Tremelimumab",{"nctId":4891,"briefTitle":4892,"status":365,"phases":5407,"primaryCompletion":4894,"completion":4894,"start":4895,"enrollment":138,"conditions":5408,"interventions":5409},[90],[4897,4898,4899,4900,4901,4902,4903,4904,4905],[4907,4847],{"trials":5411,"activeCount":101},[],{"trials":5413,"activeCount":101},[],{"trials":5415,"activeCount":101},[],{"intervention":5417,"totalTrials":440,"cells":5418},"erlotinib hydrochloride",{"EARLY_PHASE1":5419,"PHASE1":5421,"PHASE2":5423,"PHASE3":5437,"PHASE4":5439,"NA":5441},{"trials":5420,"activeCount":101},[],{"trials":5422,"activeCount":101},[],{"trials":5424,"activeCount":101},[5425,5431],{"nctId":5426,"briefTitle":5427,"status":365,"phases":5428,"primaryCompletion":2290,"completion":1133,"start":1267,"enrollment":24,"conditions":5429,"interventions":5430},"NCT00470535","Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer",[90],[1234],[5417],{"nctId":5432,"briefTitle":5433,"status":133,"phases":5434,"primaryCompletion":1112,"completion":1540,"start":1924,"enrollment":16,"conditions":5435,"interventions":5436},"NCT00524121","Erlotinib and Radiation Therapy in Treating Older Patients With Stage I, Stage II, Stage III, or Stage IV Esophageal Cancer",[90],[35],[5417],{"trials":5438,"activeCount":101},[],{"trials":5440,"activeCount":101},[],{"trials":5442,"activeCount":101},[],{"intervention":1965,"totalTrials":440,"cells":5444},{"EARLY_PHASE1":5445,"PHASE1":5447,"PHASE2":5449,"PHASE3":5459,"PHASE4":5461,"NA":5463},{"trials":5446,"activeCount":101},[],{"trials":5448,"activeCount":101},[],{"trials":5450,"activeCount":101},[5451,5455],{"nctId":1957,"briefTitle":1958,"status":133,"phases":5452,"primaryCompletion":1960,"start":1231,"enrollment":687,"conditions":5453,"interventions":5454},[90],[707],[1877,1963,1964,1965],{"nctId":816,"briefTitle":817,"status":133,"phases":5456,"primaryCompletion":819,"completion":820,"start":821,"enrollment":380,"conditions":5457,"interventions":5458},[90],[823,824,825,826,827],[57,829,830,666,831,832,833],{"trials":5460,"activeCount":101},[],{"trials":5462,"activeCount":101},[],{"trials":5464,"activeCount":101},[],{"intervention":1089,"totalTrials":440,"cells":5466},{"EARLY_PHASE1":5467,"PHASE1":5469,"PHASE2":5471,"PHASE3":5481,"PHASE4":5483,"NA":5485},{"trials":5468,"activeCount":101},[],{"trials":5470,"activeCount":101},[],{"trials":5472,"activeCount":101},[5473,5477],{"nctId":1083,"briefTitle":1084,"status":133,"phases":5474,"primaryCompletion":452,"start":454,"enrollment":785,"conditions":5475,"interventions":5476},[90],[35],[1052,500,1088,1089,1090],{"nctId":5301,"briefTitle":5302,"status":133,"phases":5478,"primaryCompletion":1124,"completion":1217,"start":5304,"enrollment":2744,"conditions":5479,"interventions":5480},[90],[20],[1236,5307,4354,5308,1089],{"trials":5482,"activeCount":101},[],{"trials":5484,"activeCount":101},[],{"trials":5486,"activeCount":101},[],{"intervention":5488,"totalTrials":440,"cells":5489},"aminolevulinic acid hydrochloride",{"EARLY_PHASE1":5490,"PHASE1":5492,"PHASE2":5494,"PHASE3":5511,"PHASE4":5513,"NA":5515},{"trials":5491,"activeCount":101},[],{"trials":5493,"activeCount":101},[],{"trials":5495,"activeCount":101},[5496,5504],{"nctId":5497,"briefTitle":5498,"status":133,"phases":5499,"primaryCompletion":5500,"start":5501,"enrollment":97,"conditions":5502,"interventions":5503},"NCT00054171","Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia",[90],"2005-07","1999-02",[15,23],[5488],{"nctId":5505,"briefTitle":3484,"status":133,"phases":5506,"primaryCompletion":5507,"completion":5507,"start":5508,"conditions":5509,"interventions":5510},"NCT00002963",[90],"2007-06","1993-11",[3490],[5488],{"trials":5512,"activeCount":101},[],{"trials":5514,"activeCount":101},[],{"trials":5516,"activeCount":101},[],{"intervention":5518,"totalTrials":440,"cells":5519},"Gabapentin",{"EARLY_PHASE1":5520,"PHASE1":5522,"PHASE2":5535,"PHASE3":5550,"PHASE4":5552,"NA":5554},{"trials":5521,"activeCount":101},[],{"trials":5523,"activeCount":101},[5524],{"nctId":5525,"briefTitle":5526,"status":133,"phases":5527,"primaryCompletion":5528,"completion":5528,"start":5529,"enrollment":212,"conditions":5530,"interventions":5532},"NCT02531906","Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation",[89],"2018-06-14","2015-04-24",[2864,3372,5531],"Stomatitis",[5518,5533,5534],"Methadone Hydrochloride","Oxycodone Hydrochloride",{"trials":5536,"activeCount":101},[5537],{"nctId":5538,"briefTitle":5539,"status":133,"phases":5540,"primaryCompletion":5541,"completion":5542,"start":5543,"enrollment":2089,"conditions":5544,"interventions":5545},"NCT03574792","Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy",[90],"2021-04-19","2021-11-11","2018-05-03",[270,275],[5518,5546,5547,5548,5549],"Methadone","Oxycodone","Venlafaxine","Venlafaxine Hydrochloride Extended Release",{"trials":5551,"activeCount":101},[],{"trials":5553,"activeCount":101},[],{"trials":5555,"activeCount":101},[],{"intervention":4973,"totalTrials":440,"cells":5557},{"EARLY_PHASE1":5558,"PHASE1":5560,"PHASE2":5562,"PHASE3":5572,"PHASE4":5574,"NA":5576},{"trials":5559,"activeCount":101},[],{"trials":5561,"activeCount":101},[],{"trials":5563,"activeCount":101},[5564,5568],{"nctId":4968,"briefTitle":4969,"status":365,"phases":5565,"primaryCompletion":4414,"start":492,"enrollment":582,"conditions":5566,"interventions":5567},[90],[1026],[4973,2293],{"nctId":816,"briefTitle":817,"status":133,"phases":5569,"primaryCompletion":819,"completion":820,"start":821,"enrollment":380,"conditions":5570,"interventions":5571},[90],[823,824,825,826,827],[57,829,830,666,831,832,833],{"trials":5573,"activeCount":101},[],{"trials":5575,"activeCount":101},[],{"trials":5577,"activeCount":101},[],{"intervention":5192,"totalTrials":97,"cells":5579},{"EARLY_PHASE1":5580,"PHASE1":5582,"PHASE2":5584,"PHASE3":5590,"PHASE4":5592,"NA":5594},{"trials":5581,"activeCount":101},[],{"trials":5583,"activeCount":101},[],{"trials":5585,"activeCount":101},[5586],{"nctId":5177,"briefTitle":5178,"status":235,"phases":5587,"primaryCompletion":5180,"start":3427,"enrollment":101,"conditions":5588,"interventions":5589},[89,90],[1543,1544,1545,5182,5183,5184,5185,5186,5187,5188,5189,5190,1574,1575,1576,1577,1578,1579,1580,1581,1582,1583,1584,1585,1586,1587,1588,1589,1590,1591,1592,1593,1594],[1596,5192],{"trials":5591,"activeCount":101},[],{"trials":5593,"activeCount":101},[],{"trials":5595,"activeCount":101},[],{"intervention":5228,"totalTrials":97,"cells":5597},{"EARLY_PHASE1":5598,"PHASE1":5600,"PHASE2":5602,"PHASE3":5608,"PHASE4":5610,"NA":5612},{"trials":5599,"activeCount":101},[],{"trials":5601,"activeCount":101},[],{"trials":5603,"activeCount":101},[5604],{"nctId":5220,"briefTitle":5221,"status":365,"phases":5605,"primaryCompletion":3127,"completion":1688,"start":5223,"enrollment":673,"conditions":5606,"interventions":5607},[89,90],[1248,5225,5226,1249],[5228,5200],{"trials":5609,"activeCount":101},[],{"trials":5611,"activeCount":101},[],{"trials":5613,"activeCount":101},[],{"intervention":5615,"totalTrials":97,"cells":5616},"axitinib",{"EARLY_PHASE1":5617,"PHASE1":5619,"PHASE2":5621,"PHASE3":5641,"PHASE4":5643,"NA":5645},{"trials":5618,"activeCount":101},[],{"trials":5620,"activeCount":101},[],{"trials":5622,"activeCount":101},[5623],{"nctId":5624,"briefTitle":5625,"status":365,"phases":5626,"primaryCompletion":4398,"completion":4398,"start":5627,"enrollment":1916,"conditions":5628,"interventions":5640},"NCT01533948","Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery",[90],"2012-01",[5629,5630,5631,2536,5632,5633,5634,5635,5636,5637,5638,5639],"Extraocular Extension Melanoma","Metastatic Intraocular Melanoma","Recurrent Intraocular Melanoma","Stage IIIA Intraocular Melanoma","Stage IIIA Melanoma","Stage IIIB Intraocular Melanoma","Stage IIIB Melanoma","Stage IIIC Intraocular Melanoma","Stage IIIC Melanoma","Stage IV Intraocular Melanoma","Stage IV Melanoma",[5615],{"trials":5642,"activeCount":101},[],{"trials":5644,"activeCount":101},[],{"trials":5646,"activeCount":101},[],{"intervention":2296,"totalTrials":97,"cells":5648},{"EARLY_PHASE1":5649,"PHASE1":5651,"PHASE2":5653,"PHASE3":5659,"PHASE4":5661,"NA":5663},{"trials":5650,"activeCount":101},[],{"trials":5652,"activeCount":101},[],{"trials":5654,"activeCount":101},[5655],{"nctId":2286,"briefTitle":2287,"status":365,"phases":5656,"primaryCompletion":2289,"completion":2289,"start":2290,"enrollment":317,"conditions":5657,"interventions":5658},[90],[23],[2216,2293,1489,1088,2294,2295,2296],{"trials":5660,"activeCount":101},[],{"trials":5662,"activeCount":101},[],{"trials":5664,"activeCount":101},[],{"intervention":4802,"totalTrials":97,"cells":5666},{"EARLY_PHASE1":5667,"PHASE1":5669,"PHASE2":5671,"PHASE3":5677,"PHASE4":5679,"NA":5681},{"trials":5668,"activeCount":101},[],{"trials":5670,"activeCount":101},[],{"trials":5672,"activeCount":101},[5673],{"nctId":4792,"briefTitle":4793,"status":133,"phases":5674,"primaryCompletion":4795,"completion":4795,"start":4796,"enrollment":159,"conditions":5675,"interventions":5676},[89,90],[4798,4799,4800],[1665,4802,1666],{"trials":5678,"activeCount":101},[],{"trials":5680,"activeCount":101},[],{"trials":5682,"activeCount":101},[],{"intervention":5684,"totalTrials":97,"cells":5685},"dutasteride",{"EARLY_PHASE1":5686,"PHASE1":5688,"PHASE2":5690,"PHASE3":5700,"PHASE4":5702,"NA":5704},{"trials":5687,"activeCount":101},[],{"trials":5689,"activeCount":101},[],{"trials":5691,"activeCount":101},[5692],{"nctId":5693,"briefTitle":5694,"status":133,"phases":5695,"primaryCompletion":5696,"completion":4438,"start":5697,"enrollment":2887,"conditions":5698,"interventions":5699},"NCT00403000","Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy",[90],"2007-03","2004-12",[26],[5684],{"trials":5701,"activeCount":101},[],{"trials":5703,"activeCount":101},[],{"trials":5705,"activeCount":101},[],{"intervention":5707,"totalTrials":97,"cells":5708},"Regorafenib",{"EARLY_PHASE1":5709,"PHASE1":5711,"PHASE2":5713,"PHASE3":5726,"PHASE4":5728,"NA":5730},{"trials":5710,"activeCount":101},[],{"trials":5712,"activeCount":101},[],{"trials":5714,"activeCount":101},[5715],{"nctId":5716,"briefTitle":5717,"status":235,"phases":5718,"primaryCompletion":5719,"start":5720,"enrollment":101,"conditions":5721,"interventions":5725},"NCT02287727","Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment",[90],"2016-10","2015-03",[552,5722,5723,5724,555,557],"Stage IIA Rectal Cancer","Stage IIB Rectal Cancer","Stage IIC Rectal Cancer",[5707],{"trials":5727,"activeCount":101},[],{"trials":5729,"activeCount":101},[],{"trials":5731,"activeCount":101},[],{"intervention":4835,"totalTrials":97,"cells":5733},{"EARLY_PHASE1":5734,"PHASE1":5736,"PHASE2":5738,"PHASE3":5744,"PHASE4":5746,"NA":5748},{"trials":5735,"activeCount":101},[],{"trials":5737,"activeCount":101},[],{"trials":5739,"activeCount":101},[5740],{"nctId":4830,"briefTitle":4831,"status":365,"phases":5741,"primaryCompletion":1541,"completion":3369,"start":1484,"enrollment":138,"conditions":5742,"interventions":5743},[90],[456],[2307,4835],{"trials":5745,"activeCount":101},[],{"trials":5747,"activeCount":101},[],{"trials":5749,"activeCount":101},[],{"intervention":5751,"totalTrials":97,"cells":5752},"Pegylated Irinotecan",{"EARLY_PHASE1":5753,"PHASE1":5755,"PHASE2":5757,"PHASE3":5769,"PHASE4":5771,"NA":5773},{"trials":5754,"activeCount":101},[],{"trials":5756,"activeCount":101},[],{"trials":5758,"activeCount":101},[5759],{"nctId":5760,"briefTitle":5761,"status":133,"phases":5762,"primaryCompletion":5763,"completion":5764,"start":5765,"enrollment":3202,"conditions":5766,"interventions":5768},"NCT01876446","Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer",[90],"2017-07-18","2020-02-24","2013-08-29",[5767],"Recurrent Small Cell Lung Carcinoma",[5751],{"trials":5770,"activeCount":101},[],{"trials":5772,"activeCount":101},[],{"trials":5774,"activeCount":101},[],{"intervention":1939,"totalTrials":97,"cells":5776},{"EARLY_PHASE1":5777,"PHASE1":5779,"PHASE2":5781,"PHASE3":5787,"PHASE4":5789,"NA":5791},{"trials":5778,"activeCount":101},[],{"trials":5780,"activeCount":101},[],{"trials":5782,"activeCount":101},[5783],{"nctId":1929,"briefTitle":1930,"status":365,"phases":5784,"primaryCompletion":1932,"completion":1933,"start":1934,"enrollment":863,"conditions":5785,"interventions":5786},[90],[1936,1937],[1939,830,1940],{"trials":5788,"activeCount":101},[],{"trials":5790,"activeCount":101},[],{"trials":5792,"activeCount":101},[],{"intervention":1940,"totalTrials":97,"cells":5794},{"EARLY_PHASE1":5795,"PHASE1":5797,"PHASE2":5799,"PHASE3":5805,"PHASE4":5807,"NA":5809},{"trials":5796,"activeCount":101},[],{"trials":5798,"activeCount":101},[],{"trials":5800,"activeCount":101},[5801],{"nctId":1929,"briefTitle":1930,"status":365,"phases":5802,"primaryCompletion":1932,"completion":1933,"start":1934,"enrollment":863,"conditions":5803,"interventions":5804},[90],[1936,1937],[1939,830,1940],{"trials":5806,"activeCount":101},[],{"trials":5808,"activeCount":101},[],{"trials":5810,"activeCount":101},[],{"intervention":5812,"totalTrials":97,"cells":5813},"BCG vaccine",{"EARLY_PHASE1":5814,"PHASE1":5816,"PHASE2":5818,"PHASE3":5829,"PHASE4":5831,"NA":5833},{"trials":5815,"activeCount":101},[],{"trials":5817,"activeCount":101},[],{"trials":5819,"activeCount":101},[5820],{"nctId":5821,"briefTitle":5822,"status":133,"phases":5823,"primaryCompletion":5824,"start":3580,"conditions":5825,"interventions":5827},"NCT00004122","BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer",[90],"2001-04",[5826],"Bladder Cancer",[5812,5828],"recombinant interferon alfa",{"trials":5830,"activeCount":101},[],{"trials":5832,"activeCount":101},[],{"trials":5834,"activeCount":101},[],{"intervention":5828,"totalTrials":97,"cells":5836},{"EARLY_PHASE1":5837,"PHASE1":5839,"PHASE2":5841,"PHASE3":5847,"PHASE4":5849,"NA":5851},{"trials":5838,"activeCount":101},[],{"trials":5840,"activeCount":101},[],{"trials":5842,"activeCount":101},[5843],{"nctId":5821,"briefTitle":5822,"status":133,"phases":5844,"primaryCompletion":5824,"start":3580,"conditions":5845,"interventions":5846},[90],[5826],[5812,5828],{"trials":5848,"activeCount":101},[],{"trials":5850,"activeCount":101},[],{"trials":5852,"activeCount":101},[],{"intervention":5854,"totalTrials":97,"cells":5855},"rasburicase",{"EARLY_PHASE1":5856,"PHASE1":5858,"PHASE2":5860,"PHASE3":5876,"PHASE4":5878,"NA":5880},{"trials":5857,"activeCount":101},[],{"trials":5859,"activeCount":101},[],{"trials":5861,"activeCount":101},[5862],{"nctId":5863,"briefTitle":5864,"status":365,"phases":5865,"primaryCompletion":2039,"completion":5866,"start":5867,"enrollment":687,"conditions":5868,"interventions":5874},"NCT01564277","Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies",[90],"2016-05-28","2011-09-29",[974,975,976,977,978,979,5869,5870,2094,2095,2057,995,996,997,5871,5872,2116,5873,1701],"Blastic Phase Chronic Myelogenous Leukemia","Contiguous Stage II Adult Burkitt Lymphoma","Stage I Adult Burkitt Lymphoma","Stage III Adult Burkitt Lymphoma","Untreated Adult Acute Lymphoblastic Leukemia",[5854,5875],"allopurinol",{"trials":5877,"activeCount":101},[],{"trials":5879,"activeCount":101},[],{"trials":5881,"activeCount":101},[],{"intervention":5875,"totalTrials":97,"cells":5883},{"EARLY_PHASE1":5884,"PHASE1":5886,"PHASE2":5888,"PHASE3":5894,"PHASE4":5896,"NA":5898},{"trials":5885,"activeCount":101},[],{"trials":5887,"activeCount":101},[],{"trials":5889,"activeCount":101},[5890],{"nctId":5863,"briefTitle":5864,"status":365,"phases":5891,"primaryCompletion":2039,"completion":5866,"start":5867,"enrollment":687,"conditions":5892,"interventions":5893},[90],[974,975,976,977,978,979,5869,5870,2094,2095,2057,995,996,997,5871,5872,2116,5873,1701],[5854,5875],{"trials":5895,"activeCount":101},[],{"trials":5897,"activeCount":101},[],{"trials":5899,"activeCount":101},[],{"intervention":1703,"totalTrials":97,"cells":5901},{"EARLY_PHASE1":5902,"PHASE1":5904,"PHASE2":5906,"PHASE3":5912,"PHASE4":5914,"NA":5916},{"trials":5903,"activeCount":101},[],{"trials":5905,"activeCount":101},[],{"trials":5907,"activeCount":101},[5908],{"nctId":1685,"briefTitle":1686,"status":365,"phases":5909,"primaryCompletion":1132,"completion":1688,"start":1689,"enrollment":440,"conditions":5910,"interventions":5911},[90],[1691,1692,1693,1694,1695,1696,1697,974,975,976,978,979,1698,1699,1700,749,1701],[949,1703,1547],{"trials":5913,"activeCount":101},[],{"trials":5915,"activeCount":101},[],{"trials":5917,"activeCount":101},[],{"intervention":5919,"totalTrials":97,"cells":5920},"Enasidenib",{"EARLY_PHASE1":5921,"PHASE1":5923,"PHASE2":5925,"PHASE3":5939,"PHASE4":5941,"NA":5943},{"trials":5922,"activeCount":101},[],{"trials":5924,"activeCount":101},[],{"trials":5926,"activeCount":101},[5927],{"nctId":5928,"briefTitle":5929,"status":235,"phases":5930,"primaryCompletion":5931,"completion":5932,"start":5933,"enrollment":101,"conditions":5934,"interventions":5938},"NCT03881735","Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation",[90],"2021-11-19","2022-11-19","2019-12-02",[5935,5936,5937,675,676],"Blasts Under 5 Percent of Peripheral Blood White Cells","Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level","IDH2 Gene Mutation",[5919],{"trials":5940,"activeCount":101},[],{"trials":5942,"activeCount":101},[],{"trials":5944,"activeCount":101},[],{"intervention":1760,"totalTrials":97,"cells":5946},{"EARLY_PHASE1":5947,"PHASE1":5949,"PHASE2":5951,"PHASE3":5957,"PHASE4":5959,"NA":5961},{"trials":5948,"activeCount":101},[],{"trials":5950,"activeCount":101},[],{"trials":5952,"activeCount":101},[5953],{"nctId":1754,"briefTitle":1755,"status":133,"phases":5954,"primaryCompletion":1267,"start":1757,"enrollment":537,"conditions":5955,"interventions":5956},[90],[23],[949,1760,461,1761],{"trials":5958,"activeCount":101},[],{"trials":5960,"activeCount":101},[],{"trials":5962,"activeCount":101},[],{"intervention":299,"totalTrials":97,"cells":5964},{"EARLY_PHASE1":5965,"PHASE1":5967,"PHASE2":5969,"PHASE3":5975,"PHASE4":5977,"NA":5979},{"trials":5966,"activeCount":101},[],{"trials":5968,"activeCount":101},[],{"trials":5970,"activeCount":101},[5971],{"nctId":283,"briefTitle":284,"status":235,"phases":5972,"primaryCompletion":286,"completion":287,"start":288,"enrollment":101,"conditions":5973,"interventions":5974},[90],[290,291,292,293,294,295],[57,297,298,71,299,47],{"trials":5976,"activeCount":101},[],{"trials":5978,"activeCount":101},[],{"trials":5980,"activeCount":101},[],{"intervention":1950,"totalTrials":97,"cells":5982},{"EARLY_PHASE1":5983,"PHASE1":5985,"PHASE2":5987,"PHASE3":5993,"PHASE4":5995,"NA":5997},{"trials":5984,"activeCount":101},[],{"trials":5986,"activeCount":101},[],{"trials":5988,"activeCount":101},[5989],{"nctId":1942,"briefTitle":1943,"status":365,"phases":5990,"primaryCompletion":1945,"completion":1945,"start":1946,"enrollment":863,"conditions":5991,"interventions":5992},[90],[1948],[830,1950,1951],{"trials":5994,"activeCount":101},[],{"trials":5996,"activeCount":101},[],{"trials":5998,"activeCount":101},[],{"intervention":1951,"totalTrials":97,"cells":6000},{"EARLY_PHASE1":6001,"PHASE1":6003,"PHASE2":6005,"PHASE3":6011,"PHASE4":6013,"NA":6015},{"trials":6002,"activeCount":101},[],{"trials":6004,"activeCount":101},[],{"trials":6006,"activeCount":101},[6007],{"nctId":1942,"briefTitle":1943,"status":365,"phases":6008,"primaryCompletion":1945,"completion":1945,"start":1946,"enrollment":863,"conditions":6009,"interventions":6010},[90],[1948],[830,1950,1951],{"trials":6012,"activeCount":101},[],{"trials":6014,"activeCount":101},[],{"trials":6016,"activeCount":101},[],{"intervention":6018,"totalTrials":97,"cells":6019},"Vaccinium myrtillus\u002FMacleaya cordata\u002FEchinacea angustifolia extract granules",{"EARLY_PHASE1":6020,"PHASE1":6022,"PHASE2":6024,"PHASE3":6033,"PHASE4":6035,"NA":6037},{"trials":6021,"activeCount":101},[],{"trials":6023,"activeCount":101},[],{"trials":6025,"activeCount":101},[6026],{"nctId":6027,"briefTitle":6028,"status":235,"phases":6029,"primaryCompletion":4398,"start":6030,"enrollment":101,"conditions":6031,"interventions":6032},"NCT01674374","Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy",[90],"2013-05",[3130,3131,3132,3133,3134,3135,3136,3137,3138,3139,3140,3141,3142,3143,3144,3145,3146,3147,3148,3149,3150,3151,3152,3153,3154,3155,3156,3157,3158,3159,3160,3167],[6018],{"trials":6034,"activeCount":101},[],{"trials":6036,"activeCount":101},[],{"trials":6038,"activeCount":101},[],{"intervention":791,"totalTrials":97,"cells":6040},{"EARLY_PHASE1":6041,"PHASE1":6043,"PHASE2":6045,"PHASE3":6051,"PHASE4":6053,"NA":6055},{"trials":6042,"activeCount":101},[],{"trials":6044,"activeCount":101},[],{"trials":6046,"activeCount":101},[6047],{"nctId":780,"briefTitle":781,"status":133,"phases":6048,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":6049,"interventions":6050},[90],[787,15,23,707,708,788,789,728],[710,791,792,793,639,794,714,795,796],{"trials":6052,"activeCount":101},[],{"trials":6054,"activeCount":101},[],{"trials":6056,"activeCount":101},[],{"intervention":793,"totalTrials":97,"cells":6058},{"EARLY_PHASE1":6059,"PHASE1":6061,"PHASE2":6063,"PHASE3":6069,"PHASE4":6071,"NA":6073},{"trials":6060,"activeCount":101},[],{"trials":6062,"activeCount":101},[],{"trials":6064,"activeCount":101},[6065],{"nctId":780,"briefTitle":781,"status":133,"phases":6066,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":6067,"interventions":6068},[90],[787,15,23,707,708,788,789,728],[710,791,792,793,639,794,714,795,796],{"trials":6070,"activeCount":101},[],{"trials":6072,"activeCount":101},[],{"trials":6074,"activeCount":101},[],{"intervention":6076,"totalTrials":97,"cells":6077},"cetuximab with irinotecan",{"EARLY_PHASE1":6078,"PHASE1":6080,"PHASE2":6082,"PHASE3":6091,"PHASE4":6093,"NA":6095},{"trials":6079,"activeCount":101},[],{"trials":6081,"activeCount":101},[],{"trials":6083,"activeCount":101},[6084],{"nctId":6085,"briefTitle":6086,"status":365,"phases":6087,"primaryCompletion":2030,"completion":2030,"start":6088,"enrollment":21,"conditions":6089,"interventions":6090},"NCT01004159","Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan",[90],"2009-09",[29],[6076],{"trials":6092,"activeCount":101},[],{"trials":6094,"activeCount":101},[],{"trials":6096,"activeCount":101},[],{"intervention":6098,"totalTrials":97,"cells":6099},"Gemcitabine, Capecitabine and Bevacizumab",{"EARLY_PHASE1":6100,"PHASE1":6102,"PHASE2":6104,"PHASE3":6114,"PHASE4":6116,"NA":6118},{"trials":6101,"activeCount":101},[],{"trials":6103,"activeCount":101},[],{"trials":6105,"activeCount":101},[6106],{"nctId":6107,"briefTitle":6108,"status":133,"phases":6109,"primaryCompletion":6110,"completion":6110,"start":1104,"enrollment":1232,"conditions":6111,"interventions":6113},"NCT01007552","A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts",[90],"2015-05",[6112],"Cholangiocarcinoma",[6098],{"trials":6115,"activeCount":101},[],{"trials":6117,"activeCount":101},[],{"trials":6119,"activeCount":101},[],{"intervention":5404,"totalTrials":97,"cells":6121},{"EARLY_PHASE1":6122,"PHASE1":6124,"PHASE2":6126,"PHASE3":6132,"PHASE4":6134,"NA":6136},{"trials":6123,"activeCount":101},[],{"trials":6125,"activeCount":101},[],{"trials":6127,"activeCount":101},[6128],{"nctId":5395,"briefTitle":5396,"status":133,"phases":6129,"primaryCompletion":5398,"completion":5399,"start":2493,"enrollment":159,"conditions":6130,"interventions":6131},[90],[5401,5402,221,226,227,228],[4907,5404,5405],{"trials":6133,"activeCount":101},[],{"trials":6135,"activeCount":101},[],{"trials":6137,"activeCount":101},[],{"intervention":5405,"totalTrials":97,"cells":6139},{"EARLY_PHASE1":6140,"PHASE1":6142,"PHASE2":6144,"PHASE3":6150,"PHASE4":6152,"NA":6154},{"trials":6141,"activeCount":101},[],{"trials":6143,"activeCount":101},[],{"trials":6145,"activeCount":101},[6146],{"nctId":5395,"briefTitle":5396,"status":133,"phases":6147,"primaryCompletion":5398,"completion":5399,"start":2493,"enrollment":159,"conditions":6148,"interventions":6149},[90],[5401,5402,221,226,227,228],[4907,5404,5405],{"trials":6151,"activeCount":101},[],{"trials":6153,"activeCount":101},[],{"trials":6155,"activeCount":101},[],{"intervention":6157,"totalTrials":97,"cells":6158},"Botulinum Toxin Type A",{"EARLY_PHASE1":6159,"PHASE1":6161,"PHASE2":6163,"PHASE3":6176,"PHASE4":6178,"NA":6180},{"trials":6160,"activeCount":101},[],{"trials":6162,"activeCount":101},[],{"trials":6164,"activeCount":101},[6165],{"nctId":6166,"briefTitle":6167,"status":133,"phases":6168,"primaryCompletion":6169,"completion":6170,"start":6171,"enrollment":6172,"conditions":6173,"interventions":6175},"NCT02965976","Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer",[90],"2022-01-28","2022-04-28","2016-12-30",33,[6174],"Esophageal Carcinoma",[6157],{"trials":6177,"activeCount":101},[],{"trials":6179,"activeCount":101},[],{"trials":6181,"activeCount":101},[],{"intervention":6183,"totalTrials":97,"cells":6184},"bupropion hydrochloride",{"EARLY_PHASE1":6185,"PHASE1":6187,"PHASE2":6189,"PHASE3":6201,"PHASE4":6203,"NA":6205},{"trials":6186,"activeCount":101},[],{"trials":6188,"activeCount":101},[],{"trials":6190,"activeCount":101},[6191],{"nctId":6192,"briefTitle":6193,"status":133,"phases":6194,"primaryCompletion":1484,"completion":4398,"start":1923,"enrollment":6195,"conditions":6196,"interventions":6200},"NCT00534001","Bupropion in Helping Adults Stop Smoking",[90],95,[5826,6197,35,456,3261,6198,15,457,20,1234,6199],"Cervical Cancer","Kidney Cancer","Tobacco Use Disorder",[6183],{"trials":6202,"activeCount":101},[],{"trials":6204,"activeCount":101},[],{"trials":6206,"activeCount":101},[],{"intervention":6208,"totalTrials":97,"cells":6209},"Inotuzumab Ozogamicin",{"EARLY_PHASE1":6210,"PHASE1":6212,"PHASE2":6214,"PHASE3":6234,"PHASE4":6236,"NA":6238},{"trials":6211,"activeCount":101},[],{"trials":6213,"activeCount":101},[],{"trials":6215,"activeCount":101},[6216],{"nctId":6217,"briefTitle":6218,"status":235,"phases":6219,"primaryCompletion":6220,"completion":6221,"start":6222,"enrollment":101,"conditions":6223,"interventions":6232},"NCT03851081","Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia",[89,90],"2023-01-21","2024-01-21","2021-01-21",[6224,6225,6226,6227,6228,6229,6230,6231],"Allogeneic Hematopoietic Stem Cell Transplantation Recipient","Blasts 5 Percent or More of Bone Marrow Nucleated Cells","Blasts 5 Percent or More of Peripheral Blood White Cells","CD22 Positive","Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells","Lymphoblasts 20 Percent or More of Peripheral Blood White Cells","Recurrent B Acute Lymphoblastic Leukemia","Refractory B Acute Lymphoblastic Leukemia",[6208,6233],"Vincristine Sulfate Liposome",{"trials":6235,"activeCount":101},[],{"trials":6237,"activeCount":101},[],{"trials":6239,"activeCount":101},[],{"intervention":6233,"totalTrials":97,"cells":6241},{"EARLY_PHASE1":6242,"PHASE1":6244,"PHASE2":6246,"PHASE3":6252,"PHASE4":6254,"NA":6256},{"trials":6243,"activeCount":101},[],{"trials":6245,"activeCount":101},[],{"trials":6247,"activeCount":101},[6248],{"nctId":6217,"briefTitle":6218,"status":235,"phases":6249,"primaryCompletion":6220,"completion":6221,"start":6222,"enrollment":101,"conditions":6250,"interventions":6251},[89,90],[6224,6225,6226,6227,6228,6229,6230,6231],[6208,6233],{"trials":6253,"activeCount":101},[],{"trials":6255,"activeCount":101},[],{"trials":6257,"activeCount":101},[],{"intervention":6259,"totalTrials":97,"cells":6260},"ortataxel",{"EARLY_PHASE1":6261,"PHASE1":6263,"PHASE2":6265,"PHASE3":6274,"PHASE4":6276,"NA":6278},{"trials":6262,"activeCount":101},[],{"trials":6264,"activeCount":101},[],{"trials":6266,"activeCount":101},[6267],{"nctId":6268,"briefTitle":6269,"status":133,"phases":6270,"primaryCompletion":6271,"start":1451,"conditions":6272,"interventions":6273},"NCT00054314","BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer",[90],"2003-04",[20],[6259],{"trials":6275,"activeCount":101},[],{"trials":6277,"activeCount":101},[],{"trials":6279,"activeCount":101},[],{"intervention":6281,"totalTrials":97,"cells":6282},"Cisplatin + celecoxib + DC vaccine",{"EARLY_PHASE1":6283,"PHASE1":6285,"PHASE2":6287,"PHASE3":6302,"PHASE4":6304,"NA":6306},{"trials":6284,"activeCount":101},[],{"trials":6286,"activeCount":101},[],{"trials":6288,"activeCount":101},[6289],{"nctId":6290,"briefTitle":6291,"status":365,"phases":6292,"primaryCompletion":368,"completion":368,"start":6293,"enrollment":1916,"conditions":6294,"interventions":6300},"NCT02432378","Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines",[89,90],"2015-09-04",[6295,6296,6297,3263,6298,6299],"Cancer of Ovary","Cancer of the Ovary","Neoplasms, Ovarian","Ovary Cancer","Ovary Neoplasms",[6281,6301],"Cisplatin + CKM + Celecoxib + DC Vaccine",{"trials":6303,"activeCount":101},[],{"trials":6305,"activeCount":101},[],{"trials":6307,"activeCount":101},[],{"intervention":6301,"totalTrials":97,"cells":6309},{"EARLY_PHASE1":6310,"PHASE1":6312,"PHASE2":6314,"PHASE3":6320,"PHASE4":6322,"NA":6324},{"trials":6311,"activeCount":101},[],{"trials":6313,"activeCount":101},[],{"trials":6315,"activeCount":101},[6316],{"nctId":6290,"briefTitle":6291,"status":365,"phases":6317,"primaryCompletion":368,"completion":368,"start":6293,"enrollment":1916,"conditions":6318,"interventions":6319},[89,90],[6295,6296,6297,3263,6298,6299],[6281,6301],{"trials":6321,"activeCount":101},[],{"trials":6323,"activeCount":101},[],{"trials":6325,"activeCount":101},[],{"intervention":6327,"totalTrials":97,"cells":6328},"Denosumab",{"EARLY_PHASE1":6329,"PHASE1":6331,"PHASE2":6333,"PHASE3":6345,"PHASE4":6347,"NA":6349},{"trials":6330,"activeCount":101},[],{"trials":6332,"activeCount":101},[],{"trials":6334,"activeCount":101},[6335],{"nctId":6336,"briefTitle":6337,"status":133,"phases":6338,"primaryCompletion":6339,"completion":6339,"start":6340,"enrollment":804,"conditions":6341,"interventions":6344},"NCT03925532","Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant",[90],"2022-11-16","2019-12-19",[6224,6342,6343],"Osteopenia","Osteoporosis",[6327],{"trials":6346,"activeCount":101},[],{"trials":6348,"activeCount":101},[],{"trials":6350,"activeCount":101},[],{"intervention":2396,"totalTrials":97,"cells":6352},{"EARLY_PHASE1":6353,"PHASE1":6355,"PHASE2":6357,"PHASE3":6363,"PHASE4":6365,"NA":6367},{"trials":6354,"activeCount":101},[],{"trials":6356,"activeCount":101},[],{"trials":6358,"activeCount":101},[6359],{"nctId":2387,"briefTitle":2388,"status":365,"phases":6360,"primaryCompletion":2390,"completion":368,"start":2391,"enrollment":97,"conditions":6361,"interventions":6362},[90],[2393,2394],[243,146,2396,2397,147,148],{"trials":6364,"activeCount":101},[],{"trials":6366,"activeCount":101},[],{"trials":6368,"activeCount":101},[],{"intervention":2397,"totalTrials":97,"cells":6370},{"EARLY_PHASE1":6371,"PHASE1":6373,"PHASE2":6375,"PHASE3":6381,"PHASE4":6383,"NA":6385},{"trials":6372,"activeCount":101},[],{"trials":6374,"activeCount":101},[],{"trials":6376,"activeCount":101},[6377],{"nctId":2387,"briefTitle":2388,"status":365,"phases":6378,"primaryCompletion":2390,"completion":368,"start":2391,"enrollment":97,"conditions":6379,"interventions":6380},[90],[2393,2394],[243,146,2396,2397,147,148],{"trials":6382,"activeCount":101},[],{"trials":6384,"activeCount":101},[],{"trials":6386,"activeCount":101},[],{"intervention":529,"totalTrials":97,"cells":6388},{"EARLY_PHASE1":6389,"PHASE1":6391,"PHASE2":6393,"PHASE3":6399,"PHASE4":6401,"NA":6403},{"trials":6390,"activeCount":101},[],{"trials":6392,"activeCount":101},[],{"trials":6394,"activeCount":101},[6395],{"nctId":513,"briefTitle":514,"status":365,"phases":6396,"primaryCompletion":516,"completion":517,"start":518,"enrollment":33,"conditions":6397,"interventions":6398},[90],[520,521,522,523,524,525,526,527],[173,174,529],{"trials":6400,"activeCount":101},[],{"trials":6402,"activeCount":101},[],{"trials":6404,"activeCount":101},[],{"intervention":373,"totalTrials":97,"cells":6406},{"EARLY_PHASE1":6407,"PHASE1":6409,"PHASE2":6411,"PHASE3":6417,"PHASE4":6419,"NA":6421},{"trials":6408,"activeCount":101},[],{"trials":6410,"activeCount":101},[],{"trials":6412,"activeCount":101},[6413],{"nctId":363,"briefTitle":364,"status":365,"phases":6414,"primaryCompletion":367,"completion":368,"start":369,"enrollment":370,"conditions":6415,"interventions":6416},[89,90],[186,188,241],[146,373,71,148],{"trials":6418,"activeCount":101},[],{"trials":6420,"activeCount":101},[],{"trials":6422,"activeCount":101},[],{"intervention":3247,"totalTrials":97,"cells":6424},{"EARLY_PHASE1":6425,"PHASE1":6427,"PHASE2":6429,"PHASE3":6435,"PHASE4":6437,"NA":6439},{"trials":6426,"activeCount":101},[],{"trials":6428,"activeCount":101},[],{"trials":6430,"activeCount":101},[6431],{"nctId":3239,"briefTitle":3240,"status":133,"phases":6432,"primaryCompletion":3242,"completion":3243,"start":3244,"enrollment":3202,"conditions":6433,"interventions":6434},[90],[20],[3170,3247],{"trials":6436,"activeCount":101},[],{"trials":6438,"activeCount":101},[],{"trials":6440,"activeCount":101},[],{"intervention":5307,"totalTrials":97,"cells":6442},{"EARLY_PHASE1":6443,"PHASE1":6445,"PHASE2":6447,"PHASE3":6453,"PHASE4":6455,"NA":6457},{"trials":6444,"activeCount":101},[],{"trials":6446,"activeCount":101},[],{"trials":6448,"activeCount":101},[6449],{"nctId":5301,"briefTitle":5302,"status":133,"phases":6450,"primaryCompletion":1124,"completion":1217,"start":5304,"enrollment":2744,"conditions":6451,"interventions":6452},[90],[20],[1236,5307,4354,5308,1089],{"trials":6454,"activeCount":101},[],{"trials":6456,"activeCount":101},[],{"trials":6458,"activeCount":101},[],{"intervention":5308,"totalTrials":97,"cells":6460},{"EARLY_PHASE1":6461,"PHASE1":6463,"PHASE2":6465,"PHASE3":6471,"PHASE4":6473,"NA":6475},{"trials":6462,"activeCount":101},[],{"trials":6464,"activeCount":101},[],{"trials":6466,"activeCount":101},[6467],{"nctId":5301,"briefTitle":5302,"status":133,"phases":6468,"primaryCompletion":1124,"completion":1217,"start":5304,"enrollment":2744,"conditions":6469,"interventions":6470},[90],[20],[1236,5307,4354,5308,1089],{"trials":6472,"activeCount":101},[],{"trials":6474,"activeCount":101},[],{"trials":6476,"activeCount":101},[],{"intervention":5546,"totalTrials":97,"cells":6478},{"EARLY_PHASE1":6479,"PHASE1":6481,"PHASE2":6483,"PHASE3":6489,"PHASE4":6491,"NA":6493},{"trials":6480,"activeCount":101},[],{"trials":6482,"activeCount":101},[],{"trials":6484,"activeCount":101},[6485],{"nctId":5538,"briefTitle":5539,"status":133,"phases":6486,"primaryCompletion":5541,"completion":5542,"start":5543,"enrollment":2089,"conditions":6487,"interventions":6488},[90],[270,275],[5518,5546,5547,5548,5549],{"trials":6490,"activeCount":101},[],{"trials":6492,"activeCount":101},[],{"trials":6494,"activeCount":101},[],{"intervention":5547,"totalTrials":97,"cells":6496},{"EARLY_PHASE1":6497,"PHASE1":6499,"PHASE2":6501,"PHASE3":6507,"PHASE4":6509,"NA":6511},{"trials":6498,"activeCount":101},[],{"trials":6500,"activeCount":101},[],{"trials":6502,"activeCount":101},[6503],{"nctId":5538,"briefTitle":5539,"status":133,"phases":6504,"primaryCompletion":5541,"completion":5542,"start":5543,"enrollment":2089,"conditions":6505,"interventions":6506},[90],[270,275],[5518,5546,5547,5548,5549],{"trials":6508,"activeCount":101},[],{"trials":6510,"activeCount":101},[],{"trials":6512,"activeCount":101},[],{"intervention":5548,"totalTrials":97,"cells":6514},{"EARLY_PHASE1":6515,"PHASE1":6517,"PHASE2":6519,"PHASE3":6525,"PHASE4":6527,"NA":6529},{"trials":6516,"activeCount":101},[],{"trials":6518,"activeCount":101},[],{"trials":6520,"activeCount":101},[6521],{"nctId":5538,"briefTitle":5539,"status":133,"phases":6522,"primaryCompletion":5541,"completion":5542,"start":5543,"enrollment":2089,"conditions":6523,"interventions":6524},[90],[270,275],[5518,5546,5547,5548,5549],{"trials":6526,"activeCount":101},[],{"trials":6528,"activeCount":101},[],{"trials":6530,"activeCount":101},[],{"intervention":5549,"totalTrials":97,"cells":6532},{"EARLY_PHASE1":6533,"PHASE1":6535,"PHASE2":6537,"PHASE3":6543,"PHASE4":6545,"NA":6547},{"trials":6534,"activeCount":101},[],{"trials":6536,"activeCount":101},[],{"trials":6538,"activeCount":101},[6539],{"nctId":5538,"briefTitle":5539,"status":133,"phases":6540,"primaryCompletion":5541,"completion":5542,"start":5543,"enrollment":2089,"conditions":6541,"interventions":6542},[90],[270,275],[5518,5546,5547,5548,5549],{"trials":6544,"activeCount":101},[],{"trials":6546,"activeCount":101},[],{"trials":6548,"activeCount":101},[],{"intervention":6550,"totalTrials":97,"cells":6551},"Chemokin Modulatory Regimen",{"EARLY_PHASE1":6552,"PHASE1":6554,"PHASE2":6556,"PHASE3":6569,"PHASE4":6571,"NA":6573},{"trials":6553,"activeCount":101},[],{"trials":6555,"activeCount":101},[],{"trials":6557,"activeCount":101},[6558],{"nctId":6559,"briefTitle":6560,"status":365,"phases":6561,"primaryCompletion":6562,"completion":6563,"start":452,"enrollment":863,"conditions":6564,"interventions":6568},"NCT01545141","Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer",[89,90],"2016-04-08","2017-04-08",[29,6565,6566,6567],"Colorectal Carcinoma","Colorectal Tumors","Neoplasms, Colorectal",[6550,6550,6550],{"trials":6570,"activeCount":101},[],{"trials":6572,"activeCount":101},[],{"trials":6574,"activeCount":101},[],{"intervention":3635,"totalTrials":97,"cells":6576},{"EARLY_PHASE1":6577,"PHASE1":6579,"PHASE2":6581,"PHASE3":6587,"PHASE4":6589,"NA":6591},{"trials":6578,"activeCount":101},[],{"trials":6580,"activeCount":101},[],{"trials":6582,"activeCount":101},[6583],{"nctId":3618,"briefTitle":3619,"status":133,"phases":6584,"primaryCompletion":3621,"completion":262,"start":3622,"enrollment":21,"conditions":6585,"interventions":6586},[90],[3624,3625,3626,3627,3628,988,991,2101,2102,2103,2105,2106,1014,1015,1016,1018,1020,1024,3629,3630,3631,3632,3633,2111,2112,2113,2114,2115,2120,2121,2122,2123,2124],[3635,2216,3636],{"trials":6588,"activeCount":101},[],{"trials":6590,"activeCount":101},[],{"trials":6592,"activeCount":101},[],{"intervention":5105,"totalTrials":97,"cells":6594},{"EARLY_PHASE1":6595,"PHASE1":6597,"PHASE2":6599,"PHASE3":6605,"PHASE4":6607,"NA":6609},{"trials":6596,"activeCount":101},[],{"trials":6598,"activeCount":101},[],{"trials":6600,"activeCount":101},[6601],{"nctId":5089,"briefTitle":5090,"status":235,"phases":6602,"primaryCompletion":5092,"completion":5092,"start":5093,"enrollment":101,"conditions":6603,"interventions":6604},[89,90],[5095,5096,5097,5098,5099,5100,5101,5102,5103,887,888,889,890,891,892,893,894,895,896,897,898,899,900,901,902,903,904,905,906,907,908,909,910,911],[243,5105],{"trials":6606,"activeCount":101},[],{"trials":6608,"activeCount":101},[],{"trials":6610,"activeCount":101},[],{"intervention":567,"totalTrials":97,"cells":6612},{"EARLY_PHASE1":6613,"PHASE1":6615,"PHASE2":6617,"PHASE3":6623,"PHASE4":6625,"NA":6627},{"trials":6614,"activeCount":101},[],{"trials":6616,"activeCount":101},[],{"trials":6618,"activeCount":101},[6619],{"nctId":543,"briefTitle":544,"status":235,"phases":6620,"primaryCompletion":546,"enrollment":101,"conditions":6621,"interventions":6622},[89,90],[548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564],[173,566,175,567],{"trials":6624,"activeCount":101},[],{"trials":6626,"activeCount":101},[],{"trials":6628,"activeCount":101},[],{"intervention":6630,"totalTrials":97,"cells":6631},"finasteride",{"EARLY_PHASE1":6632,"PHASE1":6634,"PHASE2":6636,"PHASE3":6645,"PHASE4":6647,"NA":6649},{"trials":6633,"activeCount":101},[],{"trials":6635,"activeCount":101},[],{"trials":6637,"activeCount":101},[6638],{"nctId":6639,"briefTitle":6640,"status":133,"phases":6641,"primaryCompletion":2330,"completion":2330,"start":1230,"enrollment":6642,"conditions":6643,"interventions":6644},"NCT00736645","Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer",[90],55,[26],[6630],{"trials":6646,"activeCount":101},[],{"trials":6648,"activeCount":101},[],{"trials":6650,"activeCount":101},[],{"intervention":6652,"totalTrials":97,"cells":6653},"Sipuleucel-T",{"EARLY_PHASE1":6654,"PHASE1":6656,"PHASE2":6658,"PHASE3":6667,"PHASE4":6669,"NA":6671},{"trials":6655,"activeCount":101},[],{"trials":6657,"activeCount":101},[],{"trials":6659,"activeCount":101},[6660],{"nctId":6661,"briefTitle":6662,"status":133,"phases":6663,"primaryCompletion":4398,"start":1131,"enrollment":440,"conditions":6664,"interventions":6665},"NCT02159950","Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",[90],[2528,2529,2537,2578],[6652,6666],"Tasquinimod",{"trials":6668,"activeCount":101},[],{"trials":6670,"activeCount":101},[],{"trials":6672,"activeCount":101},[],{"intervention":6666,"totalTrials":97,"cells":6674},{"EARLY_PHASE1":6675,"PHASE1":6677,"PHASE2":6679,"PHASE3":6685,"PHASE4":6687,"NA":6689},{"trials":6676,"activeCount":101},[],{"trials":6678,"activeCount":101},[],{"trials":6680,"activeCount":101},[6681],{"nctId":6661,"briefTitle":6662,"status":133,"phases":6682,"primaryCompletion":4398,"start":1131,"enrollment":440,"conditions":6683,"interventions":6684},[90],[2528,2529,2537,2578],[6652,6666],{"trials":6686,"activeCount":101},[],{"trials":6688,"activeCount":101},[],{"trials":6690,"activeCount":101},[],{"intervention":1153,"totalTrials":97,"cells":6692},{"EARLY_PHASE1":6693,"PHASE1":6695,"PHASE2":6697,"PHASE3":6703,"PHASE4":6705,"NA":6707},{"trials":6694,"activeCount":101},[],{"trials":6696,"activeCount":101},[],{"trials":6698,"activeCount":101},[6699],{"nctId":1128,"briefTitle":1129,"status":133,"phases":6700,"primaryCompletion":1131,"completion":1132,"start":1133,"enrollment":537,"conditions":6701,"interventions":6702},[90],[1135,1136,1137,1138,1139,1140,1141,1142,1143,1144,1145,1146,1147,1148,1149,1150,1151],[175,1153],{"trials":6704,"activeCount":101},[],{"trials":6706,"activeCount":101},[],{"trials":6708,"activeCount":101},[],{"intervention":1628,"totalTrials":97,"cells":6710},{"EARLY_PHASE1":6711,"PHASE1":6713,"PHASE2":6715,"PHASE3":6721,"PHASE4":6723,"NA":6725},{"trials":6712,"activeCount":101},[],{"trials":6714,"activeCount":101},[],{"trials":6716,"activeCount":101},[6717],{"nctId":1621,"briefTitle":1622,"status":133,"phases":6718,"primaryCompletion":1624,"completion":1624,"start":1625,"conditions":6719,"interventions":6720},[90],[15],[711,792,949,1628],{"trials":6722,"activeCount":101},[],{"trials":6724,"activeCount":101},[],{"trials":6726,"activeCount":101},[],{"intervention":6728,"totalTrials":97,"cells":6729},"androgen ablation",{"EARLY_PHASE1":6730,"PHASE1":6732,"PHASE2":6734,"PHASE3":6751,"PHASE4":6753,"NA":6755},{"trials":6731,"activeCount":101},[],{"trials":6733,"activeCount":101},[],{"trials":6735,"activeCount":101},[6736],{"nctId":6737,"briefTitle":6738,"status":133,"phases":6739,"primaryCompletion":6740,"completion":6741,"start":6088,"enrollment":1878,"conditions":6742,"interventions":6749},"NCT00970203","Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer",[90],"2018-10-05","2019-10-05",[6743,6744,6745,6746,26,6747,6748],"Cancer of Prostate","Cancer of the Prostate","Neoplasms, Prostate","Neoplasms, Prostatic","Prostate Neoplasms","Prostatic Cancer",[6728,6750],"DC1 vaccine",{"trials":6752,"activeCount":101},[],{"trials":6754,"activeCount":101},[],{"trials":6756,"activeCount":101},[],{"intervention":6750,"totalTrials":97,"cells":6758},{"EARLY_PHASE1":6759,"PHASE1":6761,"PHASE2":6763,"PHASE3":6769,"PHASE4":6771,"NA":6773},{"trials":6760,"activeCount":101},[],{"trials":6762,"activeCount":101},[],{"trials":6764,"activeCount":101},[6765],{"nctId":6737,"briefTitle":6738,"status":133,"phases":6766,"primaryCompletion":6740,"completion":6741,"start":6088,"enrollment":1878,"conditions":6767,"interventions":6768},[90],[6743,6744,6745,6746,26,6747,6748],[6728,6750],{"trials":6770,"activeCount":101},[],{"trials":6772,"activeCount":101},[],{"trials":6774,"activeCount":101},[],{"intervention":4218,"totalTrials":440,"cells":6776},{"EARLY_PHASE1":6777,"PHASE1":6779,"PHASE2":6794,"PHASE3":6796,"PHASE4":6798,"NA":6800},{"trials":6778,"activeCount":101},[],{"trials":6780,"activeCount":101},[6781,6785],{"nctId":4213,"briefTitle":4214,"status":133,"phases":6782,"primaryCompletion":3183,"completion":1104,"start":1925,"enrollment":945,"conditions":6783,"interventions":6784},[89],[15],[711,4218,949,950],{"nctId":6786,"briefTitle":6787,"status":365,"phases":6788,"primaryCompletion":6789,"completion":6789,"start":3486,"enrollment":370,"conditions":6790,"interventions":6792},"NCT01014546","Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis",[89],"2015-02",[6791,746,2058],"Essential Thrombocythemia",[6793],"Arsenic Trioxide",{"trials":6795,"activeCount":101},[],{"trials":6797,"activeCount":101},[],{"trials":6799,"activeCount":101},[],{"trials":6801,"activeCount":101},[],{"intervention":6803,"totalTrials":440,"cells":6804},"dovitinib lactate",{"EARLY_PHASE1":6805,"PHASE1":6807,"PHASE2":6826,"PHASE3":6828,"PHASE4":6830,"NA":6832},{"trials":6806,"activeCount":101},[],{"trials":6808,"activeCount":101},[6809,6816],{"nctId":6810,"briefTitle":6811,"status":235,"phases":6812,"primaryCompletion":1132,"start":5720,"enrollment":101,"conditions":6813,"interventions":6814},"NCT02048943","Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer",[89],[5213,5214,553,560,18],[6803,1236,6815],"paclitaxel albumin-stabilized nanoparticle formulation",{"nctId":6817,"briefTitle":6818,"status":133,"phases":6819,"primaryCompletion":6820,"completion":6821,"start":6822,"enrollment":673,"conditions":6823,"interventions":6825},"NCT01497392","Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers",[89],"2015-08-31","2017-02-07","2012-03-29",[6824,553,560,18],"Adenocarcinoma of the Pancreas",[6803,1236,1052],{"trials":6827,"activeCount":101},[],{"trials":6829,"activeCount":101},[],{"trials":6831,"activeCount":101},[],{"trials":6833,"activeCount":101},[],{"intervention":6815,"totalTrials":440,"cells":6835},{"EARLY_PHASE1":6836,"PHASE1":6838,"PHASE2":6848,"PHASE3":6850,"PHASE4":6852,"NA":6854},{"trials":6837,"activeCount":101},[],{"trials":6839,"activeCount":101},[6840,6844],{"nctId":6810,"briefTitle":6811,"status":235,"phases":6841,"primaryCompletion":1132,"start":5720,"enrollment":101,"conditions":6842,"interventions":6843},[89],[5213,5214,553,560,18],[6803,1236,6815],{"nctId":3196,"briefTitle":3197,"status":133,"phases":6845,"primaryCompletion":3199,"completion":3200,"start":3201,"enrollment":3202,"conditions":6846,"interventions":6847},[89],[866,3204,549,553,560],[3206,3106,3178,3207],{"trials":6849,"activeCount":101},[],{"trials":6851,"activeCount":101},[],{"trials":6853,"activeCount":101},[],{"trials":6855,"activeCount":101},[],{"intervention":6857,"totalTrials":440,"cells":6858},"paricalcitol",{"EARLY_PHASE1":6859,"PHASE1":6861,"PHASE2":6879,"PHASE3":6881,"PHASE4":6883,"NA":6885},{"trials":6860,"activeCount":101},[],{"trials":6862,"activeCount":101},[6863,6870],{"nctId":6864,"briefTitle":6865,"status":133,"phases":6866,"primaryCompletion":6030,"completion":3368,"start":1231,"enrollment":6867,"conditions":6868,"interventions":6869},"NCT00217477","Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer",[89],34,[18],[1236,6857],{"nctId":6871,"briefTitle":6872,"status":365,"phases":6873,"primaryCompletion":6874,"start":6875,"enrollment":1572,"conditions":6876,"interventions":6877},"NCT00258258","Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders",[89],"2009-03","2005-08",[707],[6857,6878],"zoledronic acid",{"trials":6880,"activeCount":101},[],{"trials":6882,"activeCount":101},[],{"trials":6884,"activeCount":101},[],{"trials":6886,"activeCount":101},[],{"intervention":3169,"totalTrials":440,"cells":6888},{"EARLY_PHASE1":6889,"PHASE1":6891,"PHASE2":6903,"PHASE3":6905,"PHASE4":6907,"NA":6909},{"trials":6890,"activeCount":101},[],{"trials":6892,"activeCount":101},[6893,6897],{"nctId":3124,"briefTitle":3125,"status":235,"phases":6894,"primaryCompletion":3127,"start":3128,"enrollment":101,"conditions":6895,"interventions":6896},[89],[3130,3131,3132,3133,3134,3135,3136,3137,3138,3139,3140,3141,3142,3143,3144,3145,3146,3147,3148,3149,3150,3151,3152,3153,3154,3155,3156,3157,3158,3159,3160,3161,3162,3163,3164,3165,3166,3167],[3169,3170],{"nctId":6898,"briefTitle":6899,"status":133,"phases":6900,"primaryCompletion":2227,"completion":2227,"start":5627,"enrollment":1916,"conditions":6901,"interventions":6902},"NCT01527136","Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery",[89],[18],[3169],{"trials":6904,"activeCount":101},[],{"trials":6906,"activeCount":101},[],{"trials":6908,"activeCount":101},[],{"trials":6910,"activeCount":101},[],{"intervention":4928,"totalTrials":97,"cells":6912},{"EARLY_PHASE1":6913,"PHASE1":6915,"PHASE2":6921,"PHASE3":6923,"PHASE4":6925,"NA":6927},{"trials":6914,"activeCount":101},[],{"trials":6916,"activeCount":101},[6917],{"nctId":4921,"briefTitle":4922,"status":365,"phases":6918,"primaryCompletion":4924,"completion":599,"start":4925,"enrollment":138,"conditions":6919,"interventions":6920},[89],[1713,1718,1719,1720],[4928,1722],{"trials":6922,"activeCount":101},[],{"trials":6924,"activeCount":101},[],{"trials":6926,"activeCount":101},[],{"trials":6928,"activeCount":101},[],{"intervention":617,"totalTrials":97,"cells":6930},{"EARLY_PHASE1":6931,"PHASE1":6933,"PHASE2":6939,"PHASE3":6941,"PHASE4":6943,"NA":6945},{"trials":6932,"activeCount":101},[],{"trials":6934,"activeCount":101},[6935],{"nctId":596,"briefTitle":597,"status":365,"phases":6936,"primaryCompletion":599,"completion":599,"start":600,"enrollment":97,"conditions":6937,"interventions":6938},[89],[602,603,604,605,606,607,608,609,610,611,612,613,614,615],[57,617,298],{"trials":6940,"activeCount":101},[],{"trials":6942,"activeCount":101},[],{"trials":6944,"activeCount":101},[],{"trials":6946,"activeCount":101},[],{"intervention":6948,"totalTrials":97,"cells":6949},"S-3304",{"EARLY_PHASE1":6950,"PHASE1":6952,"PHASE2":6962,"PHASE3":6964,"PHASE4":6966,"NA":6968},{"trials":6951,"activeCount":101},[],{"trials":6953,"activeCount":101},[6954],{"nctId":6955,"briefTitle":6956,"status":133,"phases":6957,"primaryCompletion":6958,"completion":468,"start":6959,"conditions":6960,"interventions":6961},"NCT00033566","S-3304 in Treating Patients With Advanced Solid Tumors",[89],"2002-12","2001-10",[18],[6948],{"trials":6963,"activeCount":101},[],{"trials":6965,"activeCount":101},[],{"trials":6967,"activeCount":101},[],{"trials":6969,"activeCount":101},[],{"intervention":6971,"totalTrials":97,"cells":6972},"ammonium tetrathiomolybdate",{"EARLY_PHASE1":6973,"PHASE1":6975,"PHASE2":6983,"PHASE3":6985,"PHASE4":6987,"NA":6989},{"trials":6974,"activeCount":101},[],{"trials":6976,"activeCount":101},[6977],{"nctId":6978,"briefTitle":6979,"status":235,"phases":6980,"primaryCompletion":4575,"completion":4575,"start":478,"enrollment":101,"conditions":6981,"interventions":6982},"NCT00560495","Radiation Therapy and Ammonium Tetrathiomolybdate in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer",[89],[20],[6971],{"trials":6984,"activeCount":101},[],{"trials":6986,"activeCount":101},[],{"trials":6988,"activeCount":101},[],{"trials":6990,"activeCount":101},[],{"intervention":6992,"totalTrials":97,"cells":6993},"Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine",{"EARLY_PHASE1":6994,"PHASE1":6996,"PHASE2":7006,"PHASE3":7008,"PHASE4":7010,"NA":7012},{"trials":6995,"activeCount":101},[],{"trials":6997,"activeCount":101},[6998],{"nctId":6999,"briefTitle":7000,"status":365,"phases":7001,"primaryCompletion":7002,"completion":7002,"start":7003,"enrollment":36,"conditions":7004,"interventions":7005},"NCT01744171","Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma",[89],"2018-06-11","2013-03-26",[2536,2568,2573,2579],[6992],{"trials":7007,"activeCount":101},[],{"trials":7009,"activeCount":101},[],{"trials":7011,"activeCount":101},[],{"trials":7013,"activeCount":101},[],{"intervention":5055,"totalTrials":97,"cells":7015},{"EARLY_PHASE1":7016,"PHASE1":7018,"PHASE2":7024,"PHASE3":7026,"PHASE4":7028,"NA":7030},{"trials":7017,"activeCount":101},[],{"trials":7019,"activeCount":101},[7020],{"nctId":5045,"briefTitle":5046,"status":365,"phases":7021,"primaryCompletion":5048,"completion":3190,"start":5049,"enrollment":1878,"conditions":7022,"interventions":7023},[89],[26,5051,5052,5053,2578],[462,5055],{"trials":7025,"activeCount":101},[],{"trials":7027,"activeCount":101},[],{"trials":7029,"activeCount":101},[],{"trials":7031,"activeCount":101},[],{"intervention":7033,"totalTrials":97,"cells":7034},"anhydrovinblastine",{"EARLY_PHASE1":7035,"PHASE1":7037,"PHASE2":7047,"PHASE3":7049,"PHASE4":7051,"NA":7053},{"trials":7036,"activeCount":101},[],{"trials":7038,"activeCount":101},[7039],{"nctId":7040,"briefTitle":7041,"status":133,"phases":7042,"primaryCompletion":7043,"completion":7044,"start":4725,"enrollment":36,"conditions":7045,"interventions":7046},"NCT00003882","Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors",[89],"2000-04","2000-09",[18],[7033],{"trials":7048,"activeCount":101},[],{"trials":7050,"activeCount":101},[],{"trials":7052,"activeCount":101},[],{"trials":7054,"activeCount":101},[],{"intervention":7056,"totalTrials":97,"cells":7057},"hematoporphyrin derivative",{"EARLY_PHASE1":7058,"PHASE1":7060,"PHASE2":7069,"PHASE3":7071,"PHASE4":7073,"NA":7075},{"trials":7059,"activeCount":101},[],{"trials":7061,"activeCount":101},[7062],{"nctId":7063,"briefTitle":7064,"status":133,"phases":7065,"primaryCompletion":1624,"start":7066,"conditions":7067,"interventions":7068},"NCT00014066","Photodynamic Therapy Plus Brachytherapy in Treating Patients With Lung Cancer",[89],"1993-03",[20],[7056],{"trials":7070,"activeCount":101},[],{"trials":7072,"activeCount":101},[],{"trials":7074,"activeCount":101},[],{"trials":7076,"activeCount":101},[],{"intervention":4994,"totalTrials":97,"cells":7078},{"EARLY_PHASE1":7079,"PHASE1":7081,"PHASE2":7087,"PHASE3":7089,"PHASE4":7091,"NA":7093},{"trials":7080,"activeCount":101},[],{"trials":7082,"activeCount":101},[7083],{"nctId":4987,"briefTitle":4988,"status":235,"phases":7084,"primaryCompletion":4052,"start":4678,"enrollment":101,"conditions":7085,"interventions":7086},[89],[609,2233,4991,4992],[3636,1088,4994,4995,1090],{"trials":7088,"activeCount":101},[],{"trials":7090,"activeCount":101},[],{"trials":7092,"activeCount":101},[],{"trials":7094,"activeCount":101},[],{"intervention":4995,"totalTrials":97,"cells":7096},{"EARLY_PHASE1":7097,"PHASE1":7099,"PHASE2":7105,"PHASE3":7107,"PHASE4":7109,"NA":7111},{"trials":7098,"activeCount":101},[],{"trials":7100,"activeCount":101},[7101],{"nctId":4987,"briefTitle":4988,"status":235,"phases":7102,"primaryCompletion":4052,"start":4678,"enrollment":101,"conditions":7103,"interventions":7104},[89],[609,2233,4991,4992],[3636,1088,4994,4995,1090],{"trials":7106,"activeCount":101},[],{"trials":7108,"activeCount":101},[],{"trials":7110,"activeCount":101},[],{"trials":7112,"activeCount":101},[],{"intervention":4938,"totalTrials":97,"cells":7114},{"EARLY_PHASE1":7115,"PHASE1":7117,"PHASE2":7123,"PHASE3":7125,"PHASE4":7127,"NA":7129},{"trials":7116,"activeCount":101},[],{"trials":7118,"activeCount":101},[7119],{"nctId":4930,"briefTitle":4931,"status":133,"phases":7120,"primaryCompletion":4933,"completion":4934,"start":4935,"enrollment":36,"conditions":7121,"interventions":7122},[89],[1712,1713,2529,1714,1715,1717,1718,1719,1720],[1722,4938],{"trials":7124,"activeCount":101},[],{"trials":7126,"activeCount":101},[],{"trials":7128,"activeCount":101},[],{"trials":7130,"activeCount":101},[],{"intervention":1349,"totalTrials":97,"cells":7132},{"EARLY_PHASE1":7133,"PHASE1":7135,"PHASE2":7141,"PHASE3":7143,"PHASE4":7145,"NA":7147},{"trials":7134,"activeCount":101},[],{"trials":7136,"activeCount":101},[7137],{"nctId":1341,"briefTitle":1342,"status":235,"phases":7138,"primaryCompletion":1344,"completion":1344,"start":325,"enrollment":101,"conditions":7139,"interventions":7140},[89],[1346,1022],[1320,1348,830,1349],{"trials":7142,"activeCount":101},[],{"trials":7144,"activeCount":101},[],{"trials":7146,"activeCount":101},[],{"trials":7148,"activeCount":101},[],{"intervention":7150,"totalTrials":97,"cells":7151},"Ribociclib",{"EARLY_PHASE1":7152,"PHASE1":7154,"PHASE2":7163,"PHASE3":7165,"PHASE4":7167,"NA":7169},{"trials":7153,"activeCount":101},[],{"trials":7155,"activeCount":101},[7156],{"nctId":7157,"briefTitle":7158,"status":365,"phases":7159,"primaryCompletion":477,"completion":4823,"start":6110,"enrollment":36,"conditions":7160,"interventions":7162},"NCT02414724","Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma",[89],[23,7161],"Solid Neoplasm",[3178,7150],{"trials":7164,"activeCount":101},[],{"trials":7166,"activeCount":101},[],{"trials":7168,"activeCount":101},[],{"trials":7170,"activeCount":101},[],{"intervention":636,"totalTrials":97,"cells":7172},{"EARLY_PHASE1":7173,"PHASE1":7175,"PHASE2":7181,"PHASE3":7183,"PHASE4":7185,"NA":7187},{"trials":7174,"activeCount":101},[],{"trials":7176,"activeCount":101},[7177],{"nctId":627,"briefTitle":628,"status":133,"phases":7178,"primaryCompletion":630,"completion":631,"start":632,"enrollment":21,"conditions":7179,"interventions":7180},[89],[20,634],[636,637,638,639],{"trials":7182,"activeCount":101},[],{"trials":7184,"activeCount":101},[],{"trials":7186,"activeCount":101},[],{"trials":7188,"activeCount":101},[],{"intervention":637,"totalTrials":97,"cells":7190},{"EARLY_PHASE1":7191,"PHASE1":7193,"PHASE2":7199,"PHASE3":7201,"PHASE4":7203,"NA":7205},{"trials":7192,"activeCount":101},[],{"trials":7194,"activeCount":101},[7195],{"nctId":627,"briefTitle":628,"status":133,"phases":7196,"primaryCompletion":630,"completion":631,"start":632,"enrollment":21,"conditions":7197,"interventions":7198},[89],[20,634],[636,637,638,639],{"trials":7200,"activeCount":101},[],{"trials":7202,"activeCount":101},[],{"trials":7204,"activeCount":101},[],{"trials":7206,"activeCount":101},[],{"intervention":5329,"totalTrials":97,"cells":7208},{"EARLY_PHASE1":7209,"PHASE1":7211,"PHASE2":7217,"PHASE3":7219,"PHASE4":7221,"NA":7223},{"trials":7210,"activeCount":101},[],{"trials":7212,"activeCount":101},[7213],{"nctId":5323,"briefTitle":5324,"status":133,"phases":7214,"primaryCompletion":5326,"completion":1164,"start":838,"conditions":7215,"interventions":7216},[89],[20],[5329,5316],{"trials":7218,"activeCount":101},[],{"trials":7220,"activeCount":101},[],{"trials":7222,"activeCount":101},[],{"trials":7224,"activeCount":101},[],{"intervention":7226,"totalTrials":97,"cells":7227},"Src kinase inhibitor KX2-391",{"EARLY_PHASE1":7228,"PHASE1":7230,"PHASE2":7240,"PHASE3":7242,"PHASE4":7244,"NA":7246},{"trials":7229,"activeCount":101},[],{"trials":7231,"activeCount":101},[7232],{"nctId":7233,"briefTitle":7234,"status":133,"phases":7235,"primaryCompletion":1230,"completion":6874,"start":1989,"enrollment":1572,"conditions":7236,"interventions":7239},"NCT00646139","KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment",[89],[23,7237,7238,18],"Lymphoproliferative Disorder","Small Intestine Cancer",[7226],{"trials":7241,"activeCount":101},[],{"trials":7243,"activeCount":101},[],{"trials":7245,"activeCount":101},[],{"trials":7247,"activeCount":101},[],{"intervention":1548,"totalTrials":97,"cells":7249},{"EARLY_PHASE1":7250,"PHASE1":7252,"PHASE2":7258,"PHASE3":7260,"PHASE4":7262,"NA":7264},{"trials":7251,"activeCount":101},[],{"trials":7253,"activeCount":101},[7254],{"nctId":1537,"briefTitle":1538,"status":133,"phases":7255,"primaryCompletion":1540,"completion":453,"start":1541,"enrollment":24,"conditions":7256,"interventions":7257},[89],[1543,1544,1545],[1547,1548,1489,792,1549,1090,1550],{"trials":7259,"activeCount":101},[],{"trials":7261,"activeCount":101},[],{"trials":7263,"activeCount":101},[],{"trials":7265,"activeCount":101},[],{"intervention":1550,"totalTrials":97,"cells":7267},{"EARLY_PHASE1":7268,"PHASE1":7270,"PHASE2":7276,"PHASE3":7278,"PHASE4":7280,"NA":7282},{"trials":7269,"activeCount":101},[],{"trials":7271,"activeCount":101},[7272],{"nctId":1537,"briefTitle":1538,"status":133,"phases":7273,"primaryCompletion":1540,"completion":453,"start":1541,"enrollment":24,"conditions":7274,"interventions":7275},[89],[1543,1544,1545],[1547,1548,1489,792,1549,1090,1550],{"trials":7277,"activeCount":101},[],{"trials":7279,"activeCount":101},[],{"trials":7281,"activeCount":101},[],{"trials":7283,"activeCount":101},[],{"intervention":7285,"totalTrials":97,"cells":7286},"Smac mimetic TL32711",{"EARLY_PHASE1":7287,"PHASE1":7289,"PHASE2":7298,"PHASE3":7300,"PHASE4":7302,"NA":7304},{"trials":7288,"activeCount":101},[],{"trials":7290,"activeCount":101},[7291],{"nctId":7292,"briefTitle":7293,"status":365,"phases":7294,"primaryCompletion":7295,"start":492,"enrollment":2744,"conditions":7296,"interventions":7297},"NCT01573780","Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors",[89],"2013-09",[18],[7285,1236],{"trials":7299,"activeCount":101},[],{"trials":7301,"activeCount":101},[],{"trials":7303,"activeCount":101},[],{"trials":7305,"activeCount":101},[],{"intervention":665,"totalTrials":97,"cells":7307},{"EARLY_PHASE1":7308,"PHASE1":7310,"PHASE2":7316,"PHASE3":7318,"PHASE4":7320,"NA":7322},{"trials":7309,"activeCount":101},[],{"trials":7311,"activeCount":101},[7312],{"nctId":641,"briefTitle":642,"status":133,"phases":7313,"primaryCompletion":644,"completion":645,"start":646,"enrollment":317,"conditions":7314,"interventions":7315},[89],[648,649,650,651,652,653,654,655,141,142,144,656,657,658,659,660,661,662,663],[146,57,665,666,667,147,148],{"trials":7317,"activeCount":101},[],{"trials":7319,"activeCount":101},[],{"trials":7321,"activeCount":101},[],{"trials":7323,"activeCount":101},[],{"intervention":3558,"totalTrials":97,"cells":7325},{"EARLY_PHASE1":7326,"PHASE1":7328,"PHASE2":7334,"PHASE3":7336,"PHASE4":7338,"NA":7340},{"trials":7327,"activeCount":101},[],{"trials":7329,"activeCount":101},[7330],{"nctId":3545,"briefTitle":3546,"status":365,"phases":7331,"primaryCompletion":3548,"completion":3549,"start":3550,"enrollment":1271,"conditions":7332,"interventions":7333},[89],[884,885,886,3552,401,3553,226,227,228,3554,3555,3556],[47,3558,3559],{"trials":7335,"activeCount":101},[],{"trials":7337,"activeCount":101},[],{"trials":7339,"activeCount":101},[],{"trials":7341,"activeCount":101},[],{"intervention":1565,"totalTrials":97,"cells":7343},{"EARLY_PHASE1":7344,"PHASE1":7346,"PHASE2":7352,"PHASE3":7354,"PHASE4":7356,"NA":7358},{"trials":7345,"activeCount":101},[],{"trials":7347,"activeCount":101},[7348],{"nctId":1552,"briefTitle":1553,"status":133,"phases":7349,"primaryCompletion":1555,"completion":1555,"start":1556,"enrollment":317,"conditions":7350,"interventions":7351},[89],[1558,1559,1560,1561,1428,1429,1562,1563],[1565,1393],{"trials":7353,"activeCount":101},[],{"trials":7355,"activeCount":101},[],{"trials":7357,"activeCount":101},[],{"trials":7359,"activeCount":101},[],{"intervention":3568,"totalTrials":97,"cells":7361},{"EARLY_PHASE1":7362,"PHASE1":7364,"PHASE2":7370,"PHASE3":7372,"PHASE4":7374,"NA":7376},{"trials":7363,"activeCount":101},[],{"trials":7365,"activeCount":101},[7366],{"nctId":3561,"briefTitle":3562,"status":133,"phases":7367,"primaryCompletion":3564,"start":3565,"enrollment":97,"conditions":7368,"interventions":7369},[89],[23],[948,3568],{"trials":7371,"activeCount":101},[],{"trials":7373,"activeCount":101},[],{"trials":7375,"activeCount":101},[],{"trials":7377,"activeCount":101},[],{"intervention":2595,"totalTrials":97,"cells":7379},{"EARLY_PHASE1":7380,"PHASE1":7382,"PHASE2":7388,"PHASE3":7390,"PHASE4":7392,"NA":7394},{"trials":7381,"activeCount":101},[],{"trials":7383,"activeCount":101},[7384],{"nctId":2584,"briefTitle":2585,"status":235,"phases":7385,"primaryCompletion":2587,"completion":2588,"start":621,"enrollment":101,"conditions":7386,"interventions":7387},[89],[226,227,228,1574,2551,1577,2555,1580,2557,1583,2562,2590,1586,2567,2591,1589,2572,2592,1592,2577,2593],[2595,778],{"trials":7389,"activeCount":101},[],{"trials":7391,"activeCount":101},[],{"trials":7393,"activeCount":101},[],{"trials":7395,"activeCount":101},[],{"intervention":7397,"totalTrials":97,"cells":7398},"DDX5 Degrader FL118",{"EARLY_PHASE1":7399,"PHASE1":7401,"PHASE2":7417,"PHASE3":7419,"PHASE4":7421,"NA":7423},{"trials":7400,"activeCount":101},[],{"trials":7402,"activeCount":101},[7403],{"nctId":7404,"briefTitle":7405,"status":235,"phases":7406,"primaryCompletion":7407,"completion":7407,"start":7408,"enrollment":101,"conditions":7409,"interventions":7416},"NCT06206876","FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma",[89],"2027-10-01","2025-10-01",[7410,7411,539,7412,7413,7414,540,7415],"Advanced Pancreatic Ductal Adenocarcinoma","Locally Advanced Pancreatic Ductal Adenocarcinoma","Refractory Pancreatic Ductal Adenocarcinoma","Stage II Pancreatic Cancer AJCC v8","Stage III Pancreatic Cancer AJCC v8","Unresectable Pancreatic Ductal Adenocarcinoma",[7397],{"trials":7418,"activeCount":101},[],{"trials":7420,"activeCount":101},[],{"trials":7422,"activeCount":101},[],{"trials":7424,"activeCount":101},[],{"intervention":2501,"totalTrials":97,"cells":7426},{"EARLY_PHASE1":7427,"PHASE1":7429,"PHASE2":7435,"PHASE3":7437,"PHASE4":7439,"NA":7441},{"trials":7428,"activeCount":101},[],{"trials":7430,"activeCount":101},[7431],{"nctId":2489,"briefTitle":2490,"status":133,"phases":7432,"primaryCompletion":1710,"completion":2492,"start":2493,"enrollment":1572,"conditions":7433,"interventions":7434},[89],[2495,2496,2497,2498,2499],[2501,81],{"trials":7436,"activeCount":101},[],{"trials":7438,"activeCount":101},[],{"trials":7440,"activeCount":101},[],{"trials":7442,"activeCount":101},[],{"intervention":4228,"totalTrials":97,"cells":7444},{"EARLY_PHASE1":7445,"PHASE1":7447,"PHASE2":7453,"PHASE3":7455,"PHASE4":7457,"NA":7459},{"trials":7446,"activeCount":101},[],{"trials":7448,"activeCount":101},[7449],{"nctId":4220,"briefTitle":4221,"status":133,"phases":7450,"primaryCompletion":4223,"completion":4224,"start":4225,"enrollment":687,"conditions":7451,"interventions":7452},[89],[1692,1693,1694,1695,1696,1697,974,975,976,978,979,1698,1699,1700,996,1701],[4228,949],{"trials":7454,"activeCount":101},[],{"trials":7456,"activeCount":101},[],{"trials":7458,"activeCount":101},[],{"trials":7460,"activeCount":101},[],{"intervention":7462,"totalTrials":97,"cells":7463},"LBH589",{"EARLY_PHASE1":7464,"PHASE1":7466,"PHASE2":7476,"PHASE3":7478,"PHASE4":7480,"NA":7482},{"trials":7465,"activeCount":101},[],{"trials":7467,"activeCount":101},[7468],{"nctId":7469,"briefTitle":7470,"status":365,"phases":7471,"primaryCompletion":4499,"completion":4499,"start":1104,"enrollment":138,"conditions":7472,"interventions":7475},"NCT01032148","Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma",[89],[7473,7474],"Hodgkin's Lymphoma","Non-Hodgkin's Lymphoma",[7462],{"trials":7477,"activeCount":101},[],{"trials":7479,"activeCount":101},[],{"trials":7481,"activeCount":101},[],{"trials":7483,"activeCount":101},[],{"intervention":3375,"totalTrials":97,"cells":7485},{"EARLY_PHASE1":7486,"PHASE1":7488,"PHASE2":7494,"PHASE3":7496,"PHASE4":7498,"NA":7500},{"trials":7487,"activeCount":101},[],{"trials":7489,"activeCount":101},[7490],{"nctId":3364,"briefTitle":3365,"status":133,"phases":7491,"primaryCompletion":3367,"completion":3368,"start":3369,"enrollment":2744,"conditions":7492,"interventions":7493},[89],[3371,3372,3373],[3375,3350],{"trials":7495,"activeCount":101},[],{"trials":7497,"activeCount":101},[],{"trials":7499,"activeCount":101},[],{"trials":7501,"activeCount":101},[],{"intervention":696,"totalTrials":97,"cells":7503},{"EARLY_PHASE1":7504,"PHASE1":7506,"PHASE2":7512,"PHASE3":7514,"PHASE4":7516,"NA":7518},{"trials":7505,"activeCount":101},[],{"trials":7507,"activeCount":101},[7508],{"nctId":681,"briefTitle":682,"status":417,"phases":7509,"primaryCompletion":684,"completion":685,"start":686,"enrollment":687,"conditions":7510,"interventions":7511},[89],[689,690,691,692,693,694],[696,57,297],{"trials":7513,"activeCount":101},[],{"trials":7515,"activeCount":101},[],{"trials":7517,"activeCount":101},[],{"trials":7519,"activeCount":101},[],{"intervention":7521,"totalTrials":97,"cells":7522},"eltrombopag olamine",{"EARLY_PHASE1":7523,"PHASE1":7525,"PHASE2":7536,"PHASE3":7538,"PHASE4":7540,"NA":7542},{"trials":7524,"activeCount":101},[],{"trials":7526,"activeCount":101},[7527],{"nctId":7528,"briefTitle":7529,"status":365,"phases":7530,"primaryCompletion":7531,"completion":7531,"start":2030,"enrollment":36,"conditions":7532,"interventions":7535},"NCT01550185","Eltrombopag Olamine in Treating Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia",[89],"2014-12",[7533,7534,1692,1693,1694,1695,1696,1697,974,975,976,978,979,1698,1699,1700,996],"Adult Acute Basophilic Leukemia","Adult Acute Eosinophilic Leukemia",[7521],{"trials":7537,"activeCount":101},[],{"trials":7539,"activeCount":101},[],{"trials":7541,"activeCount":101},[],{"trials":7543,"activeCount":101},[],{"intervention":4826,"totalTrials":97,"cells":7545},{"EARLY_PHASE1":7546,"PHASE1":7548,"PHASE2":7554,"PHASE3":7556,"PHASE4":7558,"NA":7560},{"trials":7547,"activeCount":101},[],{"trials":7549,"activeCount":101},[7550],{"nctId":4820,"briefTitle":4821,"status":133,"phases":7551,"primaryCompletion":2213,"completion":4823,"start":2030,"enrollment":3202,"conditions":7552,"interventions":7553},[89],[18],[4826,2307],{"trials":7555,"activeCount":101},[],{"trials":7557,"activeCount":101},[],{"trials":7559,"activeCount":101},[],{"trials":7561,"activeCount":101},[],{"intervention":3194,"totalTrials":97,"cells":7563},{"EARLY_PHASE1":7564,"PHASE1":7566,"PHASE2":7572,"PHASE3":7574,"PHASE4":7576,"NA":7578},{"trials":7565,"activeCount":101},[],{"trials":7567,"activeCount":101},[7568],{"nctId":3187,"briefTitle":3188,"status":235,"phases":7569,"primaryCompletion":3190,"start":3191,"enrollment":101,"conditions":7570,"interventions":7571},[89],[3176,2496,2497,2498,2499],[3194,3106,3178],{"trials":7573,"activeCount":101},[],{"trials":7575,"activeCount":101},[],{"trials":7577,"activeCount":101},[],{"trials":7579,"activeCount":101},[],{"intervention":7581,"totalTrials":97,"cells":7582},"Dalteparin",{"EARLY_PHASE1":7583,"PHASE1":7585,"PHASE2":7598,"PHASE3":7600,"PHASE4":7602,"NA":7604},{"trials":7584,"activeCount":101},[],{"trials":7586,"activeCount":101},[7587],{"nctId":7588,"briefTitle":7589,"status":133,"phases":7590,"primaryCompletion":7591,"completion":7592,"start":7593,"enrollment":1219,"conditions":7594,"interventions":7596},"NCT01061411","Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery",[89],"2015-10-14","2017-04-21","2010-02-06",[7595,2538,5226,1249],"Clear Cell Sarcoma of the Kidney",[7581,7597],"Sunitinib Malate",{"trials":7599,"activeCount":101},[],{"trials":7601,"activeCount":101},[],{"trials":7603,"activeCount":101},[],{"trials":7605,"activeCount":101},[],{"intervention":2148,"totalTrials":97,"cells":7607},{"EARLY_PHASE1":7608,"PHASE1":7610,"PHASE2":7616,"PHASE3":7618,"PHASE4":7620,"NA":7622},{"trials":7609,"activeCount":101},[],{"trials":7611,"activeCount":101},[7612],{"nctId":2141,"briefTitle":2142,"status":133,"phases":7613,"primaryCompletion":1267,"start":2144,"conditions":7614,"interventions":7615},[89],[23,2146],[2148,858],{"trials":7617,"activeCount":101},[],{"trials":7619,"activeCount":101},[],{"trials":7621,"activeCount":101},[],{"trials":7623,"activeCount":101},[],{"intervention":3735,"totalTrials":97,"cells":7625},{"EARLY_PHASE1":7626,"PHASE1":7628,"PHASE2":7634,"PHASE3":7636,"PHASE4":7638,"NA":7640},{"trials":7627,"activeCount":101},[],{"trials":7629,"activeCount":101},[7630],{"nctId":3727,"briefTitle":3728,"status":133,"phases":7631,"primaryCompletion":3730,"completion":3731,"start":3732,"enrollment":687,"conditions":7632,"interventions":7633},[89],[675,676],[3735,3736,3673],{"trials":7635,"activeCount":101},[],{"trials":7637,"activeCount":101},[],{"trials":7639,"activeCount":101},[],{"trials":7641,"activeCount":101},[],{"intervention":3736,"totalTrials":97,"cells":7643},{"EARLY_PHASE1":7644,"PHASE1":7646,"PHASE2":7652,"PHASE3":7654,"PHASE4":7656,"NA":7658},{"trials":7645,"activeCount":101},[],{"trials":7647,"activeCount":101},[7648],{"nctId":3727,"briefTitle":3728,"status":133,"phases":7649,"primaryCompletion":3730,"completion":3731,"start":3732,"enrollment":687,"conditions":7650,"interventions":7651},[89],[675,676],[3735,3736,3673],{"trials":7653,"activeCount":101},[],{"trials":7655,"activeCount":101},[],{"trials":7657,"activeCount":101},[],{"trials":7659,"activeCount":101},[],{"intervention":7661,"totalTrials":97,"cells":7662},"FACT Complex-targeting Curaxin CBL0137",{"EARLY_PHASE1":7663,"PHASE1":7665,"PHASE2":7683,"PHASE3":7685,"PHASE4":7687,"NA":7689},{"trials":7664,"activeCount":101},[],{"trials":7666,"activeCount":101},[7667],{"nctId":7668,"briefTitle":7669,"status":365,"phases":7670,"primaryCompletion":7671,"completion":7671,"start":7672,"enrollment":1572,"conditions":7673,"interventions":7682},"NCT03727789","CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma",[89],"2024-01-16","2019-07-01",[7674,7675,871,872,880,881,883,7676,7677,7678,7679,7680,7681],"Advanced Cutaneous Melanoma of the Extremity","Advanced Sarcoma of the Extremity","Recurrent Cutaneous Melanoma of the Extremity","Recurrent Sarcoma of the Extremity","Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8","Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8",[7661],{"trials":7684,"activeCount":101},[],{"trials":7686,"activeCount":101},[],{"trials":7688,"activeCount":101},[],{"trials":7690,"activeCount":101},[],{"intervention":3206,"totalTrials":97,"cells":7692},{"EARLY_PHASE1":7693,"PHASE1":7695,"PHASE2":7701,"PHASE3":7703,"PHASE4":7705,"NA":7707},{"trials":7694,"activeCount":101},[],{"trials":7696,"activeCount":101},[7697],{"nctId":3196,"briefTitle":3197,"status":133,"phases":7698,"primaryCompletion":3199,"completion":3200,"start":3201,"enrollment":3202,"conditions":7699,"interventions":7700},[89],[866,3204,549,553,560],[3206,3106,3178,3207],{"trials":7702,"activeCount":101},[],{"trials":7704,"activeCount":101},[],{"trials":7706,"activeCount":101},[],{"trials":7708,"activeCount":101},[],{"intervention":7710,"totalTrials":97,"cells":7711},"selenium",{"EARLY_PHASE1":7712,"PHASE1":7714,"PHASE2":7724,"PHASE3":7726,"PHASE4":7728,"NA":7730},{"trials":7713,"activeCount":101},[],{"trials":7715,"activeCount":101},[7716],{"nctId":7717,"briefTitle":7718,"status":133,"phases":7719,"primaryCompletion":7720,"completion":7721,"start":4535,"enrollment":24,"conditions":7722,"interventions":7723},"NCT00217516","Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer",[89],"2008-02","2008-10",[26],[7710],{"trials":7725,"activeCount":101},[],{"trials":7727,"activeCount":101},[],{"trials":7729,"activeCount":101},[],{"trials":7731,"activeCount":101},[],{"intervention":6878,"totalTrials":97,"cells":7733},{"EARLY_PHASE1":7734,"PHASE1":7736,"PHASE2":7742,"PHASE3":7744,"PHASE4":7746,"NA":7748},{"trials":7735,"activeCount":101},[],{"trials":7737,"activeCount":101},[7738],{"nctId":6871,"briefTitle":6872,"status":365,"phases":7739,"primaryCompletion":6874,"start":6875,"enrollment":1572,"conditions":7740,"interventions":7741},[89],[707],[6857,6878],{"trials":7743,"activeCount":101},[],{"trials":7745,"activeCount":101},[],{"trials":7747,"activeCount":101},[],{"trials":7749,"activeCount":101},[],{"intervention":1466,"totalTrials":97,"cells":7751},{"EARLY_PHASE1":7752,"PHASE1":7754,"PHASE2":7760,"PHASE3":7762,"PHASE4":7764,"NA":7766},{"trials":7753,"activeCount":101},[],{"trials":7755,"activeCount":101},[7756],{"nctId":1458,"briefTitle":1459,"status":133,"phases":7757,"primaryCompletion":1461,"completion":1462,"start":1463,"enrollment":687,"conditions":7758,"interventions":7759},[89],[15,23,18],[711,1466,808,809],{"trials":7761,"activeCount":101},[],{"trials":7763,"activeCount":101},[],{"trials":7765,"activeCount":101},[],{"trials":7767,"activeCount":101},[],{"intervention":7769,"totalTrials":97,"cells":7770},"icotinib hydrochloride",{"EARLY_PHASE1":7771,"PHASE1":7773,"PHASE2":7781,"PHASE3":7783,"PHASE4":7785,"NA":7787},{"trials":7772,"activeCount":101},[],{"trials":7774,"activeCount":101},[7775],{"nctId":7776,"briefTitle":7777,"status":235,"phases":7778,"primaryCompletion":4823,"start":3426,"enrollment":101,"conditions":7779,"interventions":7780},"NCT02033148","Icotinib Hydrochloride in Treating Patients With Advanced Cancers",[89],[18],[7769],{"trials":7782,"activeCount":101},[],{"trials":7784,"activeCount":101},[],{"trials":7786,"activeCount":101},[],{"trials":7788,"activeCount":101},[],{"intervention":5533,"totalTrials":97,"cells":7790},{"EARLY_PHASE1":7791,"PHASE1":7793,"PHASE2":7799,"PHASE3":7801,"PHASE4":7803,"NA":7805},{"trials":7792,"activeCount":101},[],{"trials":7794,"activeCount":101},[7795],{"nctId":5525,"briefTitle":5526,"status":133,"phases":7796,"primaryCompletion":5528,"completion":5528,"start":5529,"enrollment":212,"conditions":7797,"interventions":7798},[89],[2864,3372,5531],[5518,5533,5534],{"trials":7800,"activeCount":101},[],{"trials":7802,"activeCount":101},[],{"trials":7804,"activeCount":101},[],{"trials":7806,"activeCount":101},[],{"intervention":5534,"totalTrials":97,"cells":7808},{"EARLY_PHASE1":7809,"PHASE1":7811,"PHASE2":7817,"PHASE3":7819,"PHASE4":7821,"NA":7823},{"trials":7810,"activeCount":101},[],{"trials":7812,"activeCount":101},[7813],{"nctId":5525,"briefTitle":5526,"status":133,"phases":7814,"primaryCompletion":5528,"completion":5528,"start":5529,"enrollment":212,"conditions":7815,"interventions":7816},[89],[2864,3372,5531],[5518,5533,5534],{"trials":7818,"activeCount":101},[],{"trials":7820,"activeCount":101},[],{"trials":7822,"activeCount":101},[],{"trials":7824,"activeCount":101},[],{"intervention":7826,"totalTrials":97,"cells":7827},"CMV pp65 Peptide-loaded Alpha-type-1 Polarized Dendritic Cell Vaccine",{"EARLY_PHASE1":7828,"PHASE1":7830,"PHASE2":7843,"PHASE3":7845,"PHASE4":7847,"NA":7849},{"trials":7829,"activeCount":101},[],{"trials":7831,"activeCount":101},[7832],{"nctId":7833,"briefTitle":7834,"status":235,"phases":7835,"primaryCompletion":7836,"completion":7837,"start":7838,"enrollment":101,"conditions":7839,"interventions":7842},"NCT05589844","A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation",[89],"2024-11-16","2025-11-16","2023-03",[7840,7841],"Cytomegaloviral Infection","Hematopoietic and Lymphoid System Neoplasm",[7826],{"trials":7844,"activeCount":101},[],{"trials":7846,"activeCount":101},[],{"trials":7848,"activeCount":101},[],{"trials":7850,"activeCount":101},[],{"intervention":1405,"totalTrials":97,"cells":7852},{"EARLY_PHASE1":7853,"PHASE1":7855,"PHASE2":7861,"PHASE3":7863,"PHASE4":7865,"NA":7867},{"trials":7854,"activeCount":101},[],{"trials":7856,"activeCount":101},[7857],{"nctId":1395,"briefTitle":1396,"status":133,"phases":7858,"primaryCompletion":1398,"completion":70,"start":518,"enrollment":1399,"conditions":7859,"interventions":7860},[89],[1401,1402,1403],[62,1405,1393,1379],{"trials":7862,"activeCount":101},[],{"trials":7864,"activeCount":101},[],{"trials":7866,"activeCount":101},[],{"trials":7868,"activeCount":101},[],{"intervention":7870,"totalTrials":97,"cells":7871},"therapeutic lymphadenectomy",{"EARLY_PHASE1":7872,"PHASE1":7885,"PHASE2":7887,"PHASE3":7889,"PHASE4":7891,"NA":7893},{"trials":7873,"activeCount":101},[7874],{"nctId":7875,"briefTitle":7876,"status":133,"phases":7877,"primaryCompletion":7878,"completion":7879,"start":7880,"enrollment":36,"conditions":7881,"interventions":7884},"NCT01781741","Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer",[88],"2015-11-30","2020-10-14","2013-03-06",[3359,7882,7883,4875],"Stage IIIA Non-small Cell Lung Cancer","Stage IIIB Non-small Cell Lung Cancer",[7870],{"trials":7886,"activeCount":101},[],{"trials":7888,"activeCount":101},[],{"trials":7890,"activeCount":101},[],{"trials":7892,"activeCount":101},[],{"trials":7894,"activeCount":101},[],{"intervention":7896,"totalTrials":97,"cells":7897},"Stereotactic Body Radiation Therapy",{"EARLY_PHASE1":7898,"PHASE1":7916,"PHASE2":7918,"PHASE3":7920,"PHASE4":7922,"NA":7924},{"trials":7899,"activeCount":101},[7900],{"nctId":7901,"briefTitle":7902,"status":365,"phases":7903,"primaryCompletion":7904,"completion":7905,"start":7906,"enrollment":21,"conditions":7907,"interventions":7915},"NCT03348748","Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer",[88],"2021-07-12","2025-11-10","2017-12-18",[7908,7909,7910,7911,7912,7913,7914],"Stage I Non-Small Cell Lung Cancer AJCC v7","Stage IA Non-Small Cell Lung Carcinoma AJCC v7","Stage IB Non-Small Cell Lung Carcinoma AJCC v7","Stage II Non-Small Cell Lung Cancer AJCC v7","Stage IIA Non-Small Cell Lung Carcinoma AJCC v7","Stage IIB Non-Small Cell Lung Carcinoma AJCC v7","Stage IIIA Non-Small Cell Lung Cancer AJCC v7",[7896,7896,7896],{"trials":7917,"activeCount":101},[],{"trials":7919,"activeCount":101},[],{"trials":7921,"activeCount":101},[],{"trials":7923,"activeCount":101},[],{"trials":7925,"activeCount":101},[],{"intervention":7927,"totalTrials":97,"cells":7928},"Binimetinib",{"EARLY_PHASE1":7929,"PHASE1":7943,"PHASE2":7945,"PHASE3":7947,"PHASE4":7949,"NA":7951},{"trials":7930,"activeCount":101},[7931],{"nctId":7932,"briefTitle":7933,"status":235,"phases":7934,"primaryCompletion":7935,"completion":7936,"start":7937,"enrollment":101,"conditions":7938,"interventions":7941},"NCT04870034","Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer",[88],"2025-09-30","2026-09-30","2024-01-15",[6565,7939,32,7940],"Lung Adenocarcinoma","Pancreatic Carcinoma",[7927,7942],"Palbociclib",{"trials":7944,"activeCount":101},[],{"trials":7946,"activeCount":101},[],{"trials":7948,"activeCount":101},[],{"trials":7950,"activeCount":101},[],{"trials":7952,"activeCount":101},[],{"intervention":7942,"totalTrials":97,"cells":7954},{"EARLY_PHASE1":7955,"PHASE1":7961,"PHASE2":7963,"PHASE3":7965,"PHASE4":7967,"NA":7969},{"trials":7956,"activeCount":101},[7957],{"nctId":7932,"briefTitle":7933,"status":235,"phases":7958,"primaryCompletion":7935,"completion":7936,"start":7937,"enrollment":101,"conditions":7959,"interventions":7960},[88],[6565,7939,32,7940],[7927,7942],{"trials":7962,"activeCount":101},[],{"trials":7964,"activeCount":101},[],{"trials":7966,"activeCount":101},[],{"trials":7968,"activeCount":101},[],{"trials":7970,"activeCount":101},[],{"intervention":1236,"totalTrials":30,"cells":7972},{"EARLY_PHASE1":7973,"PHASE1":7975,"PHASE2":8013,"PHASE3":8035,"PHASE4":8037,"NA":8039},{"trials":7974,"activeCount":101},[],{"trials":7976,"activeCount":101},[7977,7981,7985,7989,7993,7997,8001,8005,8009],{"nctId":6810,"briefTitle":6811,"status":235,"phases":7978,"primaryCompletion":1132,"start":5720,"enrollment":101,"conditions":7979,"interventions":7980},[89],[5213,5214,553,560,18],[6803,1236,6815],{"nctId":7157,"briefTitle":7158,"status":365,"phases":7982,"primaryCompletion":477,"completion":4823,"start":6110,"enrollment":36,"conditions":7983,"interventions":7984},[89],[23,7161],[3178,7150],{"nctId":4526,"briefTitle":4527,"status":133,"phases":7986,"primaryCompletion":1124,"completion":3228,"start":942,"conditions":7987,"interventions":7988},[89],[18],[1236,460],{"nctId":7292,"briefTitle":7293,"status":365,"phases":7990,"primaryCompletion":7295,"start":492,"enrollment":2744,"conditions":7991,"interventions":7992},[89],[18],[7285,1236],{"nctId":6864,"briefTitle":6865,"status":133,"phases":7994,"primaryCompletion":6030,"completion":3368,"start":1231,"enrollment":6867,"conditions":7995,"interventions":7996},[89],[18],[1236,6857],{"nctId":3172,"briefTitle":3173,"status":365,"phases":7998,"primaryCompletion":2213,"completion":1132,"start":2289,"enrollment":30,"conditions":7999,"interventions":8000},[89],[3176],[3106,3178],{"nctId":3187,"briefTitle":3188,"status":235,"phases":8002,"primaryCompletion":3190,"start":3191,"enrollment":101,"conditions":8003,"interventions":8004},[89],[3176,2496,2497,2498,2499],[3194,3106,3178],{"nctId":6817,"briefTitle":6818,"status":133,"phases":8006,"primaryCompletion":6820,"completion":6821,"start":6822,"enrollment":673,"conditions":8007,"interventions":8008},[89],[6824,553,560,18],[6803,1236,1052],{"nctId":3196,"briefTitle":3197,"status":133,"phases":8010,"primaryCompletion":3199,"completion":3200,"start":3201,"enrollment":3202,"conditions":8011,"interventions":8012},[89],[866,3204,549,553,560],[3206,3106,3178,3207],{"trials":8014,"activeCount":101},[8015,8019,8023,8031],{"nctId":4572,"briefTitle":4573,"status":133,"phases":8016,"primaryCompletion":4547,"completion":4575,"start":4576,"enrollment":3202,"conditions":8017,"interventions":8018},[90],[20],[1236,460],{"nctId":1227,"briefTitle":1228,"status":133,"phases":8020,"primaryCompletion":1230,"start":1231,"enrollment":1232,"conditions":8021,"interventions":8022},[90],[1234],[499,1052,1236],{"nctId":8024,"briefTitle":8025,"status":133,"phases":8026,"primaryCompletion":1462,"completion":454,"start":4470,"conditions":8027,"interventions":8030},"NCT00084942","Gemcitabine and Capecitabine in Treating Patients With Advanced and\u002For Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder",[90],[8028,8029],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer",[1052,1236],{"nctId":5301,"briefTitle":5302,"status":133,"phases":8032,"primaryCompletion":1124,"completion":1217,"start":5304,"enrollment":2744,"conditions":8033,"interventions":8034},[90],[20],[1236,5307,4354,5308,1089],{"trials":8036,"activeCount":101},[],{"trials":8038,"activeCount":101},[],{"trials":8040,"activeCount":101},[8041],{"nctId":1263,"briefTitle":1264,"status":235,"phases":8042,"primaryCompletion":1266,"start":1267,"enrollment":101,"conditions":8043,"interventions":8044},[93],[1234],[499,1052,1236],{"intervention":1052,"totalTrials":2412,"cells":8046},{"EARLY_PHASE1":8047,"PHASE1":8049,"PHASE2":8063,"PHASE3":8097,"PHASE4":8099,"NA":8101},{"trials":8048,"activeCount":101},[],{"trials":8050,"activeCount":101},[8051,8055,8059],{"nctId":4532,"briefTitle":4533,"status":133,"phases":8052,"primaryCompletion":4535,"completion":4536,"start":1892,"enrollment":2412,"conditions":8053,"interventions":8054},[89],[806],[1052,460],{"nctId":3180,"briefTitle":3181,"status":133,"phases":8056,"primaryCompletion":3183,"completion":1104,"start":2031,"enrollment":945,"conditions":8057,"interventions":8058},[89],[18],[1052,3170,2307],{"nctId":6817,"briefTitle":6818,"status":133,"phases":8060,"primaryCompletion":6820,"completion":6821,"start":6822,"enrollment":673,"conditions":8061,"interventions":8062},[89],[6824,553,560,18],[6803,1236,1052],{"trials":8064,"activeCount":101},[8065,8069,8073,8077,8081,8085,8089,8093],{"nctId":4856,"briefTitle":4857,"status":133,"phases":8066,"primaryCompletion":4859,"completion":4860,"start":4861,"enrollment":1187,"conditions":8067,"interventions":8068},[89,90],[548,552,4863,4864,561,562,563,564],[4866,4847],{"nctId":1214,"briefTitle":1215,"status":365,"phases":8070,"primaryCompletion":1217,"start":1218,"enrollment":1219,"conditions":8071,"interventions":8072},[90],[29],[499,1052],{"nctId":1045,"briefTitle":1046,"status":365,"phases":8074,"primaryCompletion":1048,"start":1049,"enrollment":36,"conditions":8075,"interventions":8076},[89,90],[29],[1052,1053,500],{"nctId":1227,"briefTitle":1228,"status":133,"phases":8078,"primaryCompletion":1230,"start":1231,"enrollment":1232,"conditions":8079,"interventions":8080},[90],[1234],[499,1052,1236],{"nctId":8024,"briefTitle":8025,"status":133,"phases":8082,"primaryCompletion":1462,"completion":454,"start":4470,"conditions":8083,"interventions":8084},[90],[8028,8029],[1052,1236],{"nctId":1083,"briefTitle":1084,"status":133,"phases":8086,"primaryCompletion":452,"start":454,"enrollment":785,"conditions":8087,"interventions":8088},[90],[35],[1052,500,1088,1089,1090],{"nctId":1100,"briefTitle":1101,"status":365,"phases":8090,"primaryCompletion":1103,"completion":1104,"start":1105,"enrollment":370,"conditions":8091,"interventions":8092},[90],[29],[1052,500],{"nctId":1109,"briefTitle":1110,"status":133,"phases":8094,"primaryCompletion":478,"completion":1112,"start":921,"enrollment":380,"conditions":8095,"interventions":8096},[89,90],[29],[1052,500],{"trials":8098,"activeCount":101},[],{"trials":8100,"activeCount":101},[],{"trials":8102,"activeCount":101},[8103],{"nctId":1263,"briefTitle":1264,"status":235,"phases":8104,"primaryCompletion":1266,"start":1267,"enrollment":101,"conditions":8105,"interventions":8106},[93],[1234],[499,1052,1236],{"intervention":844,"totalTrials":36,"cells":8108},{"EARLY_PHASE1":8109,"PHASE1":8111,"PHASE2":8117,"PHASE3":8139,"PHASE4":8149,"NA":8151},{"trials":8110,"activeCount":101},[],{"trials":8112,"activeCount":101},[8113],{"nctId":3545,"briefTitle":3546,"status":365,"phases":8114,"primaryCompletion":3548,"completion":3549,"start":3550,"enrollment":1271,"conditions":8115,"interventions":8116},[89],[884,885,886,3552,401,3553,226,227,228,3554,3555,3556],[47,3558,3559],{"trials":8118,"activeCount":101},[8119,8123,8127,8131,8135],{"nctId":4644,"briefTitle":701,"status":133,"phases":8120,"primaryCompletion":4239,"completion":1924,"start":630,"enrollment":582,"conditions":8121,"interventions":8122},[90],[706,15,23,708,1454],[710,712,713,844,714],{"nctId":2036,"briefTitle":2037,"status":133,"phases":8124,"primaryCompletion":2039,"completion":2040,"start":2041,"enrollment":2042,"conditions":8125,"interventions":8126},[90],[2044,972,973,974,975,976,977,978,979,2045,980,2046,2047,728,2048,981,982,2049,984,2050,985,2051,986,734,2052,736,2053,988,989,2054,2055,991,744,992,746,2056,2057,2058,995,996,997,998,999,1000,1001,1002,1003,1004,2059,1005,1006,1007,1008,1009,1010,1011,1012,1014,1015,1016,606,1018,2060,1020,1021,609,2061,1022,749,2062,2063,2064,2065,752,1024,2066,756,757],[794,844,796,795,1761],{"nctId":835,"briefTitle":836,"status":133,"phases":8128,"primaryCompletion":838,"completion":838,"start":839,"enrollment":840,"conditions":8129,"interventions":8130},[90],[706,15,708,842],[710,712,639,713,844,714],{"nctId":846,"briefTitle":847,"status":133,"phases":8132,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":8133,"interventions":8134},[90],[806,15,23,707,854,18,855],[712,808,857,639,858,844,810],{"nctId":918,"briefTitle":919,"status":133,"phases":8136,"primaryCompletion":921,"completion":922,"start":468,"conditions":8137,"interventions":8138},[90],[15,23,708,924],[710,711,712,639,713,794,844,714],{"trials":8140,"activeCount":101},[8141,8145],{"nctId":929,"briefTitle":930,"status":133,"phases":8142,"primaryCompletion":932,"completion":932,"start":933,"enrollment":934,"conditions":8143,"interventions":8144},[90,91],[787,15,23,708,788,936,18,855],[710,712,808,639,858,794,844,810],{"nctId":939,"briefTitle":940,"status":133,"phases":8146,"primaryCompletion":942,"completion":943,"start":944,"enrollment":945,"conditions":8147,"interventions":8148},[91],[15],[948,711,639,949,858,950,844],{"trials":8150,"activeCount":101},[],{"trials":8152,"activeCount":101},[8153,8157],{"nctId":965,"briefTitle":966,"status":133,"phases":8154,"primaryCompletion":968,"completion":968,"start":969,"enrollment":970,"conditions":8155,"interventions":8156},[93],[972,973,974,975,976,977,978,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998,999,1000,1001,1002,1003,1004,1005,1006,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,606,1018,1019,1020,1021,609,1022,1023,1024,1025,18,855,1026],[858,639,857,844,712,808,810],{"nctId":2083,"briefTitle":2084,"status":133,"phases":8158,"primaryCompletion":2086,"completion":2087,"start":2088,"enrollment":2089,"conditions":8159,"interventions":8160},[93],[2044,1691,972,973,974,975,976,977,978,979,980,2046,2047,728,2091,981,982,2049,984,985,2051,986,2092,734,2093,2052,2094,988,789,2054,2055,991,2095,2096,2097,2098,2099,2100,2101,2102,2103,2104,2105,2106,744,2057,2058,995,996,997,998,999,1000,1001,1002,1003,1004,2059,1005,1006,1007,1008,1009,1010,1011,1012,1014,1015,1016,606,1018,2060,1020,1021,609,1022,2107,749,2062,1024,2108,2109,2110,2111,2112,2113,826,2114,2115,2116,2117,2118,2119,2120,2121,2122,827,2123,2124,1026],[794,844,710],{"intervention":2483,"totalTrials":317,"cells":8162},{"EARLY_PHASE1":8163,"PHASE1":8165,"PHASE2":8185,"PHASE3":8224,"PHASE4":8226,"NA":8228},{"trials":8164,"activeCount":101},[],{"trials":8166,"activeCount":101},[8167,8171,8175],{"nctId":2474,"briefTitle":2475,"status":365,"phases":8168,"primaryCompletion":2477,"completion":2477,"start":2478,"enrollment":370,"conditions":8169,"interventions":8170},[89],[2480,2481],[81,2483],{"nctId":3285,"briefTitle":3286,"status":365,"phases":8172,"primaryCompletion":3288,"completion":599,"start":3289,"enrollment":370,"conditions":8173,"interventions":8174},[89],[266,3291],[2483,3267],{"nctId":8176,"briefTitle":8177,"status":133,"phases":8178,"primaryCompletion":8179,"completion":8180,"start":8181,"enrollment":317,"conditions":8182,"interventions":8184},"NCT03678350","Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery",[89],"2023-11-13","2025-10-09","2021-09-17",[634,8183,3291],"Non-Small Cell Lung Carcinoma",[2483],{"trials":8186,"activeCount":101},[8187,8198,8205,8212,8220],{"nctId":8188,"briefTitle":8189,"status":133,"phases":8190,"primaryCompletion":8191,"completion":8191,"start":8192,"enrollment":1399,"conditions":8193,"interventions":8197},"NCT03735095","Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer",[89,90],"2024-07-26","2020-02-12",[8194,8183,8195,271,272,273,274,8196],"Locally Advanced Lung Carcinoma","Small Cell Lung Carcinoma","Solid Tumor",[2483],{"nctId":8199,"briefTitle":8200,"status":133,"phases":8201,"primaryCompletion":1900,"completion":4678,"start":4725,"enrollment":2412,"conditions":8202,"interventions":8203},"NCT00054002","Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma",[90],[634],[8204],"porfimer sodium",{"nctId":8206,"briefTitle":8207,"status":133,"phases":8208,"primaryCompletion":849,"completion":4547,"start":8209,"enrollment":804,"conditions":8210,"interventions":8211},"NCT00002935","Photodynamic Therapy in Treating Patients With Early Esophageal Cancer",[90],"1995-10",[35],[8204],{"nctId":8213,"briefTitle":8214,"status":133,"phases":8215,"primaryCompletion":8216,"start":8217,"conditions":8218,"interventions":8219},"NCT00002964","Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer",[90],"2004-04","1995-02",[3261],[8204],{"nctId":3401,"briefTitle":3402,"status":365,"phases":8221,"primaryCompletion":3404,"completion":3405,"start":3406,"enrollment":582,"conditions":8222,"interventions":8223},[90],[3408,3409,3410,3411,3412,3413,3414],[3267,2483],{"trials":8225,"activeCount":101},[],{"trials":8227,"activeCount":101},[],{"trials":8229,"activeCount":101},[8230],{"nctId":8231,"briefTitle":8232,"status":365,"phases":8233,"primaryCompletion":494,"completion":8234,"start":6959,"enrollment":804,"conditions":8235,"interventions":8236},"NCT00530088","Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat",[93],"2010-10",[3261],[8204,8237],"Photdynamic Therapy",{"intervention":710,"totalTrials":138,"cells":8239},{"EARLY_PHASE1":8240,"PHASE1":8242,"PHASE2":8244,"PHASE3":8266,"PHASE4":8276,"NA":8278},{"trials":8241,"activeCount":101},[],{"trials":8243,"activeCount":101},[],{"trials":8245,"activeCount":101},[8246,8250,8254,8258,8262],{"nctId":700,"briefTitle":701,"status":133,"phases":8247,"primaryCompletion":703,"completion":703,"start":704,"enrollment":21,"conditions":8248,"interventions":8249},[90],[706,15,23,707,708],[710,711,712,639,713,714],{"nctId":780,"briefTitle":781,"status":133,"phases":8251,"primaryCompletion":783,"completion":783,"start":784,"enrollment":785,"conditions":8252,"interventions":8253},[90],[787,15,23,707,708,788,789,728],[710,791,792,793,639,794,714,795,796],{"nctId":4644,"briefTitle":701,"status":133,"phases":8255,"primaryCompletion":4239,"completion":1924,"start":630,"enrollment":582,"conditions":8256,"interventions":8257},[90],[706,15,23,708,1454],[710,712,713,844,714],{"nctId":835,"briefTitle":836,"status":133,"phases":8259,"primaryCompletion":838,"completion":838,"start":839,"enrollment":840,"conditions":8260,"interventions":8261},[90],[706,15,708,842],[710,712,639,713,844,714],{"nctId":918,"briefTitle":919,"status":133,"phases":8263,"primaryCompletion":921,"completion":922,"start":468,"conditions":8264,"interventions":8265},[90],[15,23,708,924],[710,711,712,639,713,794,844,714],{"trials":8267,"activeCount":101},[8268,8272],{"nctId":929,"briefTitle":930,"status":133,"phases":8269,"primaryCompletion":932,"completion":932,"start":933,"enrollment":934,"conditions":8270,"interventions":8271},[90,91],[787,15,23,708,788,936,18,855],[710,712,808,639,858,794,844,810],{"nctId":952,"briefTitle":953,"status":133,"phases":8273,"primaryCompletion":955,"completion":955,"start":803,"enrollment":956,"conditions":8274,"interventions":8275},[91],[728],[959,57],{"trials":8277,"activeCount":101},[],{"trials":8279,"activeCount":101},[8280],{"nctId":2083,"briefTitle":2084,"status":133,"phases":8281,"primaryCompletion":2086,"completion":2087,"start":2088,"enrollment":2089,"conditions":8282,"interventions":8283},[93],[2044,1691,972,973,974,975,976,977,978,979,980,2046,2047,728,2091,981,982,2049,984,985,2051,986,2092,734,2093,2052,2094,988,789,2054,2055,991,2095,2096,2097,2098,2099,2100,2101,2102,2103,2104,2105,2106,744,2057,2058,995,996,997,998,999,1000,1001,1002,1003,1004,2059,1005,1006,1007,1008,1009,1010,1011,1012,1014,1015,1016,606,1018,2060,1020,1021,609,1022,2107,749,2062,1024,2108,2109,2110,2111,2112,2113,826,2114,2115,2116,2117,2118,2119,2120,2121,2122,827,2123,2124,1026],[794,844,710],{"intervention":712,"totalTrials":1572,"cells":8285},{"EARLY_PHASE1":8286,"PHASE1":8288,"PHASE2":8290,"PHASE3":8312,"PHASE4":8318,"NA":8320},{"trials":8287,"activeCount":101},[],{"trials":8289,"activeCount":101},[],{"trials":8291,"activeCount":101},[8292,8296,8300,8304,8308],{"nctId":700,"briefTitle":701,"status":133,"phases":8293,"primaryCompletion":703,"completion":703,"start":704,"enrollment":21,"conditions":8294,"interventions":8295},[90],[706,15,23,707,708],[710,711,712,639,713,714],{"nctId":4644,"briefTitle":701,"status":133,"phases":8297,"primaryCompletion":4239,"completion":1924,"start":630,"enrollment":582,"conditions":8298,"interventions":8299},[90],[706,15,23,708,1454],[710,712,713,844,714],{"nctId":835,"briefTitle":836,"status":133,"phases":8301,"primaryCompletion":838,"completion":838,"start":839,"enrollment":840,"conditions":8302,"interventions":8303},[90],[706,15,708,842],[710,712,639,713,844,714],{"nctId":846,"briefTitle":847,"status":133,"phases":8305,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":8306,"interventions":8307},[90],[806,15,23,707,854,18,855],[712,808,857,639,858,844,810],{"nctId":918,"briefTitle":919,"status":133,"phases":8309,"primaryCompletion":921,"completion":922,"start":468,"conditions":8310,"interventions":8311},[90],[15,23,708,924],[710,711,712,639,713,794,844,714],{"trials":8313,"activeCount":101},[8314],{"nctId":929,"briefTitle":930,"status":133,"phases":8315,"primaryCompletion":932,"completion":932,"start":933,"enrollment":934,"conditions":8316,"interventions":8317},[90,91],[787,15,23,708,788,936,18,855],[710,712,808,639,858,794,844,810],{"trials":8319,"activeCount":101},[],{"trials":8321,"activeCount":101},[8322],{"nctId":965,"briefTitle":966,"status":133,"phases":8323,"primaryCompletion":968,"completion":968,"start":969,"enrollment":970,"conditions":8324,"interventions":8325},[93],[972,973,974,975,976,977,978,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998,999,1000,1001,1002,1003,1004,1005,1006,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,606,1018,1019,1020,1021,609,1022,1023,1024,1025,18,855,1026],[858,639,857,844,712,808,810],{"intervention":810,"totalTrials":1271,"cells":8327},{"EARLY_PHASE1":8328,"PHASE1":8330,"PHASE2":8332,"PHASE3":8342,"PHASE4":8348,"NA":8350},{"trials":8329,"activeCount":101},[],{"trials":8331,"activeCount":101},[],{"trials":8333,"activeCount":101},[8334,8338],{"nctId":798,"briefTitle":799,"status":133,"phases":8335,"primaryCompletion":801,"completion":802,"start":803,"enrollment":804,"conditions":8336,"interventions":8337},[89,90],[806],[711,808,639,809,810],{"nctId":846,"briefTitle":847,"status":133,"phases":8339,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":8340,"interventions":8341},[90],[806,15,23,707,854,18,855],[712,808,857,639,858,844,810],{"trials":8343,"activeCount":101},[8344],{"nctId":929,"briefTitle":930,"status":133,"phases":8345,"primaryCompletion":932,"completion":932,"start":933,"enrollment":934,"conditions":8346,"interventions":8347},[90,91],[787,15,23,708,788,936,18,855],[710,712,808,639,858,794,844,810],{"trials":8349,"activeCount":101},[],{"trials":8351,"activeCount":101},[8352],{"nctId":965,"briefTitle":966,"status":133,"phases":8353,"primaryCompletion":968,"completion":968,"start":969,"enrollment":970,"conditions":8354,"interventions":8355},[93],[972,973,974,975,976,977,978,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998,999,1000,1001,1002,1003,1004,1005,1006,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,606,1018,1019,1020,1021,609,1022,1023,1024,1025,18,855,1026],[858,639,857,844,712,808,810],{"intervention":1090,"totalTrials":1271,"cells":8357},{"EARLY_PHASE1":8358,"PHASE1":8360,"PHASE2":8370,"PHASE3":8376,"PHASE4":8378,"NA":8380},{"trials":8359,"activeCount":101},[],{"trials":8361,"activeCount":101},[8362,8366],{"nctId":4987,"briefTitle":4988,"status":235,"phases":8363,"primaryCompletion":4052,"start":4678,"enrollment":101,"conditions":8364,"interventions":8365},[89],[609,2233,4991,4992],[3636,1088,4994,4995,1090],{"nctId":1537,"briefTitle":1538,"status":133,"phases":8367,"primaryCompletion":1540,"completion":453,"start":1541,"enrollment":24,"conditions":8368,"interventions":8369},[89],[1543,1544,1545],[1547,1548,1489,792,1549,1090,1550],{"trials":8371,"activeCount":101},[8372],{"nctId":1083,"briefTitle":1084,"status":133,"phases":8373,"primaryCompletion":452,"start":454,"enrollment":785,"conditions":8374,"interventions":8375},[90],[35],[1052,500,1088,1089,1090],{"trials":8377,"activeCount":101},[],{"trials":8379,"activeCount":101},[],{"trials":8381,"activeCount":101},[8382],{"nctId":8383,"briefTitle":8384,"status":133,"phases":8385,"primaryCompletion":1541,"completion":1974,"start":955,"enrollment":1232,"conditions":8386,"interventions":8387},"NCT00550563","DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements",[93],[29],[2294,2295,1977,1090,3636],{"intervention":481,"totalTrials":1271,"cells":8389},{"EARLY_PHASE1":8390,"PHASE1":8392,"PHASE2":8402,"PHASE3":8408,"PHASE4":8410,"NA":8412},{"trials":8391,"activeCount":101},[],{"trials":8393,"activeCount":101},[8394,8398],{"nctId":7588,"briefTitle":7589,"status":133,"phases":8395,"primaryCompletion":7591,"completion":7592,"start":7593,"enrollment":1219,"conditions":8396,"interventions":8397},[89],[7595,2538,5226,1249],[7581,7597],{"nctId":473,"briefTitle":474,"status":365,"phases":8399,"primaryCompletion":476,"completion":477,"start":478,"enrollment":184,"conditions":8400,"interventions":8401},[89],[35,456],[459,460,461,481],{"trials":8403,"activeCount":101},[8404],{"nctId":4675,"briefTitle":4676,"status":365,"phases":8405,"primaryCompletion":4678,"completion":4679,"start":4680,"enrollment":1219,"conditions":8406,"interventions":8407},[90],[457],[1963,481],{"trials":8409,"activeCount":101},[],{"trials":8411,"activeCount":101},[],{"trials":8413,"activeCount":101},[8414],{"nctId":8415,"briefTitle":8416,"status":133,"phases":8417,"primaryCompletion":574,"completion":3486,"start":955,"enrollment":21,"conditions":8418,"interventions":8419},"NCT00849186","Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer",[93],[6198],[481],{"intervention":8421,"totalTrials":582,"cells":8422},"Fluorescein Sodium",{"EARLY_PHASE1":8423,"PHASE1":8436,"PHASE2":8438,"PHASE3":8440,"PHASE4":8442,"NA":8444},{"trials":8424,"activeCount":101},[8425],{"nctId":8426,"briefTitle":8427,"status":133,"phases":8428,"primaryCompletion":8429,"completion":8429,"start":8430,"enrollment":1399,"conditions":8431,"interventions":8435},"NCT03297489","Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer",[88],"2021-02-15","2017-11-06",[4798,4800,8432,2542,2545,2547,8433,2551,2555,2557,8434,2562,2567,2572,2577],"Stage I Ovarian Cancer","Stage II Ovarian Cancer","Stage III Ovarian Cancer",[8421],{"trials":8437,"activeCount":101},[],{"trials":8439,"activeCount":101},[],{"trials":8441,"activeCount":101},[],{"trials":8443,"activeCount":101},[],{"trials":8445,"activeCount":101},[8446,8457],{"nctId":8447,"briefTitle":8448,"status":133,"phases":8449,"primaryCompletion":8450,"completion":8451,"start":8452,"enrollment":21,"conditions":8453,"interventions":8456},"NCT02857374","Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy",[93],"2018-08-28","2022-06-13","2016-11-03",[8454,8455,2556,2558,2563,2568,2573],"Stage IB Skin Melanoma","Stage IIA Skin Melanoma",[8421],{"nctId":8458,"briefTitle":8459,"status":133,"phases":8460,"primaryCompletion":8461,"completion":8462,"start":8463,"enrollment":36,"conditions":8464,"interventions":8466},"NCT01886235","Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery",[93],"2015-06-16","2020-05-06","2013-09-04",[2536,8465,8454,8455,2556,2558,2563,2568,2573,2579],"Stage IA Skin Melanoma",[8421],{"intervention":8468,"totalTrials":582,"cells":8469},"trivalent influenza vaccine",{"EARLY_PHASE1":8470,"PHASE1":8482,"PHASE2":8484,"PHASE3":8486,"PHASE4":8488,"NA":8490},{"trials":8471,"activeCount":101},[8472],{"nctId":8473,"briefTitle":8474,"status":133,"phases":8475,"primaryCompletion":8476,"completion":8476,"start":8477,"enrollment":8478,"conditions":8479,"interventions":8480},"NCT04484532","Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers",[88],"2022-06-07","2017-10-17",130,[725,741],[8481],"Trivalent Influenza Vaccine",{"trials":8483,"activeCount":101},[],{"trials":8485,"activeCount":101},[],{"trials":8487,"activeCount":101},[],{"trials":8489,"activeCount":101},[],{"trials":8491,"activeCount":101},[8492,8500],{"nctId":8493,"briefTitle":8494,"status":365,"phases":8495,"primaryCompletion":8496,"completion":2213,"start":1540,"enrollment":33,"conditions":8497,"interventions":8499},"NCT01561989","Cholecalciferol and Flu Vaccine in Treating Healthy Participants",[93],"2013-07",[8498],"Healthy, no Evidence of Disease",[8468],{"nctId":8501,"briefTitle":8502,"status":133,"phases":8503,"primaryCompletion":1892,"start":4439,"conditions":8504,"interventions":8506},"NCT00022035","Vaccine Therapy in Preventing Flu in Children With Acute Lymphoblastic Leukemia",[93],[8505,15],"Infection",[8468],{"intervention":1977,"totalTrials":582,"cells":8508},{"EARLY_PHASE1":8509,"PHASE1":8511,"PHASE2":8513,"PHASE3":8523,"PHASE4":8525,"NA":8527},{"trials":8510,"activeCount":101},[],{"trials":8512,"activeCount":101},[],{"trials":8514,"activeCount":101},[8515,8519],{"nctId":4347,"briefTitle":4348,"status":365,"phases":8516,"primaryCompletion":453,"completion":476,"start":4350,"enrollment":2744,"conditions":8517,"interventions":8518},[90],[15],[4353,2342,4354,1977],{"nctId":1971,"briefTitle":1972,"status":365,"phases":8520,"primaryCompletion":1974,"completion":1133,"start":1960,"enrollment":24,"conditions":8521,"interventions":8522},[90],[26],[1877,1977],{"trials":8524,"activeCount":101},[],{"trials":8526,"activeCount":101},[],{"trials":8528,"activeCount":101},[8529],{"nctId":8383,"briefTitle":8384,"status":133,"phases":8530,"primaryCompletion":1541,"completion":1974,"start":955,"enrollment":1232,"conditions":8531,"interventions":8532},[93],[29],[2294,2295,1977,1090,3636],{"intervention":3636,"totalTrials":582,"cells":8534},{"EARLY_PHASE1":8535,"PHASE1":8537,"PHASE2":8543,"PHASE3":8549,"PHASE4":8551,"NA":8553},{"trials":8536,"activeCount":101},[],{"trials":8538,"activeCount":101},[8539],{"nctId":4987,"briefTitle":4988,"status":235,"phases":8540,"primaryCompletion":4052,"start":4678,"enrollment":101,"conditions":8541,"interventions":8542},[89],[609,2233,4991,4992],[3636,1088,4994,4995,1090],{"trials":8544,"activeCount":101},[8545],{"nctId":3618,"briefTitle":3619,"status":133,"phases":8546,"primaryCompletion":3621,"completion":262,"start":3622,"enrollment":21,"conditions":8547,"interventions":8548},[90],[3624,3625,3626,3627,3628,988,991,2101,2102,2103,2105,2106,1014,1015,1016,1018,1020,1024,3629,3630,3631,3632,3633,2111,2112,2113,2114,2115,2120,2121,2122,2123,2124],[3635,2216,3636],{"trials":8550,"activeCount":101},[],{"trials":8552,"activeCount":101},[],{"trials":8554,"activeCount":101},[8555],{"nctId":8383,"briefTitle":8384,"status":133,"phases":8556,"primaryCompletion":1541,"completion":1974,"start":955,"enrollment":1232,"conditions":8557,"interventions":8558},[93],[29],[2294,2295,1977,1090,3636],{"intervention":1904,"totalTrials":582,"cells":8560},{"EARLY_PHASE1":8561,"PHASE1":8563,"PHASE2":8569,"PHASE3":8580,"PHASE4":8582,"NA":8584},{"trials":8562,"activeCount":101},[],{"trials":8564,"activeCount":101},[8565],{"nctId":1897,"briefTitle":1898,"status":133,"phases":8566,"primaryCompletion":1900,"start":1901,"enrollment":863,"conditions":8567,"interventions":8568},[89],[18],[1877,1904],{"trials":8570,"activeCount":101},[8571],{"nctId":8572,"briefTitle":8573,"status":365,"phases":8574,"primaryCompletion":5719,"completion":5719,"start":1509,"enrollment":263,"conditions":8575,"interventions":8577},"NCT00536991","Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer",[89,90],[2414,2537,8576,2578],"Stage III Prostate Cancer",[8578,8579],"Ketoconazole","Therapeutic Hydrocortisone",{"trials":8581,"activeCount":101},[],{"trials":8583,"activeCount":101},[],{"trials":8585,"activeCount":101},[8586],{"nctId":1985,"briefTitle":1986,"status":235,"phases":8587,"primaryCompletion":1988,"start":1989,"enrollment":101,"conditions":8588,"interventions":8589},[93],[26],[1877,1904,1992],{"intervention":392,"totalTrials":582,"cells":8591},{"EARLY_PHASE1":8592,"PHASE1":8594,"PHASE2":8600,"PHASE3":8606,"PHASE4":8608,"NA":8610},{"trials":8593,"activeCount":101},[],{"trials":8595,"activeCount":101},[8596],{"nctId":5207,"briefTitle":5208,"status":133,"phases":8597,"primaryCompletion":943,"completion":2330,"start":5210,"enrollment":2412,"conditions":8598,"interventions":8599},[89],[5212,5213,5214,560,18],[5216,5200],{"trials":8601,"activeCount":101},[8602],{"nctId":375,"briefTitle":376,"status":133,"phases":8603,"primaryCompletion":158,"completion":378,"start":379,"enrollment":380,"conditions":8604,"interventions":8605},[89,90],[382,383,384,385,386,387,388,389,390],[71,392],{"trials":8607,"activeCount":101},[],{"trials":8609,"activeCount":101},[],{"trials":8611,"activeCount":101},[8612],{"nctId":8613,"briefTitle":8614,"status":133,"phases":8615,"primaryCompletion":8616,"completion":8617,"start":8618,"enrollment":804,"conditions":8619,"interventions":8623},"NCT02072486","Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery",[93],"2019-07-19","2020-07-19","2013-11-18",[382,8620,8621,385,386,387,8622,389,390],"Localized Non-Resectable Adult Hepatocellular Carcinoma","Stage III Childhood Hepatocellular Carcinoma","Stage IV Childhood Hepatocellular Carcinoma",[392],{"intervention":3283,"totalTrials":440,"cells":8625},{"EARLY_PHASE1":8626,"PHASE1":8628,"PHASE2":8634,"PHASE3":8636,"PHASE4":8638,"NA":8640},{"trials":8627,"activeCount":101},[],{"trials":8629,"activeCount":101},[8630],{"nctId":3274,"briefTitle":3275,"status":133,"phases":8631,"primaryCompletion":3277,"completion":3277,"start":3278,"enrollment":138,"conditions":8632,"interventions":8633},[89],[2496,3280,3281,2497,2498],[3283,3267],{"trials":8635,"activeCount":101},[],{"trials":8637,"activeCount":101},[],{"trials":8639,"activeCount":101},[],{"trials":8641,"activeCount":101},[8642],{"nctId":3423,"briefTitle":3424,"status":235,"phases":8643,"primaryCompletion":3426,"completion":3426,"start":3427,"enrollment":101,"conditions":8644,"interventions":8645},[93],[3133,3135,3138,3325,3326,3329,3343,3344,3347,3167],[3350,3430],{"intervention":8647,"totalTrials":440,"cells":8648},"tivozanib",{"EARLY_PHASE1":8649,"PHASE1":8651,"PHASE2":8653,"PHASE3":8666,"PHASE4":8668,"NA":8670},{"trials":8650,"activeCount":101},[],{"trials":8652,"activeCount":101},[],{"trials":8654,"activeCount":101},[8655],{"nctId":8656,"briefTitle":8657,"status":133,"phases":8658,"primaryCompletion":8659,"completion":8660,"start":8661,"enrollment":6172,"conditions":8662,"interventions":8664},"NCT01835223","Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery",[89,90],"2018-12-24","2019-11-08","2013-07-11",[382,8663],"Non-Resectable Hepatocellular Carcinoma",[8665,8665],"Tivozanib",{"trials":8667,"activeCount":101},[],{"trials":8669,"activeCount":101},[],{"trials":8671,"activeCount":101},[8672],{"nctId":8673,"briefTitle":8674,"status":235,"phases":8675,"primaryCompletion":8676,"completion":8677,"start":8678,"enrollment":101,"conditions":8679,"interventions":8681},"NCT01769885","Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer",[93],"2013-06-14","2013-12-02","2013-03-14",[8680,5226],"Stage II Renal Cell Cancer",[8647],{"intervention":2294,"totalTrials":440,"cells":8683},{"EARLY_PHASE1":8684,"PHASE1":8686,"PHASE2":8688,"PHASE3":8694,"PHASE4":8696,"NA":8698},{"trials":8685,"activeCount":101},[],{"trials":8687,"activeCount":101},[],{"trials":8689,"activeCount":101},[8690],{"nctId":2286,"briefTitle":2287,"status":365,"phases":8691,"primaryCompletion":2289,"completion":2289,"start":2290,"enrollment":317,"conditions":8692,"interventions":8693},[90],[23],[2216,2293,1489,1088,2294,2295,2296],{"trials":8695,"activeCount":101},[],{"trials":8697,"activeCount":101},[],{"trials":8699,"activeCount":101},[8700],{"nctId":8383,"briefTitle":8384,"status":133,"phases":8701,"primaryCompletion":1541,"completion":1974,"start":955,"enrollment":1232,"conditions":8702,"interventions":8703},[93],[29],[2294,2295,1977,1090,3636],{"intervention":2295,"totalTrials":440,"cells":8705},{"EARLY_PHASE1":8706,"PHASE1":8708,"PHASE2":8710,"PHASE3":8716,"PHASE4":8718,"NA":8720},{"trials":8707,"activeCount":101},[],{"trials":8709,"activeCount":101},[],{"trials":8711,"activeCount":101},[8712],{"nctId":2286,"briefTitle":2287,"status":365,"phases":8713,"primaryCompletion":2289,"completion":2289,"start":2290,"enrollment":317,"conditions":8714,"interventions":8715},[90],[23],[2216,2293,1489,1088,2294,2295,2296],{"trials":8717,"activeCount":101},[],{"trials":8719,"activeCount":101},[],{"trials":8721,"activeCount":101},[8722],{"nctId":8383,"briefTitle":8384,"status":133,"phases":8723,"primaryCompletion":1541,"completion":1974,"start":955,"enrollment":1232,"conditions":8724,"interventions":8725},[93],[29],[2294,2295,1977,1090,3636],{"intervention":8727,"totalTrials":440,"cells":8728},"Fentanyl citrate",{"EARLY_PHASE1":8729,"PHASE1":8731,"PHASE2":8733,"PHASE3":8735,"PHASE4":8737,"NA":8739},{"trials":8730,"activeCount":101},[],{"trials":8732,"activeCount":101},[],{"trials":8734,"activeCount":101},[],{"trials":8736,"activeCount":101},[],{"trials":8738,"activeCount":101},[],{"trials":8740,"activeCount":101},[8741,8751],{"nctId":8742,"briefTitle":8743,"status":133,"phases":8744,"primaryCompletion":8745,"completion":6088,"start":8746,"enrollment":804,"conditions":8747,"interventions":8749},"NCT00538499","Fentanyl With or Without Bupivacaine in Reducing Pain in Patients Undergoing Video-Assisted Chest Surgery",[93],"2007-07-27","2004-10-28",[3372,8748],"Perioperative\u002FPostoperative Complications",[8727,8750],"Bupivacaine hydrocloride",{"nctId":8752,"briefTitle":8753,"status":133,"phases":8754,"primaryCompletion":838,"completion":4471,"start":8755,"enrollment":24,"conditions":8756,"interventions":8757},"NCT00003000","Morphine for the Treatment of Pain in Patients With Breast Cancer",[],"1992-05",[3372],[8758,8759],"fentanyl citrate","morphine sulfate",{"intervention":857,"totalTrials":440,"cells":8761},{"EARLY_PHASE1":8762,"PHASE1":8764,"PHASE2":8766,"PHASE3":8772,"PHASE4":8774,"NA":8776},{"trials":8763,"activeCount":101},[],{"trials":8765,"activeCount":101},[],{"trials":8767,"activeCount":101},[8768],{"nctId":846,"briefTitle":847,"status":133,"phases":8769,"primaryCompletion":849,"completion":850,"start":851,"enrollment":852,"conditions":8770,"interventions":8771},[90],[806,15,23,707,854,18,855],[712,808,857,639,858,844,810],{"trials":8773,"activeCount":101},[],{"trials":8775,"activeCount":101},[],{"trials":8777,"activeCount":101},[8778],{"nctId":965,"briefTitle":966,"status":133,"phases":8779,"primaryCompletion":968,"completion":968,"start":969,"enrollment":970,"conditions":8780,"interventions":8781},[93],[972,973,974,975,976,977,978,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998,999,1000,1001,1002,1003,1004,1005,1006,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,606,1018,1019,1020,1021,609,1022,1023,1024,1025,18,855,1026],[858,639,857,844,712,808,810],{"intervention":8783,"totalTrials":440,"cells":8784},"broccoli sprout extract",{"EARLY_PHASE1":8785,"PHASE1":8802,"PHASE2":8804,"PHASE3":8806,"PHASE4":8808,"NA":8810},{"trials":8786,"activeCount":101},[8787],{"nctId":8788,"briefTitle":8789,"status":133,"phases":8790,"primaryCompletion":8791,"completion":8792,"start":8793,"enrollment":804,"conditions":8794,"interventions":8800},"NCT01753908","Broccoli Sprout Extract in Treating Patients With Breast Cancer",[88],"2018-07-23","2018-08-23","2013-05-21",[8795,8796,141,2527,8797,8798,8799,2541,2544,2549,2552],"Ductal Breast Carcinoma","Ductal Breast Carcinoma In Situ","Invasive Breast Carcinoma","Lobular Breast Carcinoma","Postmenopausal",[8801],"Broccoli Sprout Extract",{"trials":8803,"activeCount":101},[],{"trials":8805,"activeCount":101},[],{"trials":8807,"activeCount":101},[],{"trials":8809,"activeCount":101},[],{"trials":8811,"activeCount":101},[8812],{"nctId":8813,"briefTitle":8814,"status":365,"phases":8815,"primaryCompletion":3368,"completion":3127,"start":3486,"enrollment":1572,"conditions":8816,"interventions":8822},"NCT01108003","Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery",[93],[8817,8818,8819,8820,8821],"Recurrent Bladder Cancer","Stage 0 Bladder Cancer","Stage I Bladder Cancer","Stage II Bladder Cancer","Transitional Cell Carcinoma of the Bladder",[8783],{"intervention":638,"totalTrials":440,"cells":8824},{"EARLY_PHASE1":8825,"PHASE1":8827,"PHASE2":8833,"PHASE3":8835,"PHASE4":8837,"NA":8839},{"trials":8826,"activeCount":101},[],{"trials":8828,"activeCount":101},[8829],{"nctId":627,"briefTitle":628,"status":133,"phases":8830,"primaryCompletion":630,"completion":631,"start":632,"enrollment":21,"conditions":8831,"interventions":8832},[89],[20,634],[636,637,638,639],{"trials":8834,"activeCount":101},[],{"trials":8836,"activeCount":101},[],{"trials":8838,"activeCount":101},[],{"trials":8840,"activeCount":101},[8841],{"nctId":8842,"briefTitle":8843,"status":133,"phases":8844,"primaryCompletion":8845,"completion":8846,"start":8847,"enrollment":8848,"conditions":8849,"interventions":8850},"NCT00732563","Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery",[93],"2012-06-29","2017-07-26","2008-07-16",100,[20],[638],{"intervention":8579,"totalTrials":440,"cells":8852},{"EARLY_PHASE1":8853,"PHASE1":8855,"PHASE2":8857,"PHASE3":8863,"PHASE4":8865,"NA":8867},{"trials":8854,"activeCount":101},[],{"trials":8856,"activeCount":101},[],{"trials":8858,"activeCount":101},[8859],{"nctId":8572,"briefTitle":8573,"status":365,"phases":8860,"primaryCompletion":5719,"completion":5719,"start":1509,"enrollment":263,"conditions":8861,"interventions":8862},[89,90],[2414,2537,8576,2578],[8578,8579],{"trials":8864,"activeCount":101},[],{"trials":8866,"activeCount":101},[],{"trials":8868,"activeCount":101},[8869],{"nctId":1985,"briefTitle":1986,"status":235,"phases":8870,"primaryCompletion":1988,"start":1989,"enrollment":101,"conditions":8871,"interventions":8872},[93],[26],[1877,1904,1992],{"intervention":8874,"totalTrials":440,"cells":8875},"varenicline",{"EARLY_PHASE1":8876,"PHASE1":8878,"PHASE2":8880,"PHASE3":8889,"PHASE4":8891,"NA":8893},{"trials":8877,"activeCount":101},[],{"trials":8879,"activeCount":101},[],{"trials":8881,"activeCount":101},[8882],{"nctId":8883,"briefTitle":8884,"status":133,"phases":8885,"primaryCompletion":1974,"completion":4398,"start":6874,"enrollment":212,"conditions":8886,"interventions":8888},"NCT00835900","An Alternative Dosing Schedule of Varenicline for Smoking Cessation",[90],[8887],"Smoking Cessation",[8874],{"trials":8890,"activeCount":101},[],{"trials":8892,"activeCount":101},[],{"trials":8894,"activeCount":101},[8895],{"nctId":8896,"briefTitle":8897,"status":133,"phases":8898,"primaryCompletion":8899,"completion":8900,"start":8901,"enrollment":8902,"conditions":8903,"interventions":8904},"NCT01771627","Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers",[93],"2014-09-28","2015-08-28","2012-10-22",300,[6199],[8874,8905],"nicotine patch",{"intervention":8907,"totalTrials":97,"cells":8908},"hepatitis B antigen peptide",{"EARLY_PHASE1":8909,"PHASE1":8911,"PHASE2":8913,"PHASE3":8915,"PHASE4":8917,"NA":8919},{"trials":8910,"activeCount":101},[],{"trials":8912,"activeCount":101},[],{"trials":8914,"activeCount":101},[],{"trials":8916,"activeCount":101},[],{"trials":8918,"activeCount":101},[],{"trials":8920,"activeCount":101},[8921],{"nctId":8922,"briefTitle":8923,"status":235,"phases":8924,"primaryCompletion":3427,"start":850,"enrollment":101,"conditions":8925,"interventions":8926},"NCT01292421","Edible Hepatitis B Vaccine Therapy in Healthy Participants Who Have Undergone Previous Vaccination",[93],[8498],[8907],{"intervention":8928,"totalTrials":97,"cells":8929},"nicotine replacement therapy",{"EARLY_PHASE1":8930,"PHASE1":8932,"PHASE2":8934,"PHASE3":8936,"PHASE4":8938,"NA":8940},{"trials":8931,"activeCount":101},[],{"trials":8933,"activeCount":101},[],{"trials":8935,"activeCount":101},[],{"trials":8937,"activeCount":101},[],{"trials":8939,"activeCount":101},[],{"trials":8941,"activeCount":101},[8942],{"nctId":8943,"briefTitle":8944,"status":133,"phases":8945,"primaryCompletion":5210,"completion":4397,"start":3228,"enrollment":8946,"conditions":8947,"interventions":8948},"NCT00957424","Acceptability of Less Harmful Alternatives to Cigarettes",[93],67,[5826,6197,35,456,3261,6198,15,457,20,1234,6199],[8928],{"intervention":8950,"totalTrials":97,"cells":8951},"Renal Cell Carcinoma\u002FCD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003",{"EARLY_PHASE1":8952,"PHASE1":8954,"PHASE2":8956,"PHASE3":8958,"PHASE4":8960,"NA":8962},{"trials":8953,"activeCount":101},[],{"trials":8955,"activeCount":101},[],{"trials":8957,"activeCount":101},[],{"trials":8959,"activeCount":101},[],{"trials":8961,"activeCount":101},[],{"trials":8963,"activeCount":101},[8964],{"nctId":8965,"briefTitle":8966,"status":365,"phases":8967,"primaryCompletion":8968,"completion":8968,"start":8969,"enrollment":370,"conditions":8970,"interventions":8972},"NCT02170389","Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer",[93],"2017-03-17","2014-10-14",[2538,8971,8680],"Stage I Renal Cell Cancer",[8950],{"intervention":8750,"totalTrials":97,"cells":8974},{"EARLY_PHASE1":8975,"PHASE1":8977,"PHASE2":8979,"PHASE3":8981,"PHASE4":8983,"NA":8985},{"trials":8976,"activeCount":101},[],{"trials":8978,"activeCount":101},[],{"trials":8980,"activeCount":101},[],{"trials":8982,"activeCount":101},[],{"trials":8984,"activeCount":101},[],{"trials":8986,"activeCount":101},[8987],{"nctId":8742,"briefTitle":8743,"status":133,"phases":8988,"primaryCompletion":8745,"completion":6088,"start":8746,"enrollment":804,"conditions":8989,"interventions":8990},[93],[3372,8748],[8727,8750],{"intervention":8759,"totalTrials":97,"cells":8992},{"EARLY_PHASE1":8993,"PHASE1":8995,"PHASE2":8997,"PHASE3":8999,"PHASE4":9001,"NA":9003},{"trials":8994,"activeCount":101},[],{"trials":8996,"activeCount":101},[],{"trials":8998,"activeCount":101},[],{"trials":9000,"activeCount":101},[],{"trials":9002,"activeCount":101},[],{"trials":9004,"activeCount":101},[9005],{"nctId":8752,"briefTitle":8753,"status":133,"phases":9006,"primaryCompletion":838,"completion":4471,"start":8755,"enrollment":24,"conditions":9007,"interventions":9008},[],[3372],[8758,8759],{"intervention":9010,"totalTrials":97,"cells":9011},"HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)",{"EARLY_PHASE1":9012,"PHASE1":9014,"PHASE2":9016,"PHASE3":9018,"PHASE4":9020,"NA":9022},{"trials":9013,"activeCount":101},[],{"trials":9015,"activeCount":101},[],{"trials":9017,"activeCount":101},[],{"trials":9019,"activeCount":101},[],{"trials":9021,"activeCount":101},[],{"trials":9023,"activeCount":101},[9024],{"nctId":9025,"briefTitle":9026,"status":235,"phases":9027,"primaryCompletion":9028,"completion":9029,"start":1104,"enrollment":101,"conditions":9030,"interventions":9032},"NCT01035437","Study for Determination of Feasibility and Toxicity of Pre-Treatment With HPPH (2-1[1-Hexyloxyethyl]-2 Devinyl Pyropheophorbide-a) Photodynamic Therapy Prior to Chemoradiation in Non-Operable Patients With Obstructive Esophageal Cancer",[93],"2011-01","2011-02",[9031],"Esophageal Neoplasm",[9010],{"intervention":9034,"totalTrials":97,"cells":9035},"calcitriol",{"EARLY_PHASE1":9036,"PHASE1":9038,"PHASE2":9040,"PHASE3":9042,"PHASE4":9044,"NA":9046},{"trials":9037,"activeCount":101},[],{"trials":9039,"activeCount":101},[],{"trials":9041,"activeCount":101},[],{"trials":9043,"activeCount":101},[],{"trials":9045,"activeCount":101},[],{"trials":9047,"activeCount":101},[9048],{"nctId":9049,"briefTitle":9050,"status":133,"phases":9051,"primaryCompletion":9052,"completion":3395,"start":9053,"enrollment":1219,"conditions":9054,"interventions":9055},"NCT00690924","Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer",[93],"2017-03-07","2008-07-17",[20,3491,6199],[9034],{"intervention":3265,"totalTrials":97,"cells":9057},{"EARLY_PHASE1":9058,"PHASE1":9060,"PHASE2":9062,"PHASE3":9064,"PHASE4":9066,"NA":9068},{"trials":9059,"activeCount":101},[],{"trials":9061,"activeCount":101},[],{"trials":9063,"activeCount":101},[],{"trials":9065,"activeCount":101},[],{"trials":9067,"activeCount":101},[],{"trials":9069,"activeCount":101},[9070],{"nctId":3255,"briefTitle":3256,"status":133,"phases":9071,"primaryCompletion":3258,"start":3259,"enrollment":440,"conditions":9072,"interventions":9073},[],[3261,20,3262,3263],[3170,3265,809],{"intervention":9075,"totalTrials":97,"cells":9076},"donor lymphocytes",{"EARLY_PHASE1":9077,"PHASE1":9079,"PHASE2":9081,"PHASE3":9083,"PHASE4":9085,"NA":9087},{"trials":9078,"activeCount":101},[],{"trials":9080,"activeCount":101},[],{"trials":9082,"activeCount":101},[],{"trials":9084,"activeCount":101},[],{"trials":9086,"activeCount":101},[],{"trials":9088,"activeCount":101},[9089],{"nctId":9090,"briefTitle":9091,"status":133,"phases":9092,"primaryCompletion":9093,"completion":9093,"start":9094,"enrollment":9095,"conditions":9096,"interventions":9097},"NCT00534118","Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant",[93],"2018-07-26","2003-10-01",39,[15,23,707,708],[9075],{"intervention":8905,"totalTrials":97,"cells":9099},{"EARLY_PHASE1":9100,"PHASE1":9102,"PHASE2":9104,"PHASE3":9106,"PHASE4":9108,"NA":9110},{"trials":9101,"activeCount":101},[],{"trials":9103,"activeCount":101},[],{"trials":9105,"activeCount":101},[],{"trials":9107,"activeCount":101},[],{"trials":9109,"activeCount":101},[],{"trials":9111,"activeCount":101},[9112],{"nctId":8896,"briefTitle":8897,"status":133,"phases":9113,"primaryCompletion":8899,"completion":8900,"start":8901,"enrollment":8902,"conditions":9114,"interventions":9115},[93],[6199],[8874,8905],{"intervention":9117,"totalTrials":97,"cells":9118},"isosulfan blue",{"EARLY_PHASE1":9119,"PHASE1":9121,"PHASE2":9123,"PHASE3":9125,"PHASE4":9127,"NA":9129},{"trials":9120,"activeCount":101},[],{"trials":9122,"activeCount":101},[],{"trials":9124,"activeCount":101},[],{"trials":9126,"activeCount":101},[],{"trials":9128,"activeCount":101},[],{"trials":9130,"activeCount":101},[9131],{"nctId":9132,"briefTitle":9133,"status":133,"phases":9134,"primaryCompletion":4535,"start":9135,"conditions":9136,"interventions":9138},"NCT00003186","Diagnostic Procedure for Identifying Patients With Metastatic Colorectal Cancer",[93],"1997-04",[29,9137],"Metastatic Cancer",[9117],{"intervention":8237,"totalTrials":97,"cells":9140},{"EARLY_PHASE1":9141,"PHASE1":9143,"PHASE2":9145,"PHASE3":9147,"PHASE4":9149,"NA":9151},{"trials":9142,"activeCount":101},[],{"trials":9144,"activeCount":101},[],{"trials":9146,"activeCount":101},[],{"trials":9148,"activeCount":101},[],{"trials":9150,"activeCount":101},[],{"trials":9152,"activeCount":101},[9153],{"nctId":8231,"briefTitle":8232,"status":365,"phases":9154,"primaryCompletion":494,"completion":8234,"start":6959,"enrollment":804,"conditions":9155,"interventions":9156},[93],[3261],[8204,8237],{"intervention":9158,"totalTrials":97,"cells":9159},"SurVaxM",{"EARLY_PHASE1":9160,"PHASE1":9162,"PHASE2":9164,"PHASE3":9166,"PHASE4":9168,"NA":9170},{"trials":9161,"activeCount":101},[],{"trials":9163,"activeCount":101},[],{"trials":9165,"activeCount":101},[],{"trials":9167,"activeCount":101},[],{"trials":9169,"activeCount":101},[],{"trials":9171,"activeCount":101},[9172],{"nctId":9173,"briefTitle":9174,"status":9175,"phases":9176,"conditions":9177,"interventions":9178},"NCT04802447","SurVaxM Expanded Access Protocol","NO_LONGER_AVAILABLE",[],[1428],[9158],{"intervention":9180,"totalTrials":97,"cells":9181},"Anastrozole",{"EARLY_PHASE1":9182,"PHASE1":9184,"PHASE2":9186,"PHASE3":9188,"PHASE4":9190,"NA":9192},{"trials":9183,"activeCount":101},[],{"trials":9185,"activeCount":101},[],{"trials":9187,"activeCount":101},[],{"trials":9189,"activeCount":101},[],{"trials":9191,"activeCount":101},[],{"trials":9193,"activeCount":101},[9194],{"nctId":9195,"briefTitle":9196,"status":133,"phases":9197,"primaryCompletion":9028,"completion":4414,"start":1266,"enrollment":326,"conditions":9198,"interventions":9199},"NCT00612560","Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics",[93],[806],[9180],{"intervention":9201,"totalTrials":97,"cells":9202},"beclomethasone dipropionate",{"EARLY_PHASE1":9203,"PHASE1":9205,"PHASE2":9207,"PHASE3":9209,"PHASE4":9211,"NA":9213},{"trials":9204,"activeCount":101},[],{"trials":9206,"activeCount":101},[],{"trials":9208,"activeCount":101},[],{"trials":9210,"activeCount":101},[],{"trials":9212,"activeCount":101},[],{"trials":9214,"activeCount":101},[9215],{"nctId":9216,"briefTitle":9217,"status":133,"phases":9218,"primaryCompletion":9219,"completion":1960,"start":9220,"enrollment":263,"conditions":9221,"interventions":9222},"NCT00055666","Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract",[93],"2005-02","2001-03",[706],[9201],{"intervention":9224,"totalTrials":97,"cells":9225},"Nicotine Replacement",{"EARLY_PHASE1":9226,"PHASE1":9228,"PHASE2":9230,"PHASE3":9232,"PHASE4":9234,"NA":9236},{"trials":9227,"activeCount":101},[],{"trials":9229,"activeCount":101},[],{"trials":9231,"activeCount":101},[],{"trials":9233,"activeCount":101},[],{"trials":9235,"activeCount":101},[],{"trials":9237,"activeCount":101},[9238],{"nctId":9239,"briefTitle":9240,"status":365,"phases":9241,"primaryCompletion":9242,"completion":9242,"start":9243,"enrollment":673,"conditions":9244,"interventions":9246},"NCT04297332","Episodic Future Thinking and Future Thinking Priming for Smoking Cessation",[93],"2023-12-28","2020-01-01",[9245],"Tobacco-Related Carcinoma",[9224],{"intervention":4083,"totalTrials":97,"cells":9248},{"EARLY_PHASE1":9249,"PHASE1":9251,"PHASE2":9253,"PHASE3":9255,"PHASE4":9257,"NA":9259},{"trials":9250,"activeCount":101},[],{"trials":9252,"activeCount":101},[],{"trials":9254,"activeCount":101},[],{"trials":9256,"activeCount":101},[],{"trials":9258,"activeCount":101},[],{"trials":9260,"activeCount":101},[9261],{"nctId":4075,"briefTitle":4076,"status":133,"phases":9262,"primaryCompletion":4078,"completion":4078,"start":4079,"enrollment":863,"conditions":9263,"interventions":9264},[93],[4081],[3997,4083,4084,4085],{"intervention":4084,"totalTrials":97,"cells":9266},{"EARLY_PHASE1":9267,"PHASE1":9269,"PHASE2":9271,"PHASE3":9273,"PHASE4":9275,"NA":9277},{"trials":9268,"activeCount":101},[],{"trials":9270,"activeCount":101},[],{"trials":9272,"activeCount":101},[],{"trials":9274,"activeCount":101},[],{"trials":9276,"activeCount":101},[],{"trials":9278,"activeCount":101},[9279],{"nctId":4075,"briefTitle":4076,"status":133,"phases":9280,"primaryCompletion":4078,"completion":4078,"start":4079,"enrollment":863,"conditions":9281,"interventions":9282},[93],[4081],[3997,4083,4084,4085],{"intervention":4085,"totalTrials":97,"cells":9284},{"EARLY_PHASE1":9285,"PHASE1":9287,"PHASE2":9289,"PHASE3":9291,"PHASE4":9293,"NA":9295},{"trials":9286,"activeCount":101},[],{"trials":9288,"activeCount":101},[],{"trials":9290,"activeCount":101},[],{"trials":9292,"activeCount":101},[],{"trials":9294,"activeCount":101},[],{"trials":9296,"activeCount":101},[9297],{"nctId":4075,"briefTitle":4076,"status":133,"phases":9298,"primaryCompletion":4078,"completion":4078,"start":4079,"enrollment":863,"conditions":9299,"interventions":9300},[93],[4081],[3997,4083,4084,4085]]